

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number  
**WO 02/08286 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**

(21) International Application Number: PCT/EP01/08367

(22) International Filing Date: 19 July 2001 (19.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/220,060 21 July 2000 (21.07.2000) US

(71) Applicant (*for all designated States except US*): **SYNGENTA PARTICIPATIONS AG** [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **SERA, Takashi** [JP/US]; Torrey Mesa Research Institute, 3115 Merryfield Row, San Diego, CA 92121 (US).

(74) Agent: **BASTIAN, Werner**; c/o Syngenta Participations AG, Intellectual Property, P.O. Box, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ZINC FINGER DOMAIN RECOGNITION CODE AND USES THEREOF

(57) **Abstract:** The present invention relates to DNA binding proteins comprising zinc finger domains in which two histidine and two cysteine residues coordinate a central zinc ion. More particularly, the invention relates to the identification of a context-independent recognition code to design zinc finger domains. This code permits identification of an amino acid for positions -1, 2, 3 and 6 of the  $\alpha$ -helical region of the zinc finger domain from four-base pair nucleotide target sequences. The invention includes zinc finger proteins (ZFPs) designed using this recognition code, nucleic acids encoding these UFPs and methods of using such ZFPs to modulate gene expression, alter genome structure, inhibit viral replication and detect alterations (e.g., nucleotide substitutions, deletions or insertions) in the binding sites for such proteins. In addition, the invention provides a rapid method of assembling a ZFP with three or more zinc finger domains using three sets of 256 oligonucleotides, where each set is designed to target the 256 different 4-base pair targets and allow production of all possible 3-finger ZFPs (i.e.,  $>>10^6$ ) from a total of 768 oligonucleotides.



**WO 02/08286 A2**

## ZINC FINGER DOMAIN RECOGNITION CODE AND USES THEREOF

The present invention relates to DNA binding proteins comprising zinc finger domains in which two histidine and two cysteine residues coordinate a central zinc ion.

5 More particularly, the invention relates to the identification of a context-independent recognition code to design zinc finger domains. This code permits identification of an amino acid for positions -1, 2, 3 and 6 of the  $\alpha$ -helical region of the zinc finger domain from four-base pair nucleotide target sequences. The invention includes zinc finger proteins (ZFPs) designed using this recognition code, nucleic acids encoding these ZFPs and  
10 methods of using such ZFPs to modulate gene expression, alter genome structure, inhibit viral replication and detect alterations (e.g., nucleotide substitutions, deletions or insertions) in the binding sites for such proteins. In addition, the invention provides a rapid method of assembling a ZFP with three or more zinc finger domains using three sets of 256 oligonucleotides, where each set is designed to target the 256 different 4-base pair targets  
15 and allow production of all possible 3-finger ZFPs (i.e.,  $>>10^6$ ) from a total of 768 oligonucleotides.

Selective gene expression is modulated by specific interaction of transcription factors with nucleotide sequences within the regulatory region of a gene. Zinc fingers are structural domains found in eukaryotic proteins which control gene transcription. The zinc  
20 finger domain of the Cys<sub>2</sub>His<sub>2</sub> class of ZFPs is a polypeptide structural motif folded around a bound zinc ion, and has a sequence of the form -X<sub>3</sub>-Cys-X<sub>2-4</sub>-Cys-X<sub>12</sub>-His-X<sub>3-5</sub>-His-X<sub>4</sub>- (SEQ ID NO: 1), wherein X is any amino acid. The zinc finger is an independent folding domain which uses a zinc ion to stabilize the packing of an antiparallel  $\beta$ -sheet against an  $\alpha$ -helix. There is a great deal of sequence variation in the amino acids designated as X,  
25 however, the two consensus histidine and cysteine residues are invariant. Although most ZFPs have a similar three dimensional structure, they bind polynucleotides having a wide range of nucleotide sequences.

Several reports have discussed how zinc finger domains recognize their target polynucleotides and have attempted to generate a recognition code describing which amino  
30 acids in the zinc finger bind to which nucleotides of the target sequence. Most of these studies emphasize a three nucleotide target site. However, the limited sequence recognition information currently available largely relates to context-specific binding. In other words,

the binding of the zinc finger domain is dependent on the sequence of the polynucleotides other than those which directly contact amino acids within the zinc finger domain. The present invention addresses these shortcomings and provides a context-independent zinc finger recognition code.

5 Further, the ability to design and artificially synthesize multi-fingered ZFPs to efficiently produce any one of many millions of choices has been limited in the art. For example, some known methods of constructing ZFPs include designing and constructing nucleic acids encoding ZFPs by phage display, random mutagenesis, combinatorial libraries, computer/rational design, affinity selection, PCR, cloning from cDNA or genomic libraries,  
10 synthetic construction and the like. (see, *e.g.*, U.S. Pat. No. 5,786,538; Wu *et al.*, Proc. Natl. Acad. Sci. USA 92:344-348 (1995); Jamieson *et al.*, Biochemistry 33:5689- 5695 (1994); Rebar & Pabo, Science 263:671-673 (1994); Choo & Klug, Proc. Natl. Acad. Sci. USA 91: 11168-11172 (1994); Desjarlais *et al.*, Proc. Natl. Acad. Sci. USA 89:7345-5349 (1992); Desjarlais *et al.*, Proc. Natl. Acad. Sci. USA 90:2256-2260 (1993); Desjarlais *et al.*,  
15 Proc. Natl. Acad. Sci. USA 91:11099-11103; Pomerantz *et al.*, Science 267:93-96 (1995); Pomerantz *et al.*, Proc. Natl. Acad. Sci. USA 92:9752-9756 (1995); and Liu *et al.*, Proc. Natl. Acad. Sci. USA 94:5525-5530 (1997); Griesman & Berg, Science 275:657-661 (1997).

Typically, a DNA is synthesized for each different individual ZFP desired,  
20 regardless of whether those proteins share some of the same domains or the number of domains in the ZFP. This can present difficulties in synthesizing large, multi-fingered ZFPs. Methods of recombinantly making ZFPs from DNA encoding individual zinc finger domains can be complicated by the difficulty of assembling the individual DNAs in the correct order, particularly when the domains have similar sequences.

25 Accordingly, there is a need in the art for a method to efficiently construct ZFPs comprising multiple zinc finger domains. The present invention addresses the shortcomings of the art and provides a modular method of assembling multi-fingered ZFPs from three sets of oligonucleotides encoding individual domains designed to allow the domains to assemble in the desired order.

30

The present invention relates to a methods of designing a zinc finger domains using 4 base-pair target sequences and determining the identity of the amino acids at positions -1, 2, 3 and 6 of the  $\alpha$ -helix of a zinc finger domain according to the recognition code tables described herein. The method is particularly useful for designing multi-fingered (i.e., multi-

5      domained) ZFPs for longer target sequences which can be divided into overlapping 4 base pair segments, where the last base of each 4 base-pair target is the first base of the next 4 base-pair target.

In a particular embodiment, the present invention provides a method of designing a zinc finger domain of the formula

10       $-X_3\text{-Cys-}X_{2-4}\text{-Cys-}X_5\text{-}Z^1\text{-X-}Z^2\text{-}Z^3\text{-}X_2\text{-}Z^6\text{-His-}X_{3-5}\text{-His-}X_4\text{-}$  (SEQ ID NO: 2),  
 wherein X is any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain, and thus X represents the framework of a  $\text{Cys}_2\text{His}_2$  zinc finger domain. To perform this method, one (1) identifies a target nucleic acid sequence having four bases, (2) determines the identity of each X, e.g., by selecting a known zinc finger framework, a

15      consensus framework or altering any of these framework as may be desired, and (3) determines the identity of amino acids at positions  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$ , which are the positions of the amino acids preceding or in the  $\alpha$ -helical portion of the zinc finger domain based on the recognition code table of the invention. Using that designed domain, a ZFP, or any other protein that is desired, can be prepared that contains that domain. The ZFP or

20      other protein can be prepared synthetically or recombinantly, but preferably recombinantly.

The preferred recognition code table of the invention is as follows for the four base target sequence:

- (i)      if the first base is G, then  $Z^6$  is arginine,  
           if the first base is A, then  $Z^6$  is glutamine,

25      if the first base is T, then  $Z^6$  is threonine, tyrosine or leucine,  
           if the first base is C, then  $Z^6$  is glutamic acid,
- (ii)     if the second base is G, then  $Z^3$  is histidine,  
           if the second base is A, then  $Z^3$  is asparagine,  
           if the second base is T, then  $Z^3$  is serine,

30      if the second base is C, then  $Z^3$  is aspartic acid,
- (iii)    if the third base is G, then  $Z^1$  is arginine,  
           if the third base is A, then  $Z^1$  is glutamine,

if the third base is T, then  $Z^1$  is threonine or methionine,

if the third base is C, then  $Z^1$  is glutamic acid,

(iv) if the complement of the fourth base is G, then  $Z^2$  is serine,

if the complement of the fourth base is A, then  $Z^2$  is asparagine,

5 if the complement of the fourth base is T, then  $Z^2$  is threonine, and

if the complement of the fourth base is C, then  $Z^2$  is aspartic acid.

In a more preferred embodiment for the above recognition code, if the first base is T, then  $Z^6$  is threonine; and if the third base is T, then  $Z^1$  is threonine (Table 1).

10 In an alternative and less preferred embodiment, the recognition code table is provided as follows:

(i) if the first base is G, then  $Z^6$  is arginine or lysine,

if the first base is A, then  $Z^6$  is glutamine or asparagine,

if the first base is T, then  $Z^6$  is threonine, tyrosine, leucine, isoleucine or methionine,

15 if the first base is C, then  $Z^6$  is glutamic acid or aspartic acid,

(ii) if the second base is G, then  $Z^3$  is histidine or lysine,

if the second base is A, then  $Z^3$  is asparagine or glutamine,

if the second base is T, then  $Z^3$  is serine, alanine or valine,

if the second base is C, then  $Z^3$  is aspartic acid or glutamic acid,

20 (iii) if the third base is G, then  $Z^1$  is arginine or lysine,

if the third base is A, then  $Z^1$  is glutamine or asparagine,

if the third base is T, then  $Z^1$  is threonine, methionine leucine or isoleucine,

if the third base is C, then  $Z^1$  is glutamic acid or aspartic acid,

25 (iv) if the complement of the fourth base is G, then  $Z^2$  is serine or arginine,


if the complement of the fourth base is A, then  $Z^2$  is asparagine or glutamine,

if the complement of the fourth base is T, then  $Z^2$  is threonine, valine or alanine, and

30 if the complement of the fourth base is C, then  $Z^2$  is aspartic acid or glutamic acid.

The invention also provides a method to design a multi-domained ZFP, in which each zinc finger domain is independently represented by the formula above. In this case however, the target nucleic acid sequence has a length of  $3N+1$  base pairs, wherein  $N$  is the number of overlapping 4 base pair segments in that target obtained by dividing the target  
 5 nucleic acid sequence into overlapping 4 base pair segments, wherein the fourth base of each segment, up to the  $N-1$  segment, is the first base of the immediately following segment. The remainder of the design method follows that for a single domain.

Another aspect of the invention provides isolated, artificial ZFPs for binding to a target nucleic acid sequence which comprise at least three zinc finger domains covalently  
 10 joined to each other with from 0 to 10 amino acid residues, wherein the amino acids at positions -1, 2, 3 and 6 of the  $\alpha$ -helix of the zinc finger are selected in accordance with a recognition code of the invention. In a particular embodiment, these ZFPs comprise at least three zinc finger domains, each independently represented by the formula



15 and the domains covalently joined to each other with a from 0 to 10 amino acid residues, wherein  $X$  is any amino acid and  $X_n$  represents the number of occurrences of  $X$  in the polypeptide chain, wherein  $Z^1$ ,  $Z^2$ ,  $Z^3$ , and  $Z^6$  are determined by the recognition code of Table 1 with the proviso that such proteins are not those provided by any one of SEQ ID NOS 3-12. As above,  $X$  represents a framework of a  $\text{Cys}_2\text{His}_2$  zinc finger domain and can  
 20 be a known zinc finger framework, a consensus framework, a framework obtained by varying the sequence any of these frameworks or any artificial framework. Preferably known frameworks are used to determine the identities of each  $X$ . The ZFPs of the invention comprise from 3 to 40 zinc finger domains, and preferably, 3 to 15 domains, 3 to 12 domains, 3 to 9 domains or 3 to 6 domains, as well as ZFPs with 3, 4, 5, 6, 7, 8 or 9  
 25 domains. In preferred embodiment the framework for determining  $X$  is that from Sp1C or Zif268. In one embodiment, the framework has the sequence of Sp1C domain 2, which sequence is -Pro-Tyr-Lys-Cys-Pro-Glu-Cys-Gly-Lys-Ser-Phe-Ser- $Z^1$ -Ser- $Z^2$ - $Z^3$ -Leu-Gln- $Z^6$ -His-Gln-Arg-Thr-His-Thr-Gly-Glu-Lys- (SEQ ID NO: 13).

30 Additionally preferred ZFPs are those wherein, independently or in any combination,  $Z^1$  is methionine in at least one of said zinc finger domains;  $Z^1$  is glutamic acid in at least one of said zinc finger domains;  $Z^2$  is threonine in at least one of said zinc finger domains;  $Z^2$  is serine in at least one of said zinc finger domains;  $Z^2$  is asparagine in at

least one of said zinc finger domains;  $Z^6$  is glutamic acid in at least one of said zinc finger domains;  $Z^6$  is threonine in at least one of said zinc finger domains;  $Z^6$  is tyrosine in at least one of said zinc finger domains;  $Z^6$  is leucine in at least one of said zinc finger domains; and/or  $Z^2$  is aspartic acid in at least one of said zinc finger domains, but  $Z^1$  is not arginine  
5 in the same domain.

The ZFPs of the invention also include the 23 groups of proteins as indicated in Table 3. Groups 1-11 represent proteins that bind the following classes of nucleotide target sequences GGAM, GGTW, GGCN, GAGW, GATM, GACD, GTGW, GTAM, GTTR, GCTN and GCCD, respectively, wherein D is G, A or T; M is G or T; R is G or A; W is A  
10 or T; and N is any nucleotide. The proteins of Groups 12-23 are generally represented by the formulas AGNN, AANN, ATNN, ACNN, TGNN, TANN, TTNN, TCNN, CGNN, CANN, CTNN, and CCNN, where N, however, does not represent any nucleotide but rather represents the nucleotides for the proteins designated as belonging to the group as set forth in Table 3.

15 Other aspects of the invention provide isolated nucleic acids encoding the ZFPs of the invention, expression vectors comprising those nucleic acids, and host cells transformed (by any method) with the expression vectors. Among other uses, such host cells can be used in a method of preparing a ZFP by culturing the host cell for a time and under conditions to express the ZFP; and recovering the ZFP.

20 Yet another aspect of the invention is directed to fusion proteins having a first segment which is a ZFP of the invention, and a second segment comprising a transposase, integrase, recombinase, resolvase, invertase, protease, DNA methyltransferase, DNA demethylase, histone acetylase, histone deacetylase, nuclease, transcriptional repressor, transcriptional activator, a single-stranded DNA binding protein, a nuclear-localization  
25 signal, a transcription-protein recruiting protein or a cellular uptake domain. In an alternative embodiment, the second segments can comprise a protein domain which exhibits transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear localization  
30 activity, transcriptional protein recruiting activity, transcriptional repressor activity or transcriptional activator activity.

Still another aspect of the invention relates to fusion proteins which comprise a first segment which is a ZFP of the invention and a second segment comprising a protein domain capable of specifically binding to a first moiety of a divalent ligand capable of uptake by a cell. Those protein domains include but are not limited to S-protein, and S-tag, antigens, haptens and/or a single chain variable region (scFv) of an antibody. Another class of fusion proteins includes those comprising a first domain encoding single chain variable region of an antibody; a second domain enclosing a nuclear localization signal; and a third domain encoding transcriptional regulatory activity.

In addition, the invention provides isolated nucleic acids encoding any of the fusion proteins of the invention, expression vectors comprising those nucleic acids, and host cells transformed (by any method) with the expression vectors. Among other uses, such host cells can be used in a method of preparing the fusion protein by culturing the host cell for a time and under conditions to express the fusion protein; and recovering the fusion protein.

A still further aspect of the invention relates to a method of binding a target nucleic acid with artificial ZFP which comprises contacting a target nucleic acid with a ZFP of the invention or a ZFP designed in accordance with the invention in an amount and for a time sufficient for said ZFP to bind to said target nucleic acid. In a preferred embodiment the ZFP is introduced into a cell via a nucleic acid encoding said ZFP.

A yet further aspect of the invention provides a method of modulating expression of a gene which comprises contacting a regulatory control element of said gene with a ZFP of the invention or a ZFP designed in accordance with the invention in an amount and for a time sufficient for said ZFP to alter expression of said gene. Modulating gene expression includes both activation and repression of the gene of interest and, in one embodiment, can be done by introducing the ZFP into a cell via a nucleic acid encoding ZFP.

Another aspect of the invention relates to a method of modulating expression of a gene which comprises contacting a target nucleic acid in sufficient proximity to said gene with a fusion protein of a ZFP of the invention or a ZFP designed in accordance with the invention fused to a transcriptional regulatory domain, wherein said fusion protein contacts said nucleic acid in an amount and for a time sufficient for said transcriptional regulatory domain to alter expression of said gene. Modulating gene expression includes both activation and repression of the gene of interest and, in one embodiment, can be done by



introducing the desired fusion protein into a cell via a nucleic acid encoding that fusion protein.

Yet another aspect of the invention provides a method of altering genomic structure which comprises contacting a target genomic site with a fusion protein of a ZFP of the invention or a ZFP designed in accordance with the invention fused to a protein domain which exhibits transposase activity, integrase activity, recombinase activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity or endonuclease activity, wherein the fusion protein contacts the target genomic site in an amount and for a time sufficient to alter genomic structure in or near said site. The fusion protein can also be introduced into the cell via a nucleic acid if desired.

Still another aspect of the inventions provides a method of inhibiting viral replication by introducing into a cell a nucleic acid encoding a ZFP of the invention or a ZFP designed in accordance with the invention, wherein said ZFP is competent to bind to a target site required for viral replication, and obtaining sufficient expression of the ZFP in the cell to inhibit viral replication. In one embodiment the fusion protein has a single-stranded DNA binding protein domain

Still another aspect of the invention provides a method of modulating expression of a gene by contacting a eukaryotic cell with a divalent ligand capable of uptake by the cell and having a first and second switch moiety of different specificity, wherein said cell contains

(i) a first nucleic acid expressing a first fusion protein of a ZFP of the invention or a ZFP designed in accordance with the invention specific for a target site in proximity to said gene fused to a protein domain capable of specifically binding said first switch moiety, and

(ii) a second nucleic acid expressing a second fusion protein comprising a first domain capable of specifically binding said second switch moiety, a second domain which is a nuclear localization signal and a third domain which is a transcriptional regulatory domain;

allowing said cell sufficient time to form a tertiary complex comprising said divalent ligand, said first fusion protein and said second fusion protein, to translocate said complex into the nucleus of said cell, to bind to said target site and to thereby allow said transcriptional

regulatory domain to alter expression of said gene. Modulating gene expression includes both activation and repression of the gene of interest.

The protein domain capable of specifically binding the first switch moiety can be an S-protein, and S-tag or a single chain variable region (scFv) of an antibody or any  
5 derivative of these that so that binding of the respective partners can be modulated by a small molecule. The first switch moiety can be, as appropriately selected, an S-protein, an S-tag or an antigen for a single chain variable region (scFv) of an antibody. Similarly, as appropriately selected the domain capable of specifically binding the second switch moiety can be an S-protein, and S-tag or a single chain variable region (scFv) of an antibody and  
10 the second switch moiety can be an S-protein, an S-tag or an antigen for a single chain variable region (scFv) of an antibody.

A further aspect of the invention relates to artificial transposases comprising a catalytic domain, a peptide dimerization domain and a ZFP domain which is a ZFP of the invention or a ZFP designed in accordance with the invention. The transposase can also  
15 comprise a terminal inverted repeat binding domain.


Another aspect of the invention provides a method of target-specific introduction of an exogenous gene into the genome of an organism by (a) introducing into a cell a first nucleic acid encoding a transposase of the invention, wherein the ZFP domain of that transposase binds a first target; a second nucleic acid encoding a second transposase of the  
20 invention, wherein the ZFP domain of that transposase binds a second target; and a third nucleic acid encoding the exogenous gene flanked by sequences capable of being bound by the terminal inverted repeat binding domain of the two transposases; and (b) forming a complex among the genome, the third nucleic acid, and the two transposases sufficient for recombination to occur and thereby introduce the exogenous gene into the genome of the  
25 organism recombination. The first and second targets can be the same or different.

Another aspect of the invention provides a method of target-specific excision an endogenous gene from the genome of an organism by (a) introducing into a cell a first nucleic acid encoding a transposase of the invention, wherein the ZFP domain binds a first target; a second nucleic acid encoding a second transposase of the invention, wherein the  
30 ZFP domain binds a second target; and wherein the endogenous gene is flanked by sequences capable of being bound said ZFP domains of said transposases; and (b) forming a complex among the genome and the two transposases sufficient for recombination to occur

and thereby excise the endogenous gene from the genome of the organism. The first and second targets can be the same or different.

Still a further aspect of the invention relates to diagnostic methods of using a ZFP of the invention or a ZFP designed in accordance with the invention. In one embodiment, a method for detecting an altered zinc finger recognition sequence which comprises (a) contacting a nucleic acid containing the zinc finger recognition sequence of interest with a ZFP of the invention or a ZFP designed in accordance with the invention specific for the recognition sequence, the ZFP conjugated to a signaling moiety and present in an amount sufficient to allow binding of the ZFP to the recognition sequence if said sequence was unaltered; and (b) detecting whether binding of the ZFP to the recognition sequence occurs to thereby ascertain that the recognition sequence is altered if the binding is diminished or abolished relative to binding of the ZFP to the unaltered sequence. Any detection or signaling moiety can be used including, but not limited to, a dye, biotin, streptavidin, a radioisotope and the like or a marker protein such as AP,  $\beta$ -gal, GUS, HRP, GFP, luciferase, and the like. The method can detect altered zinc finger recognition site with a substitution, insertion or deletion of one or more nucleotides in its sequence. In a preferred embodiment the method is used to detect single nucleotide polymorphisms (SNPs).


Yet a further aspect of the invention provides a set of 256 separate or individually-packaged oligonucleotides, each oligonucleotide comprising a nucleotide sequence encoding one of the 256 zinc finger domains represented by the formula



wherein X is any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain;  $Z^1$  is arginine, glutamine, threonine, or glutamic acid;  $Z^2$  is serine, asparagine, threonine or aspartic acid;  $Z^3$  is histidine, asparagine, serine or aspartic acid; and  $Z^6$  is arginine, glutamine, threonine, or glutamic acid. In a preferred embodiment, each X at a given position in the formula is the same in each of the 256 zinc finger domains and can be from a known zinc finger framework. The codon usage in the oligonucleotides can be also be optimized for any desired organism for which such information is available, such as, but not limited to human, mouse, rice, and *E. coli*.

In addition the invention provides a set of oligonucleotides for producing nucleic acid encoding ZFPs having three or more zinc finger domains, the set having three subsets of 256 separate or individually-packaged oligonucleotides, each oligonucleotide comprising

a nucleotide sequence encoding one of the 256 zinc finger domains represented by the formula



wherein X is any amino acid and  $X_n$  represents the number of occurrences of X in the

polypeptide chain;  $Z^1$  is arginine, glutamine, threonine, or glutamic acid;  $Z^2$  is serine,

asparagine, threonine or aspartic acid;  $Z^3$  is histidine, asparagine, serine or aspartic acid;

and  $Z^6$  is arginine, glutamine, threonine, or glutamic acid; and wherein the 3' end of the

first set oligonucleotides are sufficiently complementary to the 5' end of the second set

oligonucleotides to prime synthesis of said second set oligonucleotides therefrom, the 3'

end of the second set oligonucleotides are sufficiently complementary to the 5' end of the

third set oligonucleotides to prime synthesis of said third set oligonucleotides therefrom,

the 3' end of the first set oligonucleotides are not complementary to the 5' end of the third

set oligonucleotides, and the 3' end of the second set oligonucleotides are not

complementary to the 5' end of the first set oligonucleotides.

In a preferred embodiment of the above paragraph, each X at a given position in the

formula is the same in one, two or three of the subsets of the 256 zinc finger domains and

can be from a known zinc finger framework. The codon usage in the oligonucleotides can

be also be optimized for any desired organism for which such information is available, such

as, but not limited to human, mouse, cereal plants, tomato, corn, rice, and *E. coli*. Further,

any of the above sets can be provided in kit form and include other components that enable


one to readily practice the methods of the invention.

Another aspect of the invention relates to single-stranded or double-stranded

oligonucleotide encoding a zinc finger domain for an artificial ZFP, said oligonucleotide

being from about 84 to about 130 bases and comprising a nucleotide sequence encoding a

each zinc finger domain independently represented by the formula



and, optionally, a linker of from 0 to 10 amino acid residues; wherein X is any amino acid

and  $X_n$  represents the number of occurrences of X in the polypeptide chain;  $Z^1$  is arginine,

glutamine, threonine, methionine or glutamic acid;  $Z^2$  is serine, asparagine, threonine or

aspartic acid;  $Z^3$  is histidine, asparagine, serine or aspartic acid; and  $Z^6$  is arginine,

glutamine, threonine, tyrosine, leucine or glutamic acid.

### Brief Description of the Drawings

Figure 1 is a schematic diagram showing the binding of one unit of a zinc finger domain to a 4 base pair DNA target site. The residues at positions -1, 2, 3 and 6 each independently contact one base. Position 1 is the start of the  $\alpha$ -helix in a zinc finger domain.

Figure 2 shows known and possible base interactions with amino acids. Interactions similar to those shown between guanine and histidine can be made with other amino acids that donate hydrogen bonds (serine and lysine). Interactions similar to those shown between thymidine and threonine can be made with other hydrophobic amino acids. Interactions similar to those shown and between thymidine and threonine/serine can be made with other amino acids that donate hydrogen bonds.

Figure 3 shows the recognition of the 4<sup>th</sup> base in a 4 base pair DNA target sequence by amino acids at position 2 of a zinc finger domain.

Figure 4 is a schematic diagram of a wild type transposase (left) and engineered (artificial) transposase (right).

Figure 5 is a schematic diagram depicting methods for performing site-specific genomic knock-outs and knock-ins using ZFPs.

Figure 6 is a schematic diagram showing molecular switch methods for manipulating translocation of ZFPs into the nucleus using small molecules.

Figure 7 is a schematic diagram showing the design of a ZFP targeting the AL1 binding site in Tomato Golden Mosaic Virus. The AL1 target site is SEQ ID NO: 14; Zif1 is SEQ ID NO: 15; Zif2 is SEQ ID NO: 16; and Zif3 is SEQ ID NO: 17. Zif is zinc finger domain.

Figure 8 is depicts bar graphs showing DNA base selectivities of the Asp (left) and Gly (right) mutants at position 2 of the zinc finger domain shown.

Figure 9 is a schematic diagram showing transposition of a kanamycin resistance gene (Kan<sup>R</sup>) from a donor vector into a target sequence in an acceptor vector.

Figure 10 is a schematic diagram illustrating assembly of 6-finger ZFPs.

### I. Recognition Code and Design Methods

The present invention provides a context-independent recognition code by which zinc finger domains contact bases on a target polynucleotide sequence. This recognition

code allows the design of ZFPs which can target any desired nucleotide sequence with high affinity. Previous recognition data is largely context-dependent and was generated by the use of phage display methods and targeting of three base pair sequences (Beeril et al., *Biochemistry* 95:14631, 1998; Wu et al. *Biochemistry* 92:345, 1995; Berg et al., *Nature Struct. Biol.* 3:941, 1996). Berg et al. used three zinc finger domains in which the first and second were same, and the third was different than the first and second. Wu et al. (Proc. Natl. Acad. Sci. USA, 92, 344-348 (1995) and Beerli et al. (Proc. Natl. Acad. Sci. USA, 95, 14628-14633 (1998) used three zinc finger domains (Zif268) in which each of the three fingers was different. The present invention relates, *inter alia*, to an exactly repeating finger/frame block in that the same frame, and optionally the same finger region, is repeated. One advantage of repeating the same frame is that each zinc finger domain recognizes 4 base pairs regularly, which results in higher affinity targeting for ZFPs comprising multiple zinc finger domains, particularly when more than three domains (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12 domains or more, even up to 30 domains) are present.

Four nucleic acid-contacting residues in zinc finger domains are primarily responsible for determining specificity and affinity and occur in the same position relative to the first consensus histidine and second consensus cysteine. The first residue is seven residues to the N-terminal side of the first consensus histidine and six residues to the C-terminal side of the second consensus cysteine. This is hereinafter referred to as the “-1 position.” The other three amino acids are two, three and six residues removed from the C-terminus of the residue at position -1, and are referred to as the “2 position”, “3 position” and “6 position”, respectively. These positions are interchangeably referred to as the  $Z^{-1}$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$  positions. These amino acid residues are referred to as the base-contacting amino acids. Position 1 is the start of the  $\alpha$ -helix in a zinc finger domain. The location of amino acid positions -1, 2, 3 and 6 in a zinc finger domain, and the bases they contact in a 4 base pair DNA target sequence, are shown schematically in Fig. 1.

A zinc finger-nucleic acid recognition code is shown in Table 1 and is based on known and possible base-amino acid interactions (Fig. 2). Some interactions listed in Fig. 2 are also identified in different proteins such as H-T-4 protein, *cro* and the  $\lambda$  repressor. For recognition of the first and third DNA bases in a four base pair region, amino acids containing longer side chains were chosen. For recognition of the second and fourth bases, amino acids containing shorter side chains were chosen. For example, in the case of

guanine base recognition, arginine was chosen as an amino acid at positions -1 and 6, histidine was chosen as an amino acid at position 3 and serine was chosen as an amino acid at position 2. In all of the amino acids shown in Table 1, there is stable interaction with specific DNA bases by hydrogen bonding. In the case of thymidine base recognition, amino acid having hydrophobic side chains were also chosen (i.e., leucine for first thymidine base and methionine for third thymidine base). Other DNA base-amino acid interaction is possible; however, amino acids with the highest affinity were chosen. For example, although lysine binds to guanine, arginine was chosen because of additional hydrogen bonding.

Table 1

	1 <sup>st</sup> base	2 <sup>nd</sup> base	3 <sup>rd</sup> base	4 <sup>th</sup> base
G	Arg	His	Arg	Ser
A	Gln	Asn	Gln	Asn
T	Thr, Tyr, Leu	Ser	Thr, Met	Thr
C	Glu	Asp	Glu	Asp
	Position 6	Position 3	Position -1	Position 2

The recognition of the fourth base in a 4 base pair DNA sequence (1<sup>st</sup> base of a neighboring 3' triplet DNA) by amino acids at position 2 is shown in Fig. 3. Asp, Thr, Asn and Ser at position 2 of a zinc finger domain preferentially bind to C, T, A, and G, respectively. The fourth base is in the anti-sense nucleic acid strand.

In Table 1 (and for each 4 base-pair portion of a target sequence), the bases are always provided in 5' to 3' order. The fourth base listed in the table, however, is always the complement of the fourth base provided in the target sequence. For example, if the target sequence is written as ATCC, then it means a sense strand target sequence of 5'-ATCC-3' and an antisense strand of 3'-TAGG-5'. Thus, when the sense strand sequence ATCC is translated to amino acids from the table above, the first base of A means there is glutamine at position 6, the second base of T means there is serine at position 3 and the third base of C means there is glutamic acid at position -1. However, with the fourth base written as C, it means that it is the complement of C, i.e., G, which is found in the table and

used to identify the amino acid of position 2. In this case, the amino acid at position two is serine.


The present invention also includes a preferred recognition code table, where  $Z^6$  is threonine if the first base is T and where  $Z^1$  is threonine if the third base is T. In addition, the invention includes a recognition code table enlarged to generally provide additional conservative amino acids for those present in the recognition code of Table 1. This broader recognition code is below provided in Table 2. In Table 2, the order of amino acids listed in each box represents, from left to right, the most preferred to least preferred amino acid at that position.

Table 2

	1 <sup>st</sup> base	2 <sup>nd</sup> base	3 <sup>rd</sup> base	4 <sup>th</sup> base
G	Arg, Lys	His, Lys	Arg, Lys	Ser, Arg
A	Gln, Asn	Asn, Gln	Gln, Asn	Asn, Gln
T	Thr, Tyr, Leu, Ile, Met	Ser, Ala, Met	Thr, Met, Leu, Ile	Thr, Val, Ala
C	Glu, Asp	Asp, Glu	Glu, Asp	Asp, Glu
	Position 6	Position 3	Position -1	Position 2

The present invention makes it possible to quickly design ZFPs targeting all possible DNA base pairs by choosing 4 amino acids per zinc finger domain from the recognition code table and by combining each domain. Such a complete recognition code table does not currently exist. By using the recognition code of the present invention, it is not necessary to select all possible mutants by repeating time-consuming selection like in a phage display system. By including amino acids at position 2 in the design, it becomes feasible to make ZFPs with higher affinity and DNA sequence selectivity because four, instead of three, base pairs are targeted. Current approaches to designing ZFPs using phage target or consider only three base pairs. The present invention provides ZFPs with increases in both specificity and binding affinity.

Thus the present invention provides methods of designing zinc finger domains. A single zinc finger domain represented by the formula





wherein X is any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain, can be designed by identifying a target nucleic acid sequence of four bases; determining the identity of each X, and determining the identity of the amino acids at positions  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$  in the domain using the recognition code of Table 1, Table 2 or the preferred embodiment of Table 1. Once a zinc finger domain is designed, that domain can be included as all or part of any polypeptide chain. For example, the designed domain can be a single finger of a multi-fingered ZFP. That designed domain could also occur more than one time in a ZFP, and be contiguous with or separated from the other zinc finger domains designed in accordance with the invention. The zinc finger domain designed in accordance with the invention can also be included as a domain in non-ZFP proteins or as a domain in fusion proteins of any type. Preferably the designed domain is used to prepare a ZFP comprising that domain.

The framework determined by the identity of X can be a known zinc finger framework, a consensus framework or an alteration of any one of these frameworks provided that the altered framework maintains the overall structure of zinc finger domain. Preferred frameworks are those from Sp1C and Zif268. A more preferred framework is domain 2 from Sp1C.

The proteins containing the designed zinc finger domain can be prepared either synthetically or recombinantly, preferably recombinantly, using any of the multitude of techniques well-known in the art. When the proteins are prepared recombinantly, *e.g.*, via a DNA encoding the ZFP, the codon usage can be optimized for high expression in the organism in which that ZFP is to be expressed. Such organisms include bacteria, fungi, yeast, animals, insects and plants. More specifically the organisms, include but are not limited to, human, mouse, *E. coli*, cereal plants, rice, tomato and corn.

To design a multi-domained (*i.e.*, a multi-fingered) ZFP, the above method for designing a single domain can be followed, especially if the domains are not contiguous. However, for ZFPs with multiple contiguous domains (or domains separated by linkers as provided herein) for target sequences greater than 4 bases pairs, it has been discovered that ZFPs designed by dividing the target sequence into overlapping 4 base pair segments provides a context-independent zinc finger recognition code from which to produce ZFPs, and typically, ZFPs with high binding affinity, especially when there are more than three zinc finger domains in the ZFP.

In this method, the target sequence has a length of  $3N+1$  base pairs, wherein  $N$  is the number of overlapping 4 base pair segments in the target and is determined by dividing the target sequence into overlapping 4 base pair segments, where the fourth base of each segment, up to the  $N-1$  segment, is the first base of the immediately following segment.

- 5 The remainder of the design method for each 4 base pair segment follows that of a single domain with respect to determining the identities of each  $X$ ,  $Z^{-1}$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$ . This method is useful for designing ZFPs having from 3 to 15 domains (i.e.,  $N$  is any number from 3 to 15), and more preferably from 3 to 12 domains, from 3 to 9 domains or from 3 to 6 domains. Since ZFPs with more than 40 domains are known in the art, if desired,  $N$  can  
10 range to at least 40, if not more.

- The zinc finger domains designed in accordance with this invention are either covalently joined directly one to another or can be separated by a linker region of from 1-10 amino acids. The linker amino acids can provide flexibility or some degree of structural rigidity. The choice of linker can be, but is not necessarily, dictated by the desired affinity  
15 of the ZFP for its cognate target sequence. It is within the skill of the art to test and optimize various linker sequences to improve the binding affinity of the ZFP for its cognate target sequence. Methods of measuring binding affinity between ZFPs and their targets are well known. Typically gel shift assays are used. In one embodiment, the amino acid linker is preferably be flexible to allow each three finger domain to independently bind to its target  
20 sequence and avoid steric hindrance of each other's binding.

- The recognition code table has four amino acid positions and there are four different bases that each amino acid could target. The total number of different four base pair targets is represented by  $4^4$  or 256. Using the preferred choices from the recognition code of Table 1, the combinations of amino acids for positions -1, 2, 3 and 6 in a zinc finger  
25 domain are provided in Table 3 for all possible 4 base pair target sequences.

**Table 3**

**256 Zinc-Finger Domains for Preferred Recognition Code of Table 1**

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
1	GGGG	Arg	Asp	His	Arg	
2	GGGA	Arg	Thr	His	Arg	
3	GGGT	Arg	Asn	His	Arg	

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
4	GGGC	Arg	Ser	His	Arg	
5	GGAG	Gln	Asp	His	Arg	1
6	GGAA	Gln	Thr	His	Arg	
7	GGAT	Gln	Asn	His	Arg	1
8	GGAC	Gln	Ser	His	Arg	
9	GGTG	Thr	Asp	His	Arg	
10	GGTA	Thr	Thr	His	Arg	2
11	GGTT	Thr	Asn	His	Arg	2
12	GGTC	Thr	Ser	His	Arg	
13	GGCG	Glu	Asp	His	Arg	3
14	GGCA	Glu	Thr	His	Arg	3
15	GGCT	Glu	Asn	His	Arg	3
16	GGCC	Glu	Ser	His	Arg	3
17	GAGG	Arg	Asp	Asn	Arg	
18	GAGA	Arg	Thr	Asn	Arg	4
19	GAGT	Arg	Asn	Asn	Arg	4
20	GAGC	Arg	Ser	Asn	Arg	
21	GAAG	Gln	Asp	Asn	Arg	
22	GAAA	Gln	Thr	Asn	Arg	
23	GAAT	Gln	Asn	Asn	Arg	
24	GAAC	Gln	Ser	Asn	Arg	
25	GATG	Thr	Asp	Asn	Arg	5
26	GATA	Thr	Thr	Asn	Arg	
27	GATT	Thr	Asn	Asn	Arg	5
28	GATC	Thr	Ser	Asn	Arg	
29	GACG	Glu	Asp	Asn	Arg	6
30	GACA	Glu	Thr	Asn	Arg	6
31	GACT	Glu	Asn	Asn	Arg	6
32	GACC	Glu	Ser	Asn	Arg	
33	GTGG	Arg	Asp	Ser	Arg	

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
34	GTGA	Arg	Thr	Ser	Arg	7
35	GTGT	Arg	Asn	Ser	Arg	7
36	GTGC	Arg	Ser	Ser	Arg	
37	GTAG	Gln	Asp	Ser	Arg	8
38	GTAA	Gln	Thr	Ser	Arg	
39	GTAT	Gln	Asn	Ser	Arg	8
40	GTAC	Gln	Ser	Ser	Arg	
41	GTTG	Thr	Asp	Ser	Arg	9
42	GTTA	Thr	Thr	Ser	Arg	9
43	GTTT	Thr	Asn	Ser	Arg	
44	GTTC	Thr	Ser	Ser	Arg	
45	GTCG	Glu	Asp	Ser	Arg	
46	GTCA	Glu	Thr	Ser	Arg	
47	GTCT	Glu	Asn	Ser	Arg	
48	GTCC	Glu	Ser	Ser	Arg	
49	GCGG	Arg	Asp	Asp	Arg	
50	GCGA	Arg	Thr	Asp	Arg	
51	GCGT	Arg	Asn	Asp	Arg	
52	GCGC	Arg	Ser	Asp	Arg	
53	GCAG	Gln	Asp	Asp	Arg	
54	GCAA	Gln	Thr	Asp	Arg	
55	GCAT	Gln	Asn	Asp	Arg	
56	GCAC	Gln	Ser	Asp	Arg	
57	GCTG	Thr	Asp	Asp	Arg	10
58	GCTA	Thr	Thr	Asp	Arg	10
59	GCTT	Thr	Asn	Asp	Arg	10
60	GCTC	Thr	Ser	Asp	Arg	10
61	GCCG	Glu	Asp	Asp	Arg	11
62	GCCA	Glu	Thr	Asp	Arg	11
63	GCCT	Glu	Asn	Asp	Arg	11

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
64	GCCC	Glu	Ser	Asp	Arg	
65	AGGG	Arg	Asp	His	Gln	
66	AGGA	Arg	Thr	His	Gln	12
67	AGGT	Arg	Asn	His	Gln	12
68	AGGC	Arg	Ser	His	Gln	
69	AGAG	Gln	Asp	His	Gln	12
70	AGAA	Gln	Thr	His	Gln	
71	AGAT	Gln	Asn	His	Gln	12
72	AGAC	Gln	Ser	His	Gln	
73	AGTG	Thr	Asp	His	Gln	12
74	AGTA	Thr	Thr	His	Gln	12
75	AGTT	Thr	Asn	His	Gln	12
76	AGTC	Thr	Ser	His	Gln	12
77	AGCG	Glu	Asp	His	Gln	12
78	AGCA	Glu	Thr	His	Gln	12
79	AGCT	Glu	Asn	His	Gln	12
80	AGCC	Glu	Ser	His	Gln	12
81	AAGG	Arg	Asp	Asn	Gln	
82	AAGA	Arg	Thr	Asn	Gln	13
83	AAGT	Arg	Asn	Asn	Gln	13
84	AAGC	Arg	Ser	Asn	Gln	
85	AAAG	Gln	Asp	Asn	Gln	13
86	AAAA	Gln	Thr	Asn	Gln	13
87	AAAT	Gln	Asn	Asn	Gln	13
88	AAAC	Gln	Ser	Asn	Gln	
89	AATG	Thr	Asp	Asn	Gln	13
90	AATA	Thr	Thr	Asn	Gln	13
91	AATT	Thr	Asn	Asn	Gln	13
92	AATC	Thr	Ser	Asn	Gln	13
93	AACG	Glu	Asp	Asn	Gln	13

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
94	AACA	Glu	Thr	Asn	Gln	13
95	AACT	Glu	Asn	Asn	Gln	
96	AACC	Glu	Ser	Asn	Gln	13
97	ATGG	Arg	Asp	Ser	Gln	14
98	ATGA	Arg	Thr	Ser	Gln	14
99	ATGT	Arg	Asn	Ser	Gln	14
100	ATGC	Arg	Ser	Ser	Gln	
101	ATAG	Gln	Asp	Ser	Gln	14
102	ATAA	Gln	Thr	Ser	Gln	14
103	ATAT	Gln	Asn	Ser	Gln	14
104	ATAC	Gln	Ser	Ser	Gln	
105	ATTG	Thr	Asp	Ser	Gln	14
106	ATTA	Thr	Thr	Ser	Gln	14
107	ATTT	Thr	Asn	Ser	Gln	14
108	ATTC	Thr	Ser	Ser	Gln	14
109	ATCG	Glu	Asp	Ser	Gln	14
110	ATCA	Glu	Thr	Ser	Gln	14
111	ATCT	Glu	Asn	Ser	Gln	14
112	ATCC	Glu	Ser	Ser	Gln	14
113	ACGG	Arg	Asp	Asp	Gln	15
114	ACGA	Arg	Thr	Asp	Gln	
115	ACGT	Arg	Asn	Asp	Gln	15
116	ACGC	Arg	Ser	Asp	Gln	15
117	ACAG	Gln	Asp	Asp	Gln	15
118	ACAA	Gln	Thr	Asp	Gln	15
119	ACAT	Gln	Asn	Asp	Gln	15
120	ACAC	Gln	Ser	Asp	Gln	15
121	ACTG	Thr	Asp	Asp	Gln	15
122	ACTA	Thr	Thr	Asp	Gln	15
123	ACTT	Thr	Asn	Asp	Gln	15

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
124	ACTC	Thr	Ser	Asp	Gln	15
125	ACCG	Glu	Asp	Asp	Gln	15
126	ACCA	Glu	Thr	Asp	Gln	15
127	ACCT	Glu	Asn	Asp	Gln	15
128	ACCC	Glu	Ser	Asp	Gln	15
129	TGGG	Arg	Asp	His	Thr	
130	TGGA	Arg	Thr	His	Thr	
131	TGGT	Arg	Asn	His	Thr	
132	TGGC	Arg	Ser	His	Thr	
133	TGAG	Gln	Asp	His	Thr	16
134	TGAA	Gln	Thr	His	Thr	16
135	TGAT	Gln	Asn	His	Thr	16
136	TGAC	Gln	Ser	His	Thr	
137	TGTG	Thr	Asp	His	Thr	16
138	TGTA	Thr	Thr	His	Thr	16
139	TGTT	Thr	Asn	His	Thr	16
140	TGTC	Thr	Ser	His	Thr	16
141	TGCG	Glu	Asp	His	Thr	16
142	TGCA	Glu	Thr	His	Thr	16
143	TGCT	Glu	Asn	His	Thr	16
144	TGCC	Glu	Ser	His	Thr	16
145	TAGG	Arg	Asp	Asn	Thr	17
146	TAGA	Arg	Thr	Asn	Thr	17
147	TAGT	Arg	Asn	Asn	Thr	17
148	TAGC	Arg	Ser	Asn	Thr	
149	TAAG	Gln	Asp	Asn	Thr	
150	TAAA	Gln	Thr	Asn	Thr	
151	TAAT	Gln	Asn	Asn	Thr	
152	TAAC	Gln	Ser	Asn	Thr	
153	TATG	Thr	Asp	Asn	Thr	17

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
154	TATA	Thr	Thr	Asn	Thr	17
155	TATT	Thr	Asn	Asn	Thr	17
156	TATC	Thr	Ser	Asn	Thr	17
157	TACG	Glu	Asp	Asn	Thr	17
158	TACA	Glu	Thr	Asn	Thr	17
159	TACT	Glu	Asn	Asn	Thr	17
160	TACC	Glu	Ser	Asn	Thr	17
161	TTGG	Arg	Asp	Ser	Thr	18
162	TTGA	Arg	Thr	Ser	Thr	18
163	TTGT	Arg	Asn	Ser	Thr	18
164	TTGC	Arg	Ser	Ser	Thr	
165	TTAG	Gln	Asp	Ser	Thr	18
166	TTAA	Gln	Thr	Ser	Thr	18
167	TTAT	Gln	Asn	Ser	Thr	18
168	TTAC	Gln	Ser	Ser	Thr	
169	TTTG	Thr	Asp	Ser	Thr	18
170	TTTA	Thr	Thr	Ser	Thr	18
171	TTTT	Thr	Asn	Ser	Thr	18
172	TTTC	Thr	Ser	Ser	Thr	18
173	TTCG	Glu	Asp	Ser	Thr	18
174	TTCA	Glu	Thr	Ser	Thr	18
175	TTCT	Glu	Asn	Ser	Thr	18
176	TTCC	Glu	Ser	Ser	Thr	18
177	TCGG	Arg	Asp	Asp	Thr	
178	TCGA	Arg	Thr	Asp	Thr	
179	TCGT	Arg	Asn	Asp	Thr	
180	TCGC	Arg	Ser	Asp	Thr	
181	TCAG	Gln	Asp	Asp	Thr	19
182	TCAA	Gln	Thr	Asp	Thr	19
183	TCAT	Gln	Asn	Asp	Thr	19



No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
184	TCAC	Gln	Ser	Asp	Thr	19
185	TCTG	Thr	Asp	Asp	Thr	19
186	TCTA	Thr	Thr	Asp	Thr	19
187	TCTT	Thr	Asn	Asp	Thr	19
188	TCTC	Thr	Ser	Asp	Thr	19
189	TCCG	Glu	Asp	Asp	Thr	19
190	TCCA	Glu	Thr	Asp	Thr	19
191	TCCT	Glu	Asn	Asp	Thr	19
192	TCCC	Glu	Ser	Asp	Thr	19
193	CGGG	Arg	Asp	His	Glu	20
194	CGGA	Arg	Thr	His	Glu	
195	CGGT	Arg	Asn	His	Glu	20
196	CGGC	Arg	Ser	His	Glu	
197	CGAG	Gln	Asp	His	Glu	20
198	CGAA	Gln	Thr	His	Glu	20
199	CGAT	Gln	Asn	His	Glu	20
200	CGAC	Gln	Ser	His	Glu	
201	CGTG	Thr	Asp	His	Glu	20
202	CGTA	Thr	Thr	His	Glu	20
203	CGTT	Thr	Asn	His	Glu	20
204	CGTC	Thr	Ser	His	Glu	20
205	CGCG	Glu	Asp	His	Glu	20
206	CGCA	Glu	Thr	His	Glu	20
207	CGCT	Glu	Asn	His	Glu	20
208	CGCC	Glu	Ser	His	Glu	20
209	CAGG	Arg	Asp	Asn	Glu	
210	CAGA	Arg	Thr	Asn	Glu	21
211	CAGT	Arg	Asn	Asn	Glu	21
212	CAGC	Arg	Ser	Asn	Glu	
213	CAAG	Gln	Asp	Asn	Glu	21

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
214	CAAA	Gln	Thr	Asn	Glu	21
215	CAAT	Gln	Asn	Asn	Glu	21
216	CAAC	Gln	Ser	Asn	Glu	
217	CATG	Thr	Asp	Asn	Glu	21
218	CATA	Thr	Thr	Asn	Glu	21
219	CATT	Thr	Asn	Asn	Glu	21
220	CATC	Thr	Ser	Asn	Glu	21
221	CACG	Glu	Asp	Asn	Glu	21
222	CACA	Glu	Thr	Asn	Glu	21
223	CACT	Glu	Asn	Asn	Glu	21
224	CACC	Glu	Ser	Asn	Glu	21
225	CTGG	Arg	Asp	Ser	Glu	22
226	CTGA	Arg	Thr	Ser	Glu	
227	CTGT	Arg	Asn	Ser	Glu	22
228	CTGC	Arg	Ser	Ser	Glu	
229	CTAG	Gln	Asp	Ser	Glu	22
230	CTAA	Gln	Thr	Ser	Glu	22
231	CTAT	Gln	Asn	Ser	Glu	22
232	CTAC	Gln	Ser	Ser	Glu	
233	CTTG	Thr	Asp	Ser	Glu	22
234	CTTA	Thr	Thr	Ser	Glu	22
235	CTTT	Thr	Asn	Ser	Glu	22
236	CTTC	Thr	Ser	Ser	Glu	22
237	CTCG	Glu	Asp	Ser	Glu	22
238	CTCA	Glu	Thr	Ser	Glu	22
239	CTCT	Glu	Asn	Ser	Glu	22
240	CTCC	Glu	Ser	Ser	Glu	
241	CCGG	Arg	Asp	Asp	Glu	
242	CCGA	Arg	Thr	Asp	Glu	
243	CCGT	Arg	Asn	Asp	Glu	

No.	4-bp Target	Position -1	Position 2	Position 3	Position 6	Group
244	CCGC	Arg	Ser	Asp	Glu	
245	CCAG	Gln	Asp	Asp	Glu	23
246	CCAA	Gln	Thr	Asp	Glu	23
247	CCAT	Gln	Asn	Asp	Glu	23
248	CCAC	Gln	Ser	Asp	Glu	23
249	CCTG	Thr	Asp	Asp	Glu	23
250	CCTA	Thr	Thr	Asp	Glu	23
251	CCTT	Thr	Asn	Asp	Glu	23
252	CCTC	Thr	Ser	Asp	Glu	23
253	CCCG	Glu	Asp	Asp	Glu	23
254	CCCA	Glu	Thr	Asp	Glu	23
255	CCCT	Glu	Asn	Asp	Glu	23
256	CCCC	Glu	Ser	Asp	Glu	23

“Specifically binds” means and includes reference to binding of a zinc-finger-protein-nucleic-acid-binding domain to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 1.5-fold over background) than its binding to non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids.

When a multi-finger ZFP binds to a polynucleotide duplex (e.g. DNA, RNA, peptide nucleic acid (PNA) or any hybrids thereof) its fingers typically line up along the polynucleotide duplex with a periodicity of about one finger per 3 bases of nucleotide sequence. The binding sites of individual zinc fingers (or subsites) typically span three to four bases, and subsites of adjacent fingers usually overlap by one base. Accordingly, a three-finger ZFP XYZ binds to the 10 base pair site **abcdefghij** (where these letters indicate one of the duplex DNA) with the subsite of finger X being ghij, finger Y being defg and finger Z being abcd. The present invention encompasses multi-fingered proteins in which at least three fingers differ from a wild type zinc fingers. It also includes multi-fingered protein in which the amino acid sequence in all the fingers have been changed, including those designed by combinatorial chemistry or other protein design and binding assays but which correspond to a ZFP from the recognition code of Table 1.

It is also possible to design a ZFP to bind to a targeted polynucleotide in which more than four bases have been altered. In this case, more than one finger of the binding protein is altered. For example, in the 10 base sequence XXXdefgXXX, a three-finger binding protein could be designed in which fingers X and Z differ from the corresponding fingers in a wild type zinc finger, while finger Y will have the same polypeptide sequence as the corresponding finger in the wild type fingers which binds to the subsite defg. Binding proteins having more than three fingers can be also designed for base sequences of longer length. For example, a four finger-protein will optimally bind to a 13 base sequence, while a five-finger protein will optimally bind to a 16 base sequence. A multi-finger protein can also be designed in which some of the fingers are not involved in binding to the selected DNA. Slight variations are also possible in the spacing of the fingers and framework.

It has surprisingly been found that good binding can be obtained for ZFPs that target any contiguous 10 bases having at least three guanines (three Gs) in the first nine bases, excluding the last quadruplet of the target. It is also preferred that such targets have two or fewer cytosines.

## II. Artificial ZFPs

The present invention also relates to isolated, artificial ZFPs for binding to target nucleic acid sequences.

By “zinc finger protein”, “zinc finger polypeptide” or “ZFP” is meant a polypeptide having DNA binding domains that are stabilized by zinc and designed in accordance with the present invention with the proviso that the proteins do not include those of SEQ ID NOS: 3-12 (Table 4) or any other ZFP having three or more of the zinc finger domains designed in accordance with the recognition code of Table 1, where those domains are joined with 0 to 10 amino acids. The individual DNA binding domains are typically referred to as “fingers,” such that a ZFP or peptide has at least one finger, more typically two fingers, more preferably three fingers, or even more preferably four or five fingers, to at least six or more fingers. Each finger binds three or four base pairs of DNA. A ZFP binds to a nucleic acid sequence called a target nucleic acid sequence. Each finger usually comprises an approximately 30 amino acid, zinc-chelating, DNA-binding subdomain. A representative motif of one class, the Cys<sub>2</sub>-His<sub>2</sub> class, is -CYS-(X)<sub>2-4</sub>-CYS-(X)<sub>12</sub>-His-(X)<sub>3-5</sub>-His, where X is any amino acid, and a single zinc finger of this class consists of an alpha

helix containing the two invariant histidine residues and the two cysteine residues of a single beta turn (*see, e.g., Berg et al., Science 271:1081-1085 (1996)*) bind a zinc cation.

The ZFPs of the invention include any ZFP having one or more combination of amino acids for positions -1, 2, 3 and 6 as provided by the recognition code in Table 1

(provided that the ZFP is not in the prior art). The 256 4-base pair target sequences of the ZFPs and the corresponding amino acids for positions -1, 2, 3 and 6 are provided in Table 3 for a preferred recognition code table of the invention (namely, that of Table 1, where if the first base is T, then  $Z^6$  is threonine; and if the third base is T, then  $Z^1$  is threonine).

Preferably, a ZFP comprises from 3 to 15, 3 to 12, 3 to 9 or from 3 to 6 domains as well as three, four, five or six zinc finger domains but since ZFPs with up to 40 domains are known, the invention includes such ZFPs.

**Table 4**  
**ZFPs excluded from Claim 1**

SEQ ID. NO.	Search Database Identifier	General Description	Sequence
3	AN AAB07701	Artificial 5 finger protein to modulate gene expression	VPIPGKKKQHICHIQGCGKVYQSSDLQRHL RWHTGERPFMCTWSYCGKRFTRSSNLQRHQR THTGEKKFACPECPKRFMRSDELSRHIKTHQ NKKDGGGSGKKKQHICHIQGCGKVYGTSSNL RRHLRWHTGERPFMCTWSYCGKRFTRSSNLQ RHKRTHTGEKKFACPECPKRFMRSDHLSRHI KTHQNKKGGS
4	AN AAB07699	Artificial 3 finger protein to modulate gene expression	VPIPGKKKQHICHIQGCGKVYGTSSNLRRHL RWHTGERPFMCTWSYCGKRFTRSSNLQRHQR THTGEKKFACPECPKRFMRSDHLSRHIKTHQ NKKGGS
5	RN 160082-26-8	Synthetic zinc finger-containing DNA-binding reduced	MEKLRNGSGDPGKKKQHACPECGKSFSQSSN LQRHQRTHTGEKPYKCPECGKSFSRSSHLQQ HQRTHTGEKPYKCPECGKSFSRSDHLSRHQR THQNKK
6	RN 160082-24-6	Synthetic zinc finger-containing DNA-	MEKLRNGSGDPGKKKQHACPECGKSFSQSSN LQRHQRTHTGEKPYKCPECGKSFSSESSDLQR HQRTHTGEKPYKCPECGKSFSRSDHLSRHQR

SEQ ID. NO.	Search Database Identifier	General Description	Sequence
		binding reduced	THQNKK
7	RN 160082-20-2	Synthetic zinc finger-containing DNA-binding reduced	MEKLRNGSGDPGKKKQHACPECGKSFSQSSN LQRHQRTHTGEKPYKCPECGKSFSRSSHLQE HQRTHTGEKPYKCPECGKSFSRSDHLSRHQ THQNKK
8	RN 160082-18-8	Synthetic zinc finger-containing DNA-binding reduced	MEKLRNGSGDPGKKKQHACPECGKSFSQSSN LQRHQRTHTGEKPYKCPECGKSFSQSSNLQR HQRTHTGEKPYKCPECGKSFSRSDHLSRHQ THQNKK
9	RN 160082-17-7	Synthetic zinc finger-containing DNA-binding reduced	MEKLRNGSGDPGKKKQHACPECGKSFSQSSN LQRHQRTHTGEKPYKCPECGKSFSRSSNLQE HQRTHTGEKPYKCPECGKSFSRSDHLSRHQ THQNKK
10	RN 160082-12-2	Synthetic zinc finger-containing DNA-binding reduced	MEKLRNGSGDPGKKKQHACPECGKSFSQSSN LQRHQRTHTGEKPYKCPECGKSFSQSSDLQR HQRTHTGEKPYKCPECGKSFSRSDHLSRHQ THQNKK
11	RN 149024-80-6	Human clone HKrT1 zinc finger-containing reduced	MRLAKPKAGISRSSSQGKAYENKRKTGRQRE KWGMTIRFDSSFSRLRRSLDDKPYKCTECEK SFSQSSTLFQHQKIHTGKKSHKCADCGKSFF QSSNLIQHRRRIHTGEKPYKCDECGESFKQSS NLIQHQRRIHTGEKPYQCDECGRCFSQSSHLI QHQRTHHTGEKPYQCSECGKCFQSQSSHLRQHM KVHKEEKPRKTRGKNIRVKTHLPSWKAGTEG SLWLVSVKYRAF
12	RN 147447-74-3	Mouse clone pMLZ-4 zinc finger-containing reduced	MSEEPLNAEKNPGSEEAFESGDQAERPWGD LTAEWVSYPLOQVTDLLVHKEAHAGIRYHI CSQCGKAFSQISDLNRHQKTHHTGDRPYKCYE CGKGFSSSHLIQHQRTHHTGERPYDCNECGK SFGRSSSHLIQHQTHTGEKPHKCTEAKASA ASPHLIQHQRTHSGEKPYECEECGKSFSRSS HLAQHQRTHHTGEKPYECHECGRGFSERSDLI KHYRVHTGERPYKCDECGKNFSQNSDLVRHR RAHTGEKPYHCNECGENFSRISHLVQHQRTH

SEQ ID. NO.	Search Database Identifier	General Description	Sequence
			TGEKPYECTACGKSFSRSSHLITHQKIHTGE KPYECNECWRSFGERSDLIKHQRTHTGEKPY ECVQCGKGFTQSSNLITHQRVHTGEKPYECT ECDKSFSRSSALIKHKRVHTD

In an embodiment of the invention, the isolated, artificial ZFPs designed for binding to a target nucleic acid sequence wherein the ZFPs comprising at least three zinc finger domains, each domain independently represented by the formula

5                                $-X_3\text{-Cys-}X_{2-4}\text{-Cys-}X_5\text{-}Z^1\text{-}X\text{-}Z^2\text{-}Z^3\text{-}X_2\text{-}Z^6\text{-His-}X_{3-5}\text{-His-}X_4\text{-}$ ,

and the domains covalently joined to each other with a from 0 to 10 amino acid residues, wherein X is any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain, wherein  $Z^1$ ,  $Z^2$ ,  $Z^3$ , and  $Z^6$  are determined by the recognition code of

Table 1 with the proviso that such proteins are not those provided by any one of SEQ ID

10 NOS 3-12 (Table 4) or any other ZFP having three or more of the zinc finger domains designed in accordance with the recognition code of Table 1, where those domains are

joined with 0 to 10 amino acids.. As above, X represents a framework of a Cys<sub>2</sub>His<sub>2</sub> zinc finger domain and can be a known zinc finger framework, a consensus framework, a framework obtained by varying the sequence any of these frameworks or any artificial

15 framework. Preferably known frameworks are used to determine the identities of each X. The ZFPs of the invention comprise from 3 to 40 zinc finger domains, and preferably from

3 to 15 domains, 3 to 12 domains, 3 to 9 domains or 3 to 6 domains, as well as ZFPs with 3, 4, 5, 6, 7, 8 or 9 domains. In preferred embodiment the framework for determining X is

that from Sp1C or Zif268. In one embodiment, the framework has the sequence of Sp1C domain 2, which sequence is -Pro-Tyr-Lys-Cys-Pro-Glu-Cys-Gly-Lys-Ser-Phe-Ser- $Z^1$ -Ser- $Z^2$ - $Z^3$ -Leu-Gln- $Z^6$ -His-Gln-Arg-Thr-His-Thr-Gly-Glu-Lys- (SEQ ID NO: 13).

20 Additionally preferred ZFPs are those wherein, independently or in any combination,  $Z^1$  is methionine in at least one of said zinc finger domains;  $Z^1$  is glutamic acid in at least one of said zinc finger domains;  $Z^2$  is threonine in at least one of said zinc finger domains;  $Z^2$  is serine in at least one of said zinc finger domains;  $Z^2$  is asparagine in at least one of said zinc finger domains;  $Z^6$  is glutamic acid in at least one of said zinc finger

domains; Z<sup>6</sup> is threonine in at least one of said zinc finger domains; Z<sup>6</sup> is tyrosine in at least one of said zinc finger domains; Z<sup>6</sup> is leucine in at least one of said zinc finger domains and/or Z<sup>2</sup> is aspartic acid in at least one of said zinc finger domains, but Z<sup>-1</sup> is not arginine in the same domain.

5           The ZFPs of the invention also include the 23 groups of proteins as indicated in Table 3. Groups 1-11 represent proteins that bind the following classes of nucleotide target sequences GGAM, GGTW, GGCN, GAGW, GATM, GACD, GTGW, GTAM, GTTR, GCTN and GCCD, respectively, wherein D is G, A or T; M is G or T; R is G or A; W is A or T; and N is any nucleotide. The proteins of Groups 12-23 are generally represented by  
10       the formulas AGNN, AANN, ATNN, ACNN, TGNN, TANN, TTNN, TCNN, CGNN, CANN, CTNN, and CCNN, where N, however, does not represent any nucleotide but rather represents the nucleotides for the proteins designated as belonging to the group as set forth in Table 3.

15           Additional information relating to the ZFPs of the invention is provided throughout the specification.

          Another aspect of the invention provides isolated nucleic acids encoding the ZFPs of the invention, expression vectors comprising those nucleic acids, and host cells transformed (by any method) with the expression vectors. Among other uses, such host cells can be used in a method of preparing a ZFP by culturing the host cell for a time and  
20       under conditions to express the ZFP; and recovering the ZFP. Such embodiments, i.e., nucleic acids, host cells, expression methods are included for any protein designed in accordance with the invention as well as the fusion proteins described below.

### III. Fusion Proteins

25           In one embodiment of the invention, a ZFP fusion protein can comprise at least two DNA-binding domains, one of which is a zinc finger polypeptide, linked to the other domain via a flexible linker. The two domains can be the same or heterologous. In some embodiments of the invention, the ZFP can comprise two or more binding domains. In a preferred embodiment, at least one of these domains is a zinc finger and the other domain is  
30       another DNA binding protein such as a transcriptional activator.



The invention also includes any fusion protein with a ZFP of the invention fused to a protein of interest (POI) or a protein domain having an activity of interest. Such protein domains with a desired activity are also called effector domains.

5 In addition, the invention includes isolated fusion proteins comprising a ZFP of the invention fused to second domain (an effector domain) which is a transposase, integrase, recombinase, resolvase, invertase, protease, DNA methyltransferase, DNA demethylase, histone acetylase, histone deacetylase, nuclease, transcriptional repressor, transcriptional activator, single-stranded DNA binding protein, transcription factor recruiting protein nuclear-localization signal or cellular uptake signal. In an alternative embodiment, the  
10 second domain is a protein domain which exhibits transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear-localization signaling activity, transcriptional repressor activity, transcriptional activator activity, single-stranded DNA binding activity, transcription factor recruiting activity, or cellular uptake signaling activity.  
15

Additional fusion proteins of the invention include a ZFP of the invention fused to a protein domain capable of specifically binding to a binding moiety of a divalent ligand which can be taken up by the cell. Such cellular uptake can be by any mechanism including, but not limited to, active transport, passive transport or diffusion. The protein domain of  
20 these fusion proteins can be an S-protein, an S-tag, an antigen, a hapten or a single chain variable region (scFv), of an antibody.

The invention also includes isolated fusion proteins comprising a first domain encoding a single chain variable region of an antibody; a second domain encoding a nuclear localization signal; and a third domain encoding transcriptional regulatory activity.  
25


#### IV. Modular Assembly Method for Synthesis of Multi-finger ZFPs

A further aspect of the invention relates to providing a rapid, modular method for assembling large numbers of multi-fingered ZFPs from three sets of oligonucleotides encoding the desired individual zinc finger domains. This method thus provides a high  
30 through-put method to produce a DNA encoding a multi-fingered ZFP. In fact, with the use of robotics, the method of the invention can be automated to run parallel assembly of these DNA molecules.

As shown, in Table 3, there are 256 different four base pair targets. If a recognition code, such as the preferred version of Table 1, is used in which a single amino acid can be specified for each four variable domain positions for each of the four nucleotides, then a single unique zinc finger domain can be constructed for each of the 256 target sequences.

Now if these domains are used to create three-finger ZFPs, the number of possible ZFPs can be calculated as  $256^3$  or  $1.68 \times 10^7$ . The present method provides a way of synthesizing all of these ZFPs from 768 oligonucleotides, *i.e.*, three sets of 256 oligonucleotides. In fact, the present method can be adapted such that for each new set of 256 oligonucleotides, every possible ZFP can be made for ZFPs with one more finger.

Hence, for making a nucleic acid encoding a zinc finger protein (ZFP) having three zinc fingers domains, each domain independently represented by the formula



and said domains, independently, covalently joined with from 0 to 10 amino acid residues the method comprises:

(a) preparing a mixture, under conditions for performing a polymerase-chain reaction (PCR), comprising:

- (i) a first double-stranded oligonucleotide encoding a first zinc finger domain,
- (ii) a second double-stranded oligonucleotide encoding a second zinc finger domain,
- (iii) a third double-stranded oligonucleotide encoding a third zinc finger,
- (iv) a first PCR primer complementary to the 5' end of the first oligonucleotide,
- (v) a second PCR primer complementary to the 3' end of the third oligonucleotide,

wherein the 3' end of the first oligonucleotide is sufficiently complementary to the 5' end of the second oligonucleotide to prime synthesis of said second oligonucleotide therefrom, wherein the 3' end of the second oligonucleotide is sufficiently complementary to the 5' end of the third oligonucleotide to prime synthesis of said third oligonucleotide therefrom, and

wherein the 3' end of the first oligonucleotide is not complementary to the 5' end of the third oligonucleotide and the 3' end of the second oligonucleotide is not complementary to the 5' end of the first oligonucleotide;

(b) subjecting the mixture to a PCR; and


5 (c) recovering the nucleic acid encoding the ZFP.

The PCR the reaction is conducted under standard or typical PCR conditions for multiple cycles of heating, annealing and synthesis. The PCR amplification primers preferably include a restriction endonuclease recognition site. Such sites can facilitate cloning or, as described below, assembly of ZFPs with four or more zinc finger domains.

10 Useful restriction enzymes include

BbsI, BsaI, BsmBI, or BspMI, and most preferably BsaI.

To synthesize a nucleic acid encoding a zinc finger protein (ZFP) having four or more zinc fingers domains, each domain independently represented by the formula



15 and said domains, independently, covalently joined with from 0 to 10 amino acid residues, the method comprises:

(a) preparing a first nucleic acid according to the above method, wherein said second PCR primer includes a first restriction endonuclease recognition site;

(b) preparing a second nucleic acid according to the above method, wherein said  
20 first and second PCR primers (in this second synthesis) are complementary to the 5' and 3' ends, respectively, of the number of zinc finger domains selected for amplification, wherein said first PCR primer includes a restriction endonuclease recognition site that, when subjected to cleavage by its corresponding restriction endonuclease, produces an end having a sequence which is complementary to and can anneal to, the end produced when  
25 said second PCR primer of step (a) is subjected to cleavage by its corresponding restriction endonuclease and wherein said second PCR primer of step (b), optionally, includes a second restriction enzyme recognition site that, when subjected to cleavage produces an end that differs from and is not complementary to that produced from the first restriction endonuclease recognition site;

30 (c) optionally, preparing one or more additional nucleic acids by the above method, wherein said first and second PCR primers (of this additional synthesis) are complementary to the 5' and 3' ends, respectively, of the number of zinc finger domains selected for

amplification, wherein said first PCR primer for each additional nucleic acid includes a restriction endonuclease recognition site that, when subjected to cleavage by its corresponding restriction endonuclease, produces an end having a sequence which is complementary to and can anneal to the end produced when the second PCR primer used for preparation of the second nucleic acid, or for the additional nucleic acid that is immediately upstream of the additional nucleic acid, is subjected to cleavage by its corresponding restriction endonuclease, and wherein said second PCR primer for each additional nucleic acid, optionally, includes a restriction endonuclease recognition site that, when subjected to cleavage produces an end that differs from and is not complementary to any previously used;

(d) cleaving said first nucleic acid, said second nucleic acid and said additional nucleic acids, if prepared, with their corresponding restriction endonucleases to produce cleaved first, second and additional, if prepared, nucleic acids; and

(e) ligating said cleaved first, second and additional, if prepared, nucleic acids to produce the nucleic acid encoding a zinc finger protein (ZFP) having four or more zinc fingers domains. Useful and preferred restriction enzymes are as provided above, provide each one selected produces a unique pair of cleavable, annealable ends.

If step (c) is omitted, then a ZFP with four, five or six zinc finger domains can be made. If nucleic acid encoding a 3-finger ZFP is produced in step (b) and one additional nucleic acid is prepared by step (c), then a ZFP with seven, , eight or nine zinc finger domains can be made.

By appropriate design, the oligonucleotides can provide for optimal codon usage for an organism. such as a bacterium, a fungus, a yeast, an animal, an insect or a plant. In a preferred embodiment optimal codon usage (to maximize expression in the organism) is provided for *E. coli*, humans or mice, cereal plants, rice, tomato or corn. The method works with transgenic plants.

The nucleic acids made by this method can be incorporated in expression vectors and host cells. Those vectors and hosts can in turn be used to recombinantly express the ZFP by methods well known in the art.

The invention includes, sets of oligonucleotides comprising a number of separate oligonucleotides designed to use any combination of amino acids from the recognition code for four base pair targets in which

- (a) if the first base is G, then  $Z^6$  is arginine or lysine,  
 if the first base is A, then  $Z^6$  is glutamine or asparagine,  
 if the first base is T, then  $Z^6$  is threonine, tyrosine, leucine, isoleucine or  
 methionine,  
 5 if the first base is C, then  $Z^6$  is glutamic acid or aspartic acid,
- (b) if the second base is G, then  $Z^3$  is histidine or lysine,  
 if the second base is A, then  $Z^3$  is asparagine or glutamine,  
 if the second base is T, then  $Z^3$  is serine, alanine or valine,  
 if the second base is C, then  $Z^3$  is aspartic acid or glutamic acid,
- 10 (c) if the third base is G, then  $Z^1$  is arginine or lysine,  
 if the third base is A, then  $Z^1$  is glutamine or asparagine,  
 if the third base is T, then  $Z^1$  is threonine, methionine leucine or isoleucine,  
 if the third base is C, then  $Z^1$  is glutamic acid or aspartic acid,
- (iv) if the complement of the fourth base is G, then  $Z^2$  is serine or arginine,  
 15 if the complement of the fourth base is A, then  $Z^2$  is asparagine or  
 glutamine,  
 if the complement of the fourth base is T, then  $Z^2$  is threonine, valine or  
 alanine, and  
 if the complement of the fourth base is C, then  $Z^2$  is aspartic acid or  
 20 glutamic acid.

Preferably, the number of oligonucleotides is 256 since this represents the number of 4 base pair targets. Sets designed for the preferred recognition code of Table 1 are preferred.

## 25 V. Miscellaneous

“Organisms” as used herein include bacteria, fungi, yeast, animals, birds, insects, plants and the like. Animals include, but are not limited to, mammals (humans, primates, etc.), commercial or farm animals (fish, chickens, cows, cattle, pigs, sheeps, goats, turkeys, etc.), research animals (mice, rats, rabbits, etc.) and pets (dogs, cats, parakeets and other  
 30 pet birds, fish, etc.). As contemplated herein, particular animals may be members of multiple animal groups. Plants are described in more detail herein.

In some instances it may be that the cells of the organisms are used in a method of the invention. When cells are contemplated as an aspect of an invention herein, then in addition cells from any of the animals, organisms or plants expressly provided herein, the cells include cells isolated from such organisms and animals as well as cell lines used in research or other laboratories, including primary and secondary cell lines and the like.

Cell transformation techniques and gene delivery methods (such as those for *in vivo* use to deliver genes) are well known in the art. Any such technique can be used to deliver a nucleic acid encoding a ZFP or ZFP-fusion protein of the invention to a cell or subject, respectively.

The term "expression cassette" as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region usually codes for a protein of interest but may also code for a functional RNA of interest, for example antisense RNA or a nontranslated RNA, in the sense or antisense direction. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The zinc finger-effector fusions of the present invention are chimeric. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular DNA sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue or organ or stage of development. In the case of a plastid expression cassette, for expression of the nucleotide sequence from a plastid genome, additional elements, i.e. ribosome binding sites, may be required.

By "heterologous" DNA molecule or sequence is meant a DNA molecule or

sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally-occurring DNA sequence.

By "homologous" DNA molecule or sequence is meant a DNA molecule or sequence naturally associated with a host cell.

5 By "minimal promoter" is meant a promoter element, particularly a TATA element, that is inactive or that has greatly reduced promoter activity in the absence of upstream activation. In the presence of a suitable transcription factor, the minimal promoter functions to permit transcription.

10 A "plant" refers to any plant or part of a plant at any stage of development, including seeds, suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores, and progeny thereof. Also included are cuttings, and cell or tissue cultures. As used in conjunction with the present invention, the term "plant tissue" includes, but is not limited to, whole plants, plant cells, plant organs (e.g., leafs, stems, roots, meristems) plant seeds, protoplasts, callus, cell  
15 cultures, and any groups of plant cells organized into structural and/or functional units.

The present invention can be used, for example, to modulate gene expression, alter genome structure and the like, over a broad range of plant types, preferably the class of higher plants amenable to transformation techniques, particularly monocots and dicots. Particularly preferred are monocots such as the species of the Family Gramineae including  
20 Sorghum bicolor and Zea mays. The isolated nucleic acid and proteins of the present invention can also be used in species from the genera: Cucurbita, Rosa, Vitis, Juglans, Fragaria, Lotus, Medicago, Onobrychis, Trifolium, Trigonella, Vigna, Citrus, Linum, Geranium, Manihot, Daucus, Arabidopsis, Brassica, Raphanus, Sinapis, Atropa, Capsicum, Datura, Hyoscyamus, Lycopersicon, Nicotiana, Solanum, Petunia, Digitalis, Majorana,  
25 Ciahorium, Helianthus, Lactuca, Bromus, Asparagus, Antirrhinum, Heterocallis, Nemesis, Pelargonium, Panieum, Pennisetum, Ranunculus, Senecio, Salpiglossis, Cucumis, Browaalia, Glycine, Pisum, Phaseolus, Lolium, Oryza, Avena, Hordeum, Secale, and Triticum.

Preferred plant cell includes those from corn (Zea mays), canola (Brassica napus,  
30 Brassica rapa ssp.), alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), sunflower (Helianthus annuus), wheat (Triticum aestivum), soybean (Glycine max), tobacco (Nicotiana tabacum), potato

(*Solanum tuberosum*), peanuts (*Arachis hypogaea*), cotton (*Gossypium barbadense*, *Gossypium hirsutum*), sweet potato (*Ipomoea batatas*), cassava (*Manihot esculenta*), coffee (*Coffea* spp.), coconut (*Cocos nucifera*), pineapple (*Ananas comosus*), citrus trees (*Citrus* spp.), cocoa (*Theobroma cacao*), tea (*Camellia sinensis*), banana (*Musa* spp.), avocado (*Persea americana*), fig (*Ficus casica*), guava (*Psidium guajava*), mango (*Mangifera indica*), olive (*Olea europaea*), papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia integrifolia*), almond (*Prunus amygdalus*), sugar beets (*Beta vulgaris*), sugarcane (*Saccharum* spp.), duckweed (*Lemna* spp.), oats, barley, vegetables, ornamentals, and conifers.

10 Preferred vegetables include tomatoes (*Lycopersicon esculentum*), lettuce (e.g., *Lactuca sativa*), green beans (*Phaseolus vulgaris*), lima beans (*Phaseolus limensis*), peas (*Lathyrus* spp.), and members of the genus *Cucumis* such as cucumber (*C. sativus*), cantaloupe (*C. cantalupensis*), and musk melon (*C. melo*).

15 Preferred ornamentals include azalea (*Rhododendron* spp.), hydrangea (*Macrophylla hydrangea*), hibiscus (*Hibiscus rosasanensis*), roses (*Rosa* spp.), tulips (*Tulipa* spp.), daffodils (*Narcissus* spp.), petunias (*Petunia hybrida*), carnation (*Dianthus caryophyllus*), poinsettia (*Euphorbia pulcherrima*), and chrysanthemum.

20 Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine (*Pinus taeda*), slash pine (*Pinus elliotii*), ponderosa pine (*Pinus ponderosa*), lodgepole pine (*Pinus contorta*), and Monterey pine (*Pinus radiata*); Douglas-fir (*Pseudotsuga menziesii*); Western hemlock (*Isuga canadensis*); Sitka spruce (*Picea glauca*); redwood (*Sequoia sempervirens*); true firs such as silver fir (*Abies amabilis*) and balsam fir (*Abies balsamea*); and cedars such as Western red cedar (*Thuja plicata*) and Alaska yellow-cedar (*Chamaecyparis nootkatensis*).

25 Most preferably, plants of the present invention are crop plants (for example, corn, alfalfa, sunflower, canola, soybean, cotton, peanut, sorghum, wheat, tobacco, etc.), even more preferably corn and soybean plants, yet more preferably corn plants.

30 As used herein, "transgenic plant" or "genetically modified plant" includes reference to a plant which comprises within its genome a heterologous polynucleotide. Generally, and preferably, the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. The heterologous polynucleotide may be integrated into the genome alone or as part of a recombinant expression cassette.



“Transgenic” is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term “transgenic” as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation.

As used herein, a “target polynucleotide,” “target nucleic acid,” “target site” or other similar terminology refers to a portion of a double-stranded polynucleotide, including DNA, RNA, peptide nucleic acids (PNA) and combinations thereof, to which a zinc finger domain binds. In one preferred embodiment, the target polynucleotide is all or part of a transcriptional control element for a gene and the zinc finger domain is capable of binding to and modulating (activating or repressing) its degree of expression. A transcriptional control element may include one or more of the following: positive and negative control elements such as a promoter, an enhancer, other response elements (e.g., steroid response element, heat shock response element or metal response element), repressor binding sites, operators and silencers. The transcriptional control element can be viral, eukaryotic, or prokaryotic. A “target nucleotide sequence” also refers to a downstream sequence which can bind a protein and thereby modulate expression, typically prevent or activate transcription.

#### VI. Uses

The discovery of the zinc finger-nucleotide base recognition code of the invention allows the design of ZFPs and ZFP-fusion proteins capable of binding to and modulating the expression of any target nucleotide sequence. The target nucleotide sequence is at any location within the target gene whose expression is to be regulated which provides a suitable location for controlling expression. The target nucleotide sequence may be within the coding region or upstream or downstream thereof, but it can also be some distance away. For example enhancers are known to work at extremely long distances from the genes whose expression they modulate. For activation, targets upstream from ATG translation start codon are preferred, most preferably upstream of TATA box within about

100 bp from the start of transcription. For repression, upstream from the ATG translation start codon is also preferred, but preferably downstream from TATA box.

A protein comprising one or more zinc finger domains which binds to transcription control elements in the promoter region may cause a decrease in gene expression by  
5 blocking the binding of transcription factors that normally stimulate gene expression. In other instances, it may be desirable to increase expression of a particular protein. A ZFP which contains a transcription activator is used to cause such an increase in expression.

In another embodiment of the invention, ZFPs are fused with enzymes to target the enzymes to specific sites in the genome. These fusion proteins direct the enzyme to specific  
10 sites and allow modification of the genome and of chromatin. Such modifications can be anywhere on the genome, .e.g., in a gene or far from genes. For example, genomes can be specifically manipulated by fusing designed zinc finger domains based on the recognition code of the invention using standard molecular biology techniques with integrases or transposases to promote integration of exogenous genes into specific genomic sites  
15 (transposases or integrases), to eliminate (knock-out) specific endogenous genes (transposases) or to manipulate promoter activities by inserting one or more of the following DNA fragments: strong promoters/enhancers, tissue-specific promoters/enhancers, insulators or silencers. In other instances, a ZFP which binds to a polynucleotide having a particular sequence. In other embodiments, enzymes such as DNA  
20 methyltransferases, DNA demethylases, histone acetylases and histone deacetylases are attached to the ZFPs prepared based on the recognition code of the present invention for manipulation of chromatin structure.

For example, DNA methylation/demethylation at specific genomic sites allows manipulation of epi-genetic states (gene silencing) by altering methylation patterns, and  
25 histone acetylation/deacetylation at specific genomic sites allows manipulation of gene expression by altering the mobility and/or distribution of nucleosomes on chromatin and thereby increase access of transcription factors to the DNA. Proteases can similarly affect nucleosome mobility and distribution on DNA to modulate gene expression.

Nucleases can alter genome structure by nicking or digesting target sites and may  
30 allow introduction of exogenous genes at those sites. Invertases can alter genome structure by swapping the orientation of a DNA fragment. Resolvases can alter the genomic structure by changing the linking state of the DNA, e.g., by releasing concatemers.

Examples of some of the above regulatory proteins include, but are not limited to: transposase: Tc1 transposase, Mos1 transposase, Tn5 transposase, Mu transposase; integrase: HIV integrase, lambda integrase; recombinase: Cre recombinase, Flp recombinase, Hin recombinase; DNA methyltransferase: SssI methylase, AluI methylase, HaeIII methylase, HhaI methylase, HpaII methylase, human Dnmt1 methyltransferase; DNA demethylase: MBD2B, a candidate demethylase; histone acetylase: human GCN5, CBP (CREB-binding protein); histone deacetylase: HDAC1; nuclease: micrococcal nuclease, staphylococcal nuclease, DNase I, T7 endonuclease; resolvase: Ruv C resolvase, Holiday junction resolvase Hjc; and invertase: Hin invertase.

In another embodiment, a nuclear localization peptide is attached to the ZFP or ZFP-fusion ZFP to target the zinc finger to the nuclear compartment. In addition the ZFPs can have a cellular uptake signal attached, either alone or in conjunction with other moieties such as the above described regulatory domains and the like. Such cellular uptake signals include, but are not limited to, the minimal Tat protein transduction domain which is residues 47-57 of the human immunodeficiency virus Tat protein: YGRKKRRQRRR (SEQ ID NO: 18).

A wild type transposase 2 homodimer (Fig. 4, left panel) comprises a catalytic (cleavage) domain 4, dimerization domains 6 and terminal inverted repeat (TIR) binding domains 8. In one embodiment of the invention, zinc finger domains are substituted for the TIR domains to promote cleavage of a genomic site targeted by the zinc finger domains according to the recognition code of the invention. An artificial transposase heterodimer 10 (Fig. 4, right panel) is generated by joining catalytic domains 4 to zinc finger domains 12 via linkers 14 which comprise heterodimeric peptides including, but not limited to, jun-fos and acidic-basic heterodimer peptides. For example, the acidic peptide AQLEKELQALEKENAQLEWELQALEKELAQ (SEQ ID NO: 19) and basic peptide AQLKKKLQALKKKNAQLKWKLQALKKKLAQ (SEQ ID NO: 20) can be used as linkers and will heterodimerize. These heterodimers pull the DNA ends together after cleavage of the DNA by the catalytic domains. The zinc finger domains 12 may target the same or different sites in the genome according to the recognition code of the invention. Any desired genomic site may be targeted using these artificial transposases. The cellular system will repair (ligate) the cut ends of the DNA if they are brought in close proximity by the artificial transposase.

In another embodiment of the engineered transposases described above, the specificities of the TIRs may be altered, combined with usage of the heterodimers, to produce site-specific knock-out (KO) of a gene of interest. Alternatively, replacing the TIRs with zinc finger domains, particularly ones with different specificity (as described in the preceding paragraph) produces another class of proteins useful to make site-specific KOs.

In addition, by fusion with ZFPs, transposases (that have a catalytic domain, a dimerization domain and a TIR binding domain) can be recruited to specific genomic sites in combination with usage of the heterodimers to produce transposases having altered DNA binding specificity, resulting in site-specific knock-in (KI) of a gene of interest. For example, a zinc finger domain can be joined to the *C. elegans* transposon Tc1 via a flexible linker (e.g. (GGGGS)<sub>4</sub> (SEQ ID NO: 21) in which G=glycine and S=serine), either as zinc finger-linker-Tc1, or as Tc1-linker-zinc finger. It will be appreciated that any transposase, zinc finger domain or linker peptide may be used in these constructs.

The site-specific KO and KI strategies are summarized in Figure 5. Transposase 20 comprises catalytic domains 22 and TIR binding domains 24 joined by homodimeric or heterodimeric protein domain linkers 26. TIR binding domains 24 are engineered by standard techniques to have altered target specificities which may be the same or different, resulting in transposase 23 having altered TIR bonding domains 25. These TIRs target genomic sequences 28 and 29 which flank a gene 30 to be deleted. After binding of the TIRs to their complementary genomic sequences 28 and 29, a DNA loop 32 comprising gene 30 is formed, and the catalytic domains 22 cleave the DNA loop 32, resulting in KO of gene 30. Preferably, the catalytic domains only have cleavage, not re-ligation activity. Ligation is preferably performed by the cell to join the cleaved ends of the DNA.

In another embodiment of the invention, engineered transposases are used to perform site-specific KI of an exogenous gene. In this embodiment, transposase 20 is linked to zinc finger domains 34 which may have the same or different specificities to produce zinc finger fusion 36. In another embodiment, transposase 23 is fused to zinc finger domains 35 which may have the same or different specificities to produce transposase 40 which comprises TIRs 24 and 25 having altered DNA sequence specificity. TIRs 24 and 25 contact genomic regions 42 and 43, respectively, and zinc finger domains bind to target sequences 46 and 47, followed by cleavage of looped DNA 48 and

incorporation of gene 50 between zinc finger target sequences 46 and 47. For the KI embodiment, it is preferred that the catalytic domains of the transposase have both cleavage and ligation activities.

The ZFPs and recognition code of the present invention can be used to modulate gene expression in any organism, particularly plants. The application of ZFPs and constructs to plants is particularly preferred. Where a gene contains a suitable target nucleotide sequence in a region which is appropriate for controlling expression, the regulatory factors employed in the methods of the invention can target the endogenous nucleotide sequence. However, if the target gene lacks an appropriate unique nucleotide sequence or contains such a sequence only in a position where binding to a regulatory factor would be ineffective in controlling expression, it may be necessary to provide a “heterologous” targeted nucleotide sequence. By “heterologous” targeted nucleotide sequence is meant either a sequence completely foreign to the gene to be targeted or a sequence which resides in the gene itself, but in a different position from that wherein it is inserted as a target. Thus, it is possible completely to control the nature and position of the targeted nucleotide sequence.

In one embodiment, the zinc finger polypeptides of the present invention is used to inhibit the expression of a disease-associated gene. Preferably, the zinc finger polypeptide is not a naturally-occurring protein, but is specifically designed to inhibit the expression of the gene. The zinc finger polypeptide is designed using the amino acid-base contacts shown in Table 1 to bind to a regulatory region of a disease-associated gene and thus prevent transcription factors from binding to these sites and stimulating transcription of the gene. In one example, the disease-associated gene is an oncogene such as a BCR-ABL fusion oncogene or a ras oncogene, and the zinc finger polypeptide is designed to bind to the DNA sequence GCAGAAGCC (SEQ ID NO: 22) and is capable of inhibiting the expression of the BCR-ABL fusion oncogene.

A nucleic acid sequence of interest may also be modified using the zinc finger polypeptides of the invention by binding the zinc finger to a polynucleotide comprising a target sequence to which the zinc finger binds. Binding of a zinc finger to a target polynucleotide may be detected in various ways, including gel shift assays and the use of radiolabeled, fluorescent or enzymatically labeled zinc fingers which can be detected after binding to the target sequence. The zinc finger polypeptides can also be used as a

diagnostic reagent to detect mutations in gene sequences, to purify restriction fragments from a solution, or to visualize DNA fragments of a gel.

As used herein, “effector” or “effector protein” refer to constructs or their encoded products which are able to regulate gene expression either by activation or repression or which exert other effects on a target nucleic acid. The effector protein may include a zinc finger binding region only, but more commonly also includes a “functional domain” such as a “regulatory domain.” The regulatory domain is the portion of the effector protein or effector which enhances or represses gene expression (and is also referred to as a transcriptional regulatory domain), or may be a nuclease, recombinase, integrase or any other protein or enzyme which has a biological effect on the polynucleotide to which the ZFP binds.

The effector domain has an activity such as transcriptional regulation or modulation activity, DNA modifying activity, protein modifying activity and the like when tethered (e.g., fused) to a DNA binding domain, i.e., a ZFP. Examples of regulatory domains include proteins or effector domains of proteins, e.g., transcription factors and co-factors (e.g., KRAB, MAD, ERD, SID, nuclear factor kappa B subunit p65, early growth response factor 1, and nuclear hormone receptors, VP16, VP64), endonucleases, integrases, recombinases, methylases, methyltransferases, histone acetyltransferases, histone deacetylases and the like.

Activators and repressors include co-activators and co-repressors (Utley et al., Nature 394:498- 502 (1998); WO 00/03026). Effector domains can include, but are not limited to, DNA-binding domains from a protein that is not a ZFP, such as a restriction enzyme, a nuclear hormone receptor, a homeodomain protein such as engrailed or antenopodia, a bacterial helix-turn-helix motif protein such as lambda repressor and tet repressor, Gal4, TATA binding protein, helix-loop-helix motif proteins such as myc and myo D, leucine zipper type proteins such as fos and jun, and beta sheet motif proteins such as met, arc, and mnt repressors. Particularly preferred is the C1 activator domain of maize.

Likewise an effector domain can include, but is not limited to a transposase, integrase, recombinase, resolvase, invertase, protease, DNA methyltransferase, DNA demethylase, histone acetylase, histone deacetylase, nuclease, transcriptional repressor, transcriptional activator, a single-stranded DNA binding protein, a nuclear-localization signal, a transcription-protein recruiting protein or a cellular uptake domain. Effector

domains further include protein domains which exhibits transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear localization activity, transcriptional protein recruiting activity, transcriptional repressor activity or transcriptional activator activity.

In a preferred embodiment the ZFP having an effector domain is one that is responsive to a ligand. The effector domain can effect such a response. Example of such ligand-responsive domains are hormone receptor ligand binding domains, including, for example, the estrogen receptor domain, the ecdysone receptor system, the glucocorticosteroid receptor, and the like. Preferred inducers are small, inorganic, biodegradable, molecules. Use of ligand inducible ZFP-effector fusions is generally known as a gene switch.

The ZFP can be covalently or non-covalently associated with one or more regulatory domains, alternatively two or more regulatory domains, with the two or more domains being two copies of the same domain, or two different domains. The regulatory domains can be covalently linked to the ZFP nucleic acid binding domain, e.g., via an amino acid linker, as part of a fusion protein. The ZFPs can also be associated with a regulatory domain via a non-covalent dimerization domain, e.g., a leucine zipper, a STAT protein N terminal domain, or an FK506 binding protein (see, e.g., O'Shea, Science 254: 539 (1991), Barahmand-Pour et al., Curr. Top. Microbiol. Immunol. 211:121-128 (1996); Klemm et al., Annu. Rev. Immunol. 16:569- 592 (1998); Klemm et al., Annu. Rev. Immunol. 16:569-592 (1998); Ho et al., Nature 382:822-826 (1996); and Pomeranz et al., Biochem. 37:965 (1998)). The regulatory domain can be associated with the ZFP domain at any suitable position, including the C- or N-terminus of the ZFP.

Common regulatory domains for addition to the ZFP made using the methods of the invention include, e.g., DNA-binding domains from transcription factors, effector domains from transcription factors (activators, repressors, co-activators, co-repressors), silencers, nuclear hormone receptors, and chromatin associated proteins and their modifiers (e.g., methylases, kinases, acetylases and deacetylases).

Transcription factor polypeptides from which one can obtain a regulatory domain include those that are involved in regulated and basal transcription. Such polypeptides include transcription factors, their effector domains, coactivators, silencers, nuclear

hormone receptors (see, e.g., Goodrich et al., *Cell* 84:825-30 (1996) for a review of proteins and nucleic acid elements involved in transcription; transcription factors in general are reviewed in Barnes and Adcock, *Clin. Exp. Allergy* 25 Suppl. 2:46-9 (1995) and Roeder, *Methods Enzymol.* 273:165-71 (1996)). Databases dedicated to transcription factors are also known (see, e.g., *Science* 269:630 (1995)). Nuclear hormone receptor transcription factors are described in, for example, Rosen et al., *J. Med. Chem.* 38:4855- 74 (1995). The C/EBP family of transcription factors are reviewed in Wedel et al., *Immunobiology* 193:171-85 (1995). Coactivators and co-repressors that mediate transcription regulation by nuclear hormone receptors are reviewed in, for example, Meier, *Eur. J. Endocrinol.* 134(2):158-9 (1996); Kaiser et al., *Trends Biochem. Sci.* 21:342-5 (1996); and Utley et al., *Nature* 394:498-502 (1998)). GATA transcription factors, which are involved in regulation of hematopoiesis, are described in, for example, Simon, *Nat. Genet.* 11:9-11 (1995); Weiss et al., *Exp. Hematol.* 23:99-107. TATA box binding protein (TBP) and its associated TAF polypeptides (which include TAF30, TAF55, TAF80, TAF10, TAFI 50, and TAF250) are described in Goodrich & Tjian, *Curr. Opin. Cell Biol.* 6:403-9 (1994) and Hurley, *Curr. Opin. Struct. Biol.* 6:69-75 (1996). The STAT family of transcription factors are reviewed in, for example, Barahmand-Pour et al., *Curr. Top. Microbiol. Immunol.* 211:121-8 (1996). Transcription factors involved in disease are reviewed in Aso et al., *J Clin. Invest.* 97:1561-9 (1996).

In one embodiment, the KRAB repression domain from the human KOX- I protein is used as a transcriptional repressor (Thiesen et al., *New Biologist* 2:363-374 (1990); Margolin et al., *Proc. Natl. Acad. Sci. U.S.A.* 91:4509-4513 (1994); Pengue et al., *Nucl. Acids Res.* 22:2908-2914 (1994); Witzgall et al., *Proc. Natl. Acad. Sci. U.S.A.* 91:4514-4518 (1994)). In another embodiment, KAP-1, a KRAB co-repressor, is used with KRAB (Friedman et al., *Genes Dev.* 10:2067-2078 (1996)). Alternatively, KAP- I can be used alone with a ZFP. Other preferred transcription factors and transcription factor domains that act as transcriptional repressors include MAD (see, e.g., Sommer et al., *J Biol. Chem.* 273:6632-6642 (1998); Gupta et al., *Oncogene* 16:1149- 1159 (1998); Queva et al., *Oncogene* 16:967-977 (1998); Larsson et al., *Oncogene* :737-748 (1997); Laherty et al., *Cell* 89:349-356 (1997); and Cultraro et al., *Mol Cell. Biol.* 17:2353-2359 (1997)); FKHR (forkhead in rhabdosarcoma gene; Ginsberg et al., *Cancer Res.* 15:3542-3546 (1998); Epstein et al., *Mol. Cell. Biol.* 18:4118-4130 (1998)); EGR- I (early growth response gene



product- 1; Yan et al., Proc. Natl. Acad. Sci. U.S.A. 95:8298-8303 (1998); and Liu et al., Cancer Gene Ther. 5:3-28 (1998)); the ets2 repressor factor repressor domain (ERD; Sgouras et al., EMBO J 14:4781- 4793 ((1995)); and the MAD smSIN3 interaction domain (SID; Ayer et al., Mol. Cell. Biol. 16:5772-5781 (1996)).

5 In one embodiment, the HSV VP 16 activation domain is used as a transcriptional activator (see, e.g., Hagmann et al., J Virol. 71:5952- 5962 (1997)). Other preferred transcription factors that could supply activation domains include the VP64 activation domain (Selpel et al., EMBO J 11:4961-4968 (1996)); nuclear hormone receptors (see, e.g., Torchia et al., Curr. Opin. Cell. Biol. 10:373-383 (1998)); the p65 subunit of nuclear  
10 factor kappa B (Bitko & Barik, J Virol. 72:5610-5618 (1998) and Doyle & Hunt, Neuroreport 8:2937-2942 (1997)); and EGR-I (early growth response gene product-1; Yan et al., Proc. Natl. Acad. Sci. U.S.A. 95:8298-8303 (1998); and Liu et al., Cancer Gene Ther. 5:3-28 (1998)).

Kinases, phosphatases, and other proteins that modify polypeptides involved in gene  
15 regulation are also useful as regulatory domains for ZFPs. Such modifiers are often involved in switching on or off transcription mediated by, for example, hormones. Kinases involved in transcription regulation are reviewed in Davis, Mol. Reprod. Dev. 42:459-67 (1995), Jackson et al., Adv. Second Messenger Phosphoprotein Res. 28:279-86 (1993), and Boulikas, Crit. Rev. Eukaryot. Gene Expr. 5:1-77 (1995), while phosphatases are  
20 reviewed in, for example, Schonthal & Semin, Cancer Biol. 6:239-48 (1995). Nuclear tyrosine kinases are described in Wang, Trends Biochem. Sci. 19:373-6 (1994).

As described, useful domains can also be obtained from the gene products of oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members) and their associated factors and modifiers. Oncogenes are described in, for example, Cooper,  
25 Oncogenes, 2nd ed., The Jones and Bartlett Series in Biology, Boston, MA, Jones and Bartlett Publishers, 1995. The ets transcription factors are reviewed in Waslylk et al., Eur. J Biochem. 211:7-18 (1993). Myc oncogenes are reviewed in, for example, Ryan et al., Biochem. J. 314:713-21 (1996). The Jun and fos transcription factors are described in, for example, The Fos and Jun Families of Transcription Factors, Angel & Herrlich, eds.  
30 (1994). The max oncogene is reviewed in Hurlin et al., Cold Spring Harb. Symp. Quant. Biol. 59:109- 16. The myb gene family is reviewed in Kanei-Ishii et al., Curr. Top.

Microbiol. Immunol. 211:89-98 (1996). The mos family is reviewed in Yew et al., Curr. Opin. Genet. Dev. 3:19-25 (1993).

In another embodiment, histone acetyltransferase is used as a transcriptional activator (see, e.g., Jin & Scotto, Mol. Cell. Biol. 18:4377-4384 (1998); Wolffe, Science 272:371-372 (1996); Taunton et al., Science 272:408-411 (1996); and Hassig et al., Proc. Natl. Acad. Sci. U.S.A. 95:3519-3524 (1998)). In another embodiment, histone deacetylase is used as a transcriptional repressor (see, e.g., Jin & Scotto, Mol. Cell. Biol. 18:4377-4384 (1998); Syntichaki & Thireos, J Biol. Chem. 273:24414-24419 (1998); Sakaguchi et al., Genes Dev. 12:2831-2841 (1998); and Martinez et al., J Biol. Chem. 273:23781-23785 (1998)).

In addition to regulatory domains, often the ZFP is expressed as a fusion protein such as maltose binding protein ("MBP"), glutathione S transferase (GST), hexahistidine, c-myc, and the FLAG epitope, for ease of purification, monitoring expression, or monitoring cellular and subcellular localization.

The nucleic acid sequence encoding a ZFP can be modified to improve expression of the ZFP in plants by using codon preference. When the nucleic acid is prepared or altered synthetically, advantage can be taken of known codon preferences of the intended plant host where the nucleic acid is to be expressed. For example, although nucleic acid sequences of the present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray et al. Nucl. Acids Res. 17: 477-498 (1989)). Thus, the maize preferred codon for a particular amino acid may be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants are listed in Table 4 of Murray et al., supra.

The targeted sequence may be any given sequence of interest for which a complementary ZFP is designed. Targeted genes include both structural and regulatory genes, such that targeted control or effector activity either directly or indirectly via a regulatory control. Thus single genes or gene families can be controlled.

The targeted gene may, as is the case for the maize MIPS gene and AP3 gene, be endogenous to the plant cells or plant wherein expression is regulated or may be a transgene which has been inserted into the cells or plants in order to provide a production

system for a desired protein or which has been added to the genetic complement in order to modulate the metabolism of the plant or plant cells.

It may be desirable in some instances to modify plant cells or plants with families of transgenes representing, for example, a metabolic pathway. In those instances, it may be desirable to design the constructs so that the family can be regulated as a whole - *e.g.*, by designing the control regions of the members of the family with similar or identical targets for the ZFP portion of the effector protein. Such sharing of target sequences in gene families may occur naturally in endogenously produced metabolic sequences.

In most instances, it is desirable to provide the expression system for the effector protein with control sequences that are tissue specific so that the desired gene regulation can occur selectively in the desired portion of the plant. For example, to repress MIPS expression, it is desirable to provide the effector protein with control sequences that are selectively effective in seeds. With respect to the AP3 gene, effector proteins for regulation of expression would be designed for selective expression in flowering portions of the plant. However, in some instances, it may be desirable to have the genetic control expressible in all tissues for example in instances where an insect resistance gene is the target. In such cases, as well, it may be desirable to place the expression system for the effector protein under control of an inducible promoter so that inducer can be supplied to the plant only when the need arises, for example, activation of an insect resistance gene.

In one embodiment, ZFPs can be used to create functional "gene knockouts" and "gain of function" mutations in a host cell or plant by repression or activation of the target gene expression. Repression or activation may be of a structural gene, one encoding a protein having for example enzymatic activity, or of a regulatory gene, one encoding a protein that in turn regulates expression of a structural gene. Expression of a negative regulatory protein can cause a functional gene knockout of one or more genes, under its control. Conversely, a zinc finger having a negative regulatory domain can repress a positive regulatory protein to knockout or prevent expression of one or more genes under control of the positive regulatory protein.

The ZFPs of the invention and fusion proteins of the invention, particularly those useful for modulating gene expression can be used for functional genomics applications and target validation applications such as those described in WO 01/19981 to Case *et al.*

The present invention also provides recombinant expression cassettes comprising a ZFP-encoding nucleic acid of the present invention. A nucleic acid sequence coding for the desired polynucleotide of the present invention can be used to construct a recombinant expression cassette which can be introduced into a desired host cell. A recombinant  
5 expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences which will direct the transcription of the polynucleotide in the intended host cell, such as tissues of a transformed plant.

For example, plant expression vectors may include (1) a cloned plant gene under the  
10 transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region (e.g., one conferring inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific/selective expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a  
15 polyadenylation signal.

A plant promoter fragment can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive  
20 promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the P- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, the ubiquitin I promoter, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Patent No. 5,683,439), the Nos promoter, the pEmu promoter, the rubisco promoter, the GRP 1 - 8 promoter, and other transcription initiation regions from various plant genes known to  
25 those of skill in the art.

Alternatively, the plant promoter can direct expression of a polynucleotide of the present invention in a specific tissue or may be otherwise under more precise environmental or developmental control. Such promoters are referred to here as "inducible" promoters. Environmental conditions that may effect transcription by inducible promoters include  
30 pathogen attack, anaerobic conditions, or the presence of light. Examples of inducible promoters include the AdhI promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPKK promoter which is

inducible by light. Examples of promoters under developmental control include promoters that initiate transcription only, or preferentially, in certain tissues, such as leaves, roots, fruit, seeds, or flowers. An exemplary promoter is the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051). The operation of a promoter may also vary  
5 depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in recombinant expression cassettes to drive  
10 expression of antisense nucleic acids to reduce, increase, or alter concentration and/or composition of the proteins of the present invention in a desired tissue. Thus, in some embodiments, the nucleic acid construct will comprise a promoter functional in a plant cell, such as in *Zea mays*, operably linked to a polynucleotide of the present invention. Promoters useful in these embodiments include the endogenous promoters driving  
15 expression of a polypeptide of the present invention.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide so as to up or down regulate its expression. For example, endogenous promoters can be altered in vivo by mutation, deletion, and/or  
20 substitution (U.S. Patent 5,565,350; PCT/US93/03868), or isolated promoters can be introduced into a plant cell in the proper orientation and distance from a gene of the present invention so as to control the expression of the gene. Gene expression can be modulated under conditions suitable for plant growth so as to alter the total concentration and/or alter the composition of the polypeptides of the present invention in plant cell.

A variety of promoters will be useful in the invention, particularly to control the expression of the ZFP and ZFP-effector fusions, the choice of which will depend in part upon the desired level of protein expression and desired tissue-specific, temporal specific, or environmental cue-specific control, if any in a plant cell. Constitutive and tissue specific promoters are of particular interest. Such constitutive promoters include, for example, the  
30 core promoter of the *Rsyn7*, the core CaMV 35S promoter (Odell et al. (1985) *Nature* 313:810-812), rice actin (McElroy et al. (1990) *Plant Cell* 2:163-171); ubiquitin (Christensen et al. (1989) *Plant Mol. Biol.* 12:619-632 and Christensen et al. (1992) *Plant*

*Mol. Biol.* 18:675-689), pEMU (Last et al. (1991) *Theor. Appl. Genet.* 81:581-588), MAS (Velten et al. (1984) *EMBO J.* 3:2723-2730), and constitutive promoters described in, for example, U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; and 5,608,142.

5 Tissue-specific promoters can be utilized to target enhanced expression within a particular plant tissue. Tissue-specific promoters include those described by Yamamoto et al. (1997) *Plant J.* 12(2):255-265, Kawamata et al. (1997) *Plant Cell Physiol.* 38(7):792-803, Hansen et al. (1997) *Mol. Gen. Genet.* 254(3):337, Russell et al. (1997) *Transgenic Res.* 6(2):157-168, Rinehart et al. (1996) *Plant Physiol.* 112(3):1331, Van Camp et al.  
10 (1996) *Plant Physiol.* 112(2):525-535, Canevascini et al. (1996) *Plant Physiol.* 112(2):513-524, Yamamoto et al. (1994) *Plant Cell Physiol.* 35(5):773-778, Lam (1994) *Results Probl. Cell Differ.* 20:181-196, Orozco et al. (1993) *Plant Mol. Biol.* 23(6):1129-1138, Matsuoka et al. (1993) *Proc. Natl. Acad. Sci. USA* 90(20):9586-9590, and Guevara-Garcia et al. (1993) *Plant J.* 4(3):495-505. Such promoters can be modified, if  
15 necessary, for weak expression.

Leaf-specific promoters are known in the art, and include those described in, for example, Yamamoto et al. (1997) *Plant J.* 12(2):255-265, Kwon et al. (1994) *Plant Physiol.* 105:357-67, Yamamoto et al. (1994) *Plant Cell Physiol.* 35(5):773-778, Gotor et al. (1993) *Plant J.* 3:509-18, Orozco et al. (1993) *Plant Mol. Biol.* 23(6):1129-1138, and  
20 Matsuoka et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90(20):9586-9590.

Any combination of constitutive or inducible and non-tissue specific or tissue specific may be used to control ZFP expression. The desired control may be temporal, developmental or environmentally controlled using the appropriate promoter.

Environmentally controlled promoters are those that respond to assault by pathogen,  
25 pathogen toxin, or other external compound (e.g., intentionally applied small molecule inducer). An example of a temporal or developmental promoter is a fruit ripening-dependent promoter. Particularly preferred are the inducible PR1 promoter, the maize ubiquitin promoter, and ORS.

Thus, the present invention provides compositions, and methods for making,  
30 heterologous promoters and/or enhancers operably linked to a ZFP and ZFP-effector fusion encoding polynucleotide of the present invention.

Methods for identifying promoters with a particular expression pattern, in terms of, e.g., tissue type, cell type, stage of development, and/or environmental conditions, are well known in the art. See, e.g., *The Maize Handbook*, Chapters 114-115, Freeling and Walbot, Eds., Springer, New York (1994); *Corn and Corn Improvement*, Pediton, Chapter 6, Sprague and Dudley, Eds., American Society of Agronomy, Madison, Wisconsin (1988).

In the process of isolating promoters expressed under particular environmental conditions or stresses, or in specific tissues, or at particular developmental stages, a number of genes are identified that are expressed under the desired circumstances, in the desired tissue, or at the desired stage. Further analysis will reveal expression of each particular gene in one or more other tissues of the plant. One can identify a promoter with activity in the desired tissue or condition but that do not have activity in any other common tissue. Such genes can be good candidates for regulation in accordance with the methods of the invention.

In plants, further upstream from the TATA box, at positions -80 to -100, there is typically a promoter element (i.e., the CAAT box) with a series of adenines surrounding the trinucleotide G (or T) N G. J. Messing et al., in *Genetic Engineering in Plants*, Kosage, Meredith and Hollaender, Eds., pp. 221-227 1983. In maize, there is no well conserved CAAT box but there are several short, conserved protein-binding motifs upstream of the TATA box. These include motifs for the trans-acting transcription factors involved in light regulation, anaerobic induction, hormonal regulation, or anthocyanin biosynthesis, as appropriate for each gene.

Plant transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (Crossway et al. (1986) *Biotechniques* 4:320-334), electroporation (Riggs et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:5602-5606, *Agrobacterium*-mediated transformation (Townsend et al., U.S. Pat. No. 5,563,055), direct gene transfer (Paszkowski et al. (1984) *EMBO J.* 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford et al., U. S. Patent No. 4,945,050; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in *Plant Cell, Tissue, and Organ Culture: Fundamental Methods*, ed. Gamborg and Phillips (Springer-Verlag, Berlin); and McCabe et

al. (1988) *Biotechnology* 6:923-926). Also see Weissinger et al. (1988) *Ann. Rev. Genet.* 22:421-477; Sanford et al. (1987) *Particulate Science and Technology* 5:27-37 (onion); Christou et al. (1988) *Plant Physiol.* 87:671- 674 (soybean); McCabe et al. (1988) *BioTechnology* 6:923-926 (soybean); Finer and McMullen (1991) *In Vitro Cell Dev. Biol.* 27P: 175-182 (soybean); Singh et al. (1998) *Theor. Appl. Genet.* 96:319-324 (soybean); Datta et al. (1990) *Biotechnology* 8:736-740 (rice); Klein et al. (1988) *Proc. Natl. Acad Sci. USA* 85:4305-4309 (maize); Klein et al. (1988) *Biotechnology* 6:559-563 (maize); Tomes, U.S. Patent No. 5,240,855; Buising et al., U.S. Patent Nos. 5,322, 783 and 5,324,646; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in *Plant Cell, Tissue, and Organ Culture: Fundamental Methods*, ed. Gamborg (Springer-Verlag, Berlin) (maize); Klein et al. (1988) *Plant Physiol.* 91:440-444 (maize); Fromm et al. (1990) *Biotechnology* 8:833-839 (maize); Hooykaas-Van Slogteren et al. (1984) *Nature (London)* 311:763-764; Bowen et al., U.S. Patent No. 5,736,369 (cereals); Bytebier et al. (1987) *Proc. Natl. Acad Sci. USA* 84:5345-5349 (Liliaceae); De Wet et al. (1985) in *The Experimental Manipulation of Ovule Tissues*, ed. Chapman et al. (Longman, New York), pp. 197-209 (pollen); Kaeppler et al. (1990) *Plant Cell Reports* 9:415- 418 and Kaeppler et al. (1992) *Theor. Appl. Genet.* 84:560-566 (whisker- mediated transformation); D'Halluin et al. (1992) *Plant Cell* 4:1495-1505 (electroporation); Li et al. (1993) *Plant Cell Reports* 12:250-255 and Christou and Ford (1995) *Annals of Botany* 75:407-413 (rice); Osjoda et al. (1996) *Nature Biotechnology* 14:745-750 (maize via *Agrobacterium tumefaciens*); all of which are herein incorporated by reference.

The ZFP with optional effector domain can be targeted to a specific organelle within the plant cell. Targeting can be achieved with providing the ZFP an appropriate targeting peptide sequence, such as a secretory signal peptide (for secretion or cell wall or membrane targeting, a plastid transit peptide, a chloroplast transit peptide, a mitochondrial target peptide, a vacuole targeting peptide, or a nuclear targeting peptide, and the like. For examples of plastid organelle targeting sequences see WO00/12732. Plastids are a class of plant organelles derived from proplastids and include chloroplasts, leucoplasts, amyloplasts, and chromoplasts. The plastids are major sites of biosynthesis in plants. In addition to photosynthesis in the chloroplast, plastids are also sites of lipid biosynthesis, nitrate reduction to ammonium, and starch storage. And while plastids contain their own



circular genome, most of the proteins localized to the plastids are encoded by the nuclear genome and are imported into the organelle from the cytoplasm.

The modified plant may be grown into plants by conventional methods. See, for example, McCormick et al. (1986) Plant Cell. Reports :81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved.

Assays to determine the efficiency by which the modulation of the target gene or protein of interest occurs are known. In brief, in one embodiment, a reporter gene such as P-glucuronidase (GUS), chloramphenicol acetyl transferase (CAT), or green fluorescent protein (GFP) is operably linked to the target gene sequence controlling promoter, ligated into a transformation vector, and transformed into a plant or plant cell.

ZFPs useful in the invention comprise at least one zinc finger polypeptide linked via a linker, preferably a flexible linker, to at least a second DNA binding domain, which optionally is a second zinc finger polypeptide. The ZFP may contain more than two DNA-binding domains, as well as one or more regulator domains. The zinc finger polypeptides of the invention can be engineered to recognize a selected target site in the gene of choice.

Typically, a backbone from any suitable Cys<sub>2</sub>His<sub>2</sub>-ZFP, such as SPA, SPIC, or ZIF268, is used as the scaffold for the engineered zinc finger polypeptides (see, e.g., Jacobs, EMBO J. 11:45 07 (1992); Desjarlais & Berg, Proc. Natl. Acad. Sci. USA 90:2256-2260 (1993)). A number of methods can then be used to design and select a zinc finger polypeptide with high affinity for its target. A zinc finger polypeptide can be designed or selected to bind to any suitable target site in the target gene, with high affinity.

As to amino acid and nucleic acid sequences, individual substitutions, deletions or additions that alter, add or delete a single amino acid or nucleotide or a small percentage of amino acids or nucleotides in the sequence create a "conservatively modified variant," where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants and alleles of the invention.

The following groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Serine (S), Threonine (T); 3) Aspartic acid (D), Glutamic acid (E); 4) Asparagine (N), Glutamine (Q); 5) Cysteine (C), Methionine (M); 6) Arginine (R), Lysine (K), Histidine (H); 7) Isoleucine (I), Leucine (L), Valine (V); and 8) Phenylalanine (F), Tyrosine (Y), Tryptophan (W). (see, e.g., Creighton, Proteins (1984) for a discussion of amino acid properties).

Thus, the invention contemplates gene regulation which may be tissue specific or not, inducible or not, and which may occur in plant cells either in culture or in intact plants. Useful activation or repression levels can vary, depending on how tightly the target gene is regulated, the effects of low level changes in regulation, and similar factors. Desirably, the change in gene expression is modified by about 1.5-fold to 2-fold; more desirably, about 3-fold to 5-fold; preferably about 8- to 10- to 15-fold; more preferably 20- to 25- to 30-fold; most preferably 40-, 50-, 75-, or 100-fold, or more. In this context, modification of expression level refers to either activation or repression of normal levels of gene expression in the absence of the activator/repressor activity. Measured activity of a particular ZFP-effector fusion varied somewhat from plant to plant as a result of the effect of the chromosomal location of integration of the ZFP-effector construct.

Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of *Agrobacterium tumefaciens* described by Rogers et al., Meth. in Enzymol., 153:253-277 (1987). These vectors are plant integrating vectors in that on transformation, the vectors integrate a portion of vector DNA into the genome of the host plant. Exemplary *A. tumefaciens* vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl et al., Gene, 61: 1 - 11 (1987) and Berger et al., Proc. Natl. Acad. Sci. U.S.A., 86:8402-8406 (1989). Another useful vector is plasmid pBI101.2.

The method of the invention is particularly appealing to the plant breeder because it has the effect of providing a dominant trait, which minimizes the level of crossbreeding necessary to develop a phenotypically desirable species which is also commercially valuable. Typically, modification of the plant genome by conventional methods creates heterozygotes where the modified gene is phenotypically recessive. Crossbreeding is required to obtain homozygous forms where the recessive characteristic is found in the phenotype. This crossbreeding is laborious and time consuming. The need for such

crossbreeding is eliminated in the case of the present invention which provides an immediate phenotypic effect.

In one embodiment, the ZFP can be designed to bind to non-contiguous target sequences. For example, a target sequence for a six-finger ZFP can be a ten base pair sequence (recognized by three fingers) with intervening bases (that do not contact the zinc finger nucleic acid binding domain) between a second ten base pair sequence (recognized by a second set of three fingers). The number of intervening bases can vary, such that one can compensate for this intervening distance with an appropriately designed amino acid linker between the two three-finger parts of ZFP. A range of intervening nucleic acid bases in a target binding site is preferably 20 or less bases, more preferably 10 or less, and even more preferably 6 or less bases. Of course, the linker maintains the reading frame between the linked parts of ZFP protein.

A minimum length of a linker is the length that would allow the two zinc finger domains to be connected without providing steric hindrance to the domains or the linker. A linker that provides more than the minimum length is a "flexible linker." Determining the length of minimum linkers and flexible linkers can be performed using physical or computer models of DNA-binding proteins bound to their respective target sites as are known in the art.

The six-finger zinc finger peptides can use a conventional "TGEKP" linker to connect two three-finger zinc finger peptides or to add additional fingers to a three-finger protein. Other zinc finger peptide linkers, both natural and synthetic, are also suitable. In addition to such linkers, the domains can be covalently joined with from 1 to 10 additional amino acids. Such additional amino acids may be most beneficial when used after every third zinc-finger domain in a multifinger ZFP.

A useful zinc finger framework is that of Berg (see Kim et al., *Nature Struct. Biol.* **3**:940-945, 1996; Kim et al., *J. Mol. Biol.* **252**:1-5, 1995; Shi et al., *Chemistry and Biology* **2**:83-89, 1995), however, others are suitable. Examples of known zinc finger nucleotide binding polypeptides that can be truncated, expanded, and/or mutagenized according to the present invention in order to change the function of a nucleotide sequence containing a zinc finger nucleotide binding motif includes TFIIIA and Zif268. Other zinc finger nucleotide binding proteins will be known to those of skill in the art. The murine Cys<sub>2</sub>-His<sub>2</sub> ZFP Zif268 is structurally the most well characterized of the ZFPs (Pavletich and Pabo, Science


252:809-817 (1991), Elrod- Erickson et al. (1996) Structure (London) 4, 1171-1180, Swirnoff et al. (1995) Mol, Cell. Biol. 15:2275-2287). DNA recognition in each of the three zinc finger domains of this protein is mediated by residues in the N-terminus of the alpha-helix contacting primarily three nucleotides on a single strand of the DNA. The operator binding site for this three finger protein is 5'-GCGTGGGCG-'3. Structural studies of Zif268 and other related zinc finger-DNA complexes (Elrod-Erickson, M., Benson, T. E. & Pabo, C. O. (1998) Structure (London) 6, 451-464, Kim and Berg, (1996) Nature Structural Biology 3, 940-945, Pavletich and Pabo, (1993) Science 261, 1701-7, Houbaviy et al. (1996) Proc Natl. Acad. Sci. U S A 93, 13577-82, Fairall et al. (1993) Nature (London) 366, 483-7, Wuttke et al. (1997) J. Mol. Biol. 273, 183-206., Nolte et al. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2938-2943, Narayan, et al. (1997) J. Biol. Chem. 272, 7801-7809) have shown that residues from primarily three positions on the  $\alpha$ -helix, -1, 3, and 6, are involved in specific base contacts. Typically, the residue at position -1 of the  $\alpha$ -helix contacts the 3' base of that finger's subsite while positions 3 and 6 contact the middle base and the 5' base, respectively.

Any suitable method of protein purification known to those of skill in the art can be used to purify the ZFPs of the invention (see Ausubel, supra, Sambrook, supra). In addition, any suitable host can be used, e.g. , bacterial cells, insect cells, yeast cells, mammalian cells, and the like.


In an embodiment, longer genomic sequences are targeted using multi-finger ZFPs linked to other multi-fingered ZFPs using flexible linkers including, but not limited to, GGGGS, GGGS and GGS (these sequences can be part of the 1-10 additional amino acids in the ZFPs of the invention; SEQ ID NO:23, residues 2-5 of SEQ ID NO:23; and residues 3-5 of SEQ ID NO:23, respectively). Non-palindromic sequences may be targeted using dimerization peptides such as acidic and basic peptides, optionally in combination with a flexible linker, in which ZFPs are attached to the acidic and basic peptides (effector domain-acidic or basic peptide-ZFP). At the other end of the acidic and basic peptides are effector peptides, such as activation domains. These domains may be assembled in any order. For example, the arrangement of ZFP-effector domain-acidic or basic peptide is also within the scope of the present invention. In addition, it is not required that a zinc finger peptide be attached to both the acidic and basic peptides; one or the other or both is within the scope of the invention. The need for two ZFPs will depend upon the affinity of the first

ZFP. These constructs can be used for combinatorial transcriptional regulation (Briggs, et al.) using the heterodimer described above. The protein only dimerizes when both halves are expressed. Thus, activation or inhibition of gene expression will only occur when both halves of the protein are expressed in the same cell at the same time. For example, two  
5 promoters may be used for expression in plants, one tissue-specific and one temporal. Activation of gene expression will only occur when both halves of the heterodimer are expressed.


The present invention also relates to “molecular switches” or “chemical switches” which are used to promote translocation of ZFPs generated according to the recognition  
10 code of the present invention to the nucleus to promote transcription of a gene of interest. The molecular switch is, in one embodiment, a divalent chemical ligand which is bound by an engineered receptor, such as a steroid hormone receptor, and which is also bound by an engineered ZFP (Fig. 6). The receptor-ligand-zinc finger complex enters the nucleus where the ZFP binds to its target site. An example is a complex comprising a ZFP linked by a  
15 divalent chemical ligand having moieties A and B to a nuclear localization signal which is operably linked to an effector domain such as an activation domain (AD) or repression domain (RD). A construct encoding a ZFP and an antibody specific for moiety A (or an active fragment of such antibody) is expressed in a cell. A second construct, encoding an engineered nuclear localization signal/effector domain and an antibody specific for moiety B  
20 (or an active fragment of such antibody) is separately expressed in the same cell. Upon addition to the cell of the divalent chemical that includes moiety A and moiety B linked together, the affinity of each separately expressed fusion protein for either moiety A or moiety B mediates formation of a complex in which the engineered ZFP is physically linked to the nuclear localization and effector domains. This embodiment permits very specific  
25 inducibility of localization of the complex to the nucleus by dosing cells with the divalent chemical. Numerous possibilities exist for moieties A and B. The criteria are that the moiety is sufficiently antigenic to allow selection of a monoclonal antibody specific for that moiety, and that the two moieties, linked together, form a compound that can enter and act within a cell to mediate formation of the complex. In one embodiment, moiety A can have  
30 a structure, for example, as depicted below:



moiety B can have a structure, for example, as depicted below:



and moieties A and B can be linked by a linker of any suitable length, having units such as those depicted below:



Any compound capable of entry into cell and having moieties against which antibodies can be raised is suitable for this aspect of the invention. This embodiment of the invention permits sequence-specific localization of the effector domain to allow it to act on the selected promoter, causing an alteration of gene expression in the cell which can, for example, produce a desired phenotype. In the absence of the divalent chemical, such a phenotype is not manifest, because the site specificity conferred by the ZFP is not joined to the nuclear localization and effector activity of the engineered effector protein.

Accordingly, induction of the site specific effector activity is achieved by addition of the divalent chemical.

In a preferred embodiment, a chemical switch is used which is a divalent chemical comprising two linked compounds. These compounds may be any compounds to which antibodies can be raised linked by a short linker, for example,  $\text{CH}_2\text{CH}_2$ . In one preferred embodiment, a single chain antibody (e.g., a single chain  $\text{F}_v$  (scFv)) binds to one portion of the divalent chemical to link it to a ZFP. The other portion of the divalent chemical binds to a second single chain antibody, for example a single chain  $\text{F}_v$  (scFv), which recognizes and binds to a nuclear targeting sequence (e.g., nuclear localization signal) which is

operably linked to an effector domain, preferably an activator or repressor domain (Fig. 6). Thus, translocation of the ZFP into the nucleus will only occur in the presence of the divalent chemical. In an alternative embodiment, the effector domain is bound to the ZFP which is in turn bound to a single chain antibody. However, because the effector-ZFP-  
5 antibody complex may diffuse into the nucleus in the absence of the divalent chemical, it is preferable that the ZFP and effector domains are on separate proteins. Even if the ZFP-antibody diffuses into the nucleus, it would at worst be a negative regulator, not an activator, until the chemical is present. This is also not as preferred because it is more preferable to manipulate the translocation of both the ZFP and effector domain.

10 The chemical switch embodiments of the invention are also applicable to engineering other useful inducible gene expression systems. For example, using this approach, artificial defense mechanisms can be engineered into a plant. When pathogens infect plants, small molecule "elicitors" are often produced. The antibodies in the molecular switch system can thus be specific to such elicitor compounds, such that only in the presence of elicitors is the  
15 inducible gene expression complex formed, allowing an engineered response to the pathogenic infection. In this manner, plant defense genes can be directly and immediately activated without influence of "suppressors" produced by pathogens when pathogens infect the plant. In a preferred embodiment, two scFvs (scFv-1 and scFv-2) are produced. Each scFv recognizes a different part of an elicitor (that is, different epitopes on the elicitor  
20 molecule). The zinc finger/scFv-1 fusion protein and the NLS-AD-scFv-2 fusion protein bind to the elicitor, creating the gene activation complex capable of localization to the nucleus, and plant defense genes are selectively activated based on the design of the ZFP. By this approach, plant defense genes are only activated in the presence of the pathogen.

Another embodiment of the invention relating to combinatorial transcriptional  
25 regulation involves the S-tag, S-protein system. The S-tag is a short peptide (15 amino acids) and S-protein is a small protein (104 amino acids). The affinity of the S-tag and S-protein complex is high ( $K_d=1\text{nM}$ ). The S-tag/S-protein system can be used in a chemical switch system. In this embodiment, the S-tag is conjugated to a ZFP, and the S-protein is conjugated to a nuclear localization signal (NLS) which is conjugated to an activation  
30 domain (AD) or to a repressor. The S-tag-zinc finger and S-protein-NLS-AD constructs are expressed using two different promoters, resulting in formation of a zinc finger-S-tag-S-protein-NLS-AD complex. The chemical switch involves the use of S-tag and S-protein

mutants which cannot interact unless a small molecule or chemical is present to link the S-tag and S-protein together. These small molecules can also be used to disrupt wild type S-tag-S-protein interaction.

In another embodiment of the invention, ZFPs or fusion proteins comprising zinc  
5 finger domains and single strand DNA binding protein (SSB) are used to inhibit viral replication. Geminivirus replication can be inhibited using zinc finger domains or zinc finger-SSB fusion proteins which are targeted to "direct repeat" sequences or "stem-loop" structures which are conserved in all gemini viruses, which are nicked to provide a primer for rolling circle replication of the viral genome. For example, AL1 is a tobacco mosaic  
10 virus (TMV) site-specific endonuclease which binds to a specific site on TMV. After binding, AL1 cleaves the viral DNA in the stem-loop to begin rolling circle viral replication. A ZFP or zinc finger-SSB fusion protein is engineered using the recognition code of the invention, such that the SSB portion binds to the cleavage site, and the zinc finger domain binds adjacent to this site. Alternatively, a ZFP alone is used which is designed to bind to  
15 the AL1 binding or cleavage site, thus preventing AL1 from binding to its binding site or to the stem-loop structure. Thus, ZFPs competitively inhibit binding of AL1 to its target site. These types of ZFPs or zinc-finger SSB fusion proteins can be designed to target any desired binding site in any DNA or RNA virus which is involved in viral replication. In addition, because the stem-loop structure is conserved in all geminiviruses, the nick site of  
20 all such viruses can be blocked using similar ZFPs or zinc finger-SSB fusions.

Another embodiment of the invention relates to methods for detecting an altered zinc finger recognition sequence. In this method a nucleic acid containing the zinc finger recognition sequence of interest is contacted with a ZFP of the invention that is specific for the sequence and conjugated to a signaling moiety, the ZFP present in an amount sufficient  
25 to allow binding of the ZFP to its recognition (i.e., target) sequence if said sequence was unaltered. The extents of ZFP binding is then determined by detecting the signaling moiety and thereby ascertain whether the normal level of binding to the zinc finger recognition sequence has changed. If the binding is diminished or abolished relative to binding of said ZFP to the unaltered sequence, then the recognition sequence has been altered. This  
30 method is capable of detecting altered zinc finger recognition site in which a mutation (substitution), insertion or deletion of one or more nucleotides has occurred in the site. The method is useful for detecting single nucleotide polymorphisms (SNPs).



Any convenient signaling moiety or system can be used. Examples of signaling moieties include, but are not limited to, dyes, biotin, radioactive labels, streptavidin and marker proteins. Many marker proteins are known, but not limited to,  $\beta$ -galactosidase, GUS ( $\beta$ -glucuronidase), green fluorescent proteins, including fluorescent mutants thereof which have altered spectral properties (*i.e.*, exhibit blue or yellow fluorescence, horse radish peroxidase, alkaline phosphatase, antibodies, antigens and the like.

In addition, the present invention contemplates a method of diagnosing a disease associated with abnormal genomic structure. Examples of such diseases are those where there is an increased copy number of particular nucleic acid sequences. For example, the high copy number of the indicated sequences is found in persons with the indicated disease relative to the copy number in a healthy individual: (CAG)<sub>n</sub> for Huntington disease, Friedreich ataxia; (CGG)<sub>n</sub> for Fragile X site A; (CCG)<sub>n</sub> for Fragile X site E; and (CTG)<sub>n</sub> for myotonic dystrophy.

This method comprises (a) isolating cells, blood or a tissue sample from a subject; (b) contacting nucleic acid in or from the cells, blood or tissue sample with a ZFP of the invention (with specificity for the target of the disease in question) linked to a signaling moiety and, also, optionally, fused to a cellular uptake domain; and (c) detecting binding of the protein to the nucleic acid to thereby make a diagnosis. If necessary, the amount of binding can be quantitated and this may aid in assessing the severity or progression of the disease in some cases. The method can be performed by fixing the cells, blood or tissue appropriately so that the nucleic acids are detected in situ or by extracting the nucleic acids from the cells, blood or tissue and then performing the detection and optional quantitation step.

## VII. Pharmaceutical Formulations

Therapeutic formulations of the ZFPs, fusion proteins or nucleic acids encoding those ZFPs or fusion proteins of the invention are prepared for storage by mixing those entities having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and

concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol);  
5 low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or  
10 dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN<sup>TM</sup>, PLURONICS<sup>TM</sup> or polyethylene glycol (PEG).

The formulation herein may also contain more than one active compound as  
15 necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example,  
20 hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

25 The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide variant, which matrices are in the form of shaped articles, e.g.,  
30 films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-

glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

Those of skill in the art can readily determine the amounts of the ZFPs, fusion proteins or nucleic acids encoding those ZFPs or fusion proteins to be included in any pharmaceutical composition and the appropriate dosages for the contemplated use.

Throughout this application, various publications, patents, and patent applications have been referred to. The teachings and disclosures of these publications, patents, and patent applications in their entireties are hereby incorporated by reference into this application.

It is to be understood and expected that variations in the principles of invention herein disclosed in exemplary embodiments may be made by one skilled in the art and it is intended that such modifications, changes, and substitutions are to be included within the scope of the present invention.

### Example 1

#### Design of ZFP using recognition code

To confirm the amino acid-base contacts shown in Table 1, a ZFP targeting the AL1 binding site in the tomato golden mosaic virus genome was designed. As shown in Fig. 7, the target site, 5'-AGTAAGGTAG-3' (SEQ ID NO: 14), was divided into three regions each having four DNA base pairs (Step 1). These regions were overlapping in that the fourth base of the first region became the first base of the second region, and the fourth

base of the second region became the first base of the third region. Thus, three zinc fingers are used to target a 10 base pair region of nucleic acid. Next, four amino acids per four DNA base pairs were chosen from the table for use with the Sp1C-domain 2 frame work described by Berg (Step 2). Amino acids other than those at positions -1, 2, 3 and 6 were not modified. DNA oligomers corresponding to the peptide sequence were synthesized by standard methods using a DNA synthesizer (Step 3). These three zinc finger domains were then assembled by one polymerase chain reaction (PCR) to construct the ZFP targeting the AL1 site (Step 4). The DNA fragments were cloned into the EcoRI/HindIII sites of a pET21-a vector (Novagen). The resulting plasmids were introduced into *E. coli* BL21(DE3)pLysS for protein overexpression and purified by cation exchange column chromatography (Step 5). A 60 mL culture was grown to OD<sub>600</sub>=0.75 at 37°C, induced with 1 mM IPTG for 3 hours, and lysed by freeze thaw in cold lysis buffer (100 mM Tris-HCl, pH 8.0, 1 M NaCl, 5 mM dithiothreitol (DTT), 1 mM ZnCl<sub>2</sub>. After treatment with polyethyleneimine (pH 7, 0.6%) and precipitation with 40% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, the resulting pellet was redissolved in 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM DTT, 0.1 mM ZnCl<sub>2</sub> and purified using a Bio-Rex 70 cation exchange column, eluting with 0.3 mM NaCl buffer. All purified proteins were >95% homogeneous as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

## Example 2

### Determination of affinity of ZFP for target sequence

To test the affinity of the synthesized ZFP for the target sequence, a gel shift experiment was performed using an AL1 target polynucleotide (5'-TATATATAAGTAAGGTAGTATATATA-3'; SEQ ID NO: 24). As a positive control, the ZFP Zif268 and a target polynucleotide for this protein (5'-TATATATAGCGTGGGCGTTATATATA-3'; SEQ ID NO: 25) were also used. The targeting site of each ZFP is underlined. The concentrations of AL1 ZFP in the assay were 0, 14, 21, 28, 35, 70 and 88 mM. The concentrations of Zif268 were 2.6, 3.3, 6.6, 13 and 20 μM. Prior to the assay, target polynucleotides were labeled at the 5'-end with [γ-<sup>32</sup>P]ATP. ZFPs were preincubated on ice for 40 minutes in 10 μL of 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.1 mM ZnCl<sub>2</sub>, 1 mg/ml BSA, 10% glycerol containing the end-labeled probe (1 pmol). Poly (dA-dT)<sub>2</sub> was then added, and incubation was

continued for 20 minutes before electrophoresis on a 6% nondenaturing polyacrylamide gel (0.5 x tris-borate buffer) at 140 volts for 2 hours at 4°C. half-maximal binding of the AL1 and Zif268 ZFP was observed at 18 nM and 4 nM, respectively. The affinity of the AL1 ZFP for its target sequence is also comparable to the ZFPs selected using phage display (30-40 nM, PCT WO95/19431; Liu et al., *Proc. Natl. Acad. Sci. U.S.A.* **94**:5525-5530, 1997).

### Example 3

#### Determination of DNA base specificity

To determine DNA base specificity, the following study was conducted. Based on Fig. 3, the aspartic acid at position 2 in the first zinc finger domain is expected to bind to the cytosine at the 3' end of the 4 base pair region. A gel shift assay was performed as described above, using the AL1 ZFP (14, 21 and 35 nM concentrations) and the following end-labeled polynucleotides: 5'-(TA)<sub>4</sub>AGTAAGGTAG(TA)<sub>4</sub> (SEQ ID NO: 26); 5'-(TA)<sub>4</sub>AGTAAGGTAA(TA)<sub>4</sub> (SEQ ID NO: 27); 5'-(TA)<sub>4</sub>AGTAAGGTAT(TA)<sub>4</sub> (SEQ ID NO: 28); and 5'-(TA)<sub>4</sub>AGTAAGGTAC(TA)<sub>4</sub> (SEQ ID NO: 29). SEQ ID NO: 24 is the wild-type target sequence having a G at the 3' end of the 10 base pair sequence. The other three polynucleotides have point mutations at this position (A, T and C in SEQ ID NOS: 27, 28, and 29, respectively - base is underlined). Significant binding of the AL1 ZFP only occurred when the protein was incubated with SEQ ID NO: 27. Very little binding to SEQ ID NOS: 27, 28, or 29 was observed, thus confirming the specific interaction of aspartic acid at position 2 with guanine at the 3' end of the four base pair region.

### Example 4

#### Recognition code

The complete recognition code is confirmed by individually screening amino acids at positions -1, 2, 3 and 6 of a ZFP. For example, in the screening of amino acids at position 2, the protein comprising three zinc finger domains:

PYKCPECCKGSFSDS~~X~~ALQRHQRTHTGEKPYKCPECCKGSFSSQSSNLQKHQRTHTGEKPYKCPECCKGSFSSRSDHLQRHQRTHTGEK (SEQ ID NO: 30)

is used for the screening (X, underlined at position 2, is mutated). The first zinc finger domain is used to identify DNA base specificity at position 2 because the domain (Asp, Ala and Arg at positions -1, 3, and 6, respectively) is known to bind to DNA randomly. The degenerate DNA probes 5'-GGGGAANNNY-3' (N=equimolar mixture of G, A, T, or C; Y=G, A, T or C; SEQ ID NO: 31) are used in order to identify the DNA base specificity of amino acids at position 2 without the influence of DNA base-amino acid interactions at other positions.

The Asp and Gly mutant proteins were prepared and the DNA base specificity was investigated using the gel shift assay. The following <sup>32</sup>P-labeled duplexes were used: 5'-(TA)<sub>4</sub>GGGGAANNNG(TA)<sub>4</sub> (1) (SEQ ID NO: 32); 5'-(TA)<sub>4</sub>GGGGAANNNA(TA)<sub>4</sub> (2) (SEQ ID NO: 33); 5'-(TA)<sub>4</sub>GGGGAANNNT(TA)<sub>4</sub> (3) (SEQ ID NO: 34); and 5'-(TA)<sub>4</sub>GGGGAANNNC(TA)<sub>4</sub> (4) (SEQ ID NO: 35). As shown in Fig. 8, the Asp mutant preferentially bound to 5'-GGGGAANNNG-3' (Probe 1; bases 9-18 of SEQ ID NO: 32). The mutation from Asp to Gly resulted in loss of selectivity as shown in Fig. 8. This shows that aspartic acid at position 2 independently recognizes the cytosine base at the 4<sup>th</sup> position in the DNA target. The recognition of the cytosine base at the 4<sup>th</sup> position by the aspartic acid at position 2, which is predicted in Table 1, was experimentally confirmed. The complete recognition code is confirmed by repeating similar experiments with other amino acids.

### Example 5

#### Engineering of transposases and transposition assay

The *C. elegans* transposase Tc1 is useful to demonstrate creation of a site-specific, genetic knock-in using a ZFP fused to Tc1. The transposition method is summarized in Fig. 9. A marker fragment or plasmid containing the homogeneous TIRs is used which contains a selectable marker gene (e.g., kanamycin resistance) between the TIRs. An acceptor vector comprising a target region (e.g., 1 or 2 Zif268 binding sites), a normal origin of replication and ampicillin resistance is combined with the TIR-kanamycin-TIR linear fragment, or with a donor vector comprising this construct, tetracycline resistance and a pSC101<sup>TS</sup> ori temperature-sensitive origin of replication. In this case the TIRs are the same (homoassay); however, a similar assay can be done using different TIRs and different TIR binding domains (such as that from *C. elegans* transposase

Tc30)(heteroassay). The transposition reaction is performed using the ZFP-transposase fusion protein followed by *E. coli* transformation and, in the case of the donor vector, heat treatment to eliminate the unreacted donor vector, resulting in a vector in which the TIR-kanamycin-TIR construct has been inserted into the Zif268 target site of the acceptor  
 5 vector. Transposition efficiency is determined by comparing the titer of ampicillin resistant *E. coli* to ampicillin-kanamycin resistant *E. coli*.

### Example 6

#### General Scheme for Producing Three-Finger ZFPs

10 Each finger of the ZFP was designed to have the same frame work sequence, PYKCPECGKSFSXSSXXLQXHQRTHTGEK (SEQ ID NO: 13), wherein X, at positions – 1, 2, 3 and 6, are determined according to the zinc finger recognition code of Table 1 and the desired target sequence. The DNA for each finger was designed to enable the assembly of DNA encoding three zinc finger domains in correct orientation by PCR. Three pairs of  
 15 DNA oligonucleotides were synthesized, each pair being two overlapping oligomers coding for one specific finger domain as follows:

#### First Zinc Finger Domain (Zif-1)

Zif-1, sense-oligomer (Primer 1)

5'-GGGGAGAAGCCGTATAAATGTCCGGAATGTGGTAAAAGTTTTAGCNNN

20 AGCNNNNNNNTTG-3' (SEQ ID NO: 36)

Zif-1, antisense-oligomer (Primer 2)

5'-TTTGTATGGTTTTTTCACCGGTATGGGTACGCTGATGNNNCTGCAANNN

NNNGCTNNNGCT-3' (SEQ ID NO: 37)

#### Second Zinc Finger Domain (Zif-2)

25 Zif-2, sense-oligomer (Primer 3)

5'-GGTGAAAAACCATACAAATGTCCAGAGTGCGGCAAATCTTCTCTNNN

TCTNNNNNNNCTT-3' (SEQ ID NO: 38)

Zif-2, antisense-oligomer (Primer 4)

5'-CTTGTAAGGCTTCTCGCCAGTGTGAGTACGCTGATGNNNCTGAAGNNN

30 NNNAGANNNAGA-3' (SEQ ID NO: 39)

#### Third Zinc Finger Domain (Zif-3)

Zif-3, sense-oligomer (Primer 5)

5'GGCGAGAAGCCTTACAAGTGCCCTGAATGCGGGAAGAGCTTTAGTNNN  
AGTNNNNN-3 (SEQ ID NO: 40)

Zif-3, antisense-oligomer (Primer 6)

5'-CTTCTCCCCCGTGTGCGTGCGTTGGTGNNNTTGTAANNNNNNACTNNN  
5 ACTAAAG-3' (SEQ ID NO: 41)

In each of these DNA-encoding finger domains, N is G, A, T, or C.

The 18 nucleotides at the 3' end of each DNA oligonucleotide in each pair are complementary to each other. The first two DNA oligonucleotide sequences of each pair are annealed and filled in by Klenow Fragment to produce a DNA fragment coding one  
10 finger. Moreover, in order to ensure correct orientation of the zinc finger domains, the 18-bp at the 5' end of the Zif-2 DNA fragment is complementary to 18-bp at 3' end of Zif-1, and 18-bp of 3' end of Zif-2 to 18-bp at 5' end of Zif-3. Therefore, these three finger DNAs can be assembled in correct orientation by specific primers, OTS-007 and OTS-008.

OTS-007:

15 5'-GGGCCCCGGTCTCGAATTCGGGGAGAAGCCGTATAAATGTCCGGAA-3' (SEQ ID NO: 42)

OTS-008:

5'-CCCGGGGGTCTCAAGCTTTTACTTCTCCCCCGTGTGCGTGCGTTGGTG-3'  
(SEQ ID NO: 43)

20

### Example 7

#### 3-finger ZFP for the L1 site of beet curly top virus (BCTV)

Based on the target DNA sequence of BCTV, 5'-TTGGGTGCTC-3' (SEQ ID NO: 44), a DNA encoding the 3-finger protein was designed. Six oligonucleotides were  
25 synthesized as shown:

Zif-1, sense-oligomer (OTS-254)

5'-GGGGAGAAGCCGTATAAATGTCCGGAATGTGGTAAAAGTTTTAGCACC  
AGCAGCGATTTG-3' (SEQ ID NO: 45)

Zif-1, antisense-oligomer (OTS-255)

30 5'-TTTGTATGGTTTTTCACCGGTATGGGTACGCTGATGACGCTGCAAATC  
GCTGCTGGTGCT-3' (SEQ ID NO: 46)

Zif-2, sense-oligomer (OTS-256)



5'-GGTGAAAAACCATACAAATGTCCAGAGTGCGGCAAATCTTTCTCTACC  
TCTGATCATCTT-3' (SEQ ID NO: 47)

Zif-2, antisense-oligomer (OTS-257)

5'-CTTGTAAGGCTTCTCGCCAGTGTGAGTACGCTGATGACGCTGAAGATG  
5 ATCAGAGGTAGA-3' (SEQ ID NO: 48)

Zif-3, sense-oligomer (OTS-258)

5'GGCGAGAAGCCTTACAAGTGCCCTGAATGCGGGAAGAGCTTTAGTCGT  
AGTGATAG-3' (SEQ ID NO: 49)

Zif-3, antisense-oligomer (OTS-259)

10 5'-CTTCTCCCCCGTGTGCGTGCGTTGGTGGGTTTGTAAGCTATCACTACG  
ACTAAAG-3' (SEQ ID NO: 50)

#### 1) Annealing

5 µl of both OTS-254 and OTS-256, both OTS-256 and OTS-257, and both OTS-  
258 and OTS-259 (all, 100 pmol/µl) was added to 10 µl of TEN buffer (20 mM Tris-HCl  
15 (pH 8.0)/2 mM EDTA/200 mM NaCl), respectively, incubated at 95 °C for 5 min, and then  
left in the heating block at room temperature until it reached room temperature.

1 µl of each annealed sample was incubated at 37 °C for 1 hr in 20 µl of the  
reaction buffer containing 5 units of Klenow Fragment and 0.25 mM of dNTP mixture.  
After incubation, 5 µl of H<sub>2</sub>O was added to each reaction mixture to adjust the DNA  
20 concentration to 1 pmol/µl.

#### 2) PCR Assembly

The following was mixed and PCR was performed:

	H <sub>2</sub> O	36.5 µl
	10 X Vent Buffer	5 µl
25	dNTP mixture (2.5 mM each)	4 µl
	OTS-007 (100 pmol/µl)	0.5 µl
	OTS-008 (100 pmol/µl)	0.5 µl
	Filled-in Samples: OTS-254/255	1 µl
	OTS-256/257	1 µl
30	OTS-258/259	1 µl
	Vent DNA polymerase	0.5 µl

The reaction product was analyzed on a 2% agarose gel and produced the expected 300-bp DNA fragment as the single major band. After cloning of this product into a pET-21a vector, DNA sequencing confirmed that these three DNA fragments were assembled in the correct orientation to produce the artificial ZFP targeting the L1 binding site of BCTV. No random assembled product was observed.

### Example 8

#### Assembly of 5-finger domains

A 5-finger ZFP was designed to target the 16-bp sequence of the promoter of *Arabidopsis* DREB1A gene.

1) Preparation of DNAs encoding a 3-finger and a 2-finger ZFPs with PCR primers containing the BsaI restriction site

The sequence of 5'-ATA GTT TAC GTG GCA T-3' (SEQ ID NO: 51) in the DREB1A promoter was chosen as the target DNA by the artificial ZFP, and it was divided into two 10-bp DNAs, 5'-ATA GTT TAC G-3' (Target A)(SEQ ID NO: 52) and 5'-TAC GTG GCA T-3' (Target B)(SEQ ID NO: 53). As described in Example 7, DNA of a 2-finger ZFP for Target B (Zif A) and DNA of a 3-finger ZFP for Target A (Zif B) were prepared. Since the 3' end of the ZifA DNA is ligated with 5' end of the ZifB DNA, the Zif A DNA was amplified by PCR with primers OTS-007 and OTS-430 and the ZifB DNA with primers OTS-431 and OTS-008. The reactions were analyzed on a 2% agarose gel and produced the expected DNAs for 2- and 3-fingered ZFPs for ZifA and ZifB, respectively.

2) BsaI digestion

Both PCR products (0.5 µg of each) were digested at 50°C for 1 hr in the 60 µl reaction buffer containing 20 units of BsaI endonuclease enzyme. After purifying with a ChromaSpin+TE-100 column, phenol extraction was performed to remove BsaI. The two digested DNA fragments were directly ligated using a DNA ligase enzyme (16°C, overnight). The reaction was analyzed on a 2% agarose gel and more than 80% of the product was the expected ligation product. The mixture was used for cloning into a pET-21a vector, and sequencing confirmed that the 5-finger domains were assembled in correct orientation.

OTS-430:

5'-TTCAGGGCGGTCTCTCGGCTTCTCGCCAGTGTGAGTACGCTGATG-3' (SEQ ID NO: 54) (underlined nucleotides are the BsaI site)

OTS-431:

5'-CGAATTCGGGTCTCAGCCGTATAAATGTCCGGAATGTGGTAAAA-3' (SEQ ID NO: 55) (underlined nucleotides are the BsaI site).

### Example 9

#### Modular Assembly of Six-Finger ZFPs

Fig. 10 shows a method of assembling 6-finger ZFPs. For example, a 3-finger DNA is amplified from the DNA of a 3-finger protein Zif-A by PCR primers OTS-007 and OTS-429, and a second 3-finger DNA is amplified from DNA of the 3-finger protein Zif-B by OTS-431 and OTS-008.

OTS-429:

5'-TGCGGCCGGGTCTCTCGGCTTCTCCCCCGTGTGCGTGCGTTGGTG-3' (SEQ ID NO: 56) (underlined nucleotides are the BsaI site).

After amplification, the DNA fragments are digested with BsaI, which produces 5'-CGGC-3' and 5'-GCCG-3' sticky ends from ZifA and ZifB, respectively (Fig. 10). These sticky ends are complementary to each other, and the two digested DNA fragments can be assembled in correct orientation by a DNA ligase enzyme e.g., T4 DNA ligase. By using different primer sets, 4- and 5-finger proteins are prepared.

### Example 10

#### Assembly of Six-Finger Domains Into ZFPs

A 6-finger ZFP was designed to target the whole L1 site of BCTV (Clone 5, Table 5).

#### 1) Preparation of two 3-finger DNAs

The L1 target site is 5'-TTG GGT GCT TTG GGT GCT C-3' (SEQ ID NO: 57), and was divided into two 10-bp DNAs, 5'-TTG GGT GCT T-3' (Target A)(SEQ ID NO: 58) and 5'-TTG GGT GCT C-3' (Target B)(SEQ ID NO: 59), for ZFP design. DNAs of a 3-finger protein targeting Target B (ZifA) and another 3-finger protein binding to Target A (ZifB) were prepared according to the method described in Example 7 using PCR with primers OTS-007 and OTS-429 for ZifA, and with primers OTS-431 and OTS-008 for

ZifB. The reaction was analyzed on a 2% agarose gel and the expected DNA fragments were obtained.

## 2) BsaI digestion

Both PCR products (0.5 µg of each) were digested at 50 °C for 1 hr in the 60 µl reaction buffer containing 20 units of BsaI endonuclease enzyme. After purifying with a ChromaSpin+TE-100 column, phenol extraction was performed to remove BsaI. The two digested DNA fragments were directly ligated using a DNA ligase enzyme (16°C, overnight). The reaction was analyzed on a 2% agarose gel and more than 80% of the product was the expected ligation product. The mixture was used for cloning into a pET-21a vector, and it was confirmed that the 6-finger domains were assembled in correct orientation.

## Example 11

### High affinity 6-finger ZFPs

As described in Example 10, the DNA of Clone 5 was cloned into the EcoRI/HindIII sites of an *E. coli* expression vector of pET-21a. After expression in an *E. coli* strain BL21(DE3) pLysS, the protein was purified >95% homogeneous as judged by SDS/PAGE.

To determine the affinity of the artificial ZFP Clone 5, a gel shift assay was performed using a radiolabeled L1 target DNA duplex,

5'-TATATATATTGGGTGCTTTGGGTGCTCTATATATA-3'. (SEQ ID NO: 60)  
The concentrations of Clone 5 were 0, 0.003, 0.01, 0.03, 0.1 and 1 nM. The ZFPs were preincubated on ice for 40 minutes in 10 µl of 10 mM Tris-HCl, pH 7.5/100 mM NaCl/1 mM MgCl<sub>2</sub>/0.1 mM ZnCl<sub>2</sub>/1 mg/ml BSA/10% glycerol containing the radiolabeled probe (0.03 fmol per 10 µl of buffer). 1 µg of poly(dA-dT)<sub>2</sub> was then added, and incubation was continued for 20 minutes before loading onto a 6% nondenaturing polyacrylamide gel (0.5X TB) and electrophoresing at 140 V for 2 hr at 4 °C. The radioactive signals were exposed on x-ray films.

For Clone 5, the vast majority of the DNA probe is bound to the protein even at 3 pM. Hence, the dissociation constant is less than 3 pM. Two additional ZFPs were synthesized (Clones 6 and 7; Table 4) and produced proteins with similar high affinities.

## Example 12

### Design, Production and Analysis of Additional ZFPs

Additional multi-fingered ZFPs were designed and synthesized according to the strategy of Examples 7 and 9 using the Sp1C domain 2 framework and the amino acids at positions -1, 2, 3 and 6 as shown in Table 2. The targets sequences for each ZFP and the dissociation constant of the ZFP for its target is provided in Table 4.

In tomato golden mosaic virus (TGMV) and beet curly top virus (BCTV) genomes, the target sites are critical sites for the gemini viral replication (Clones 1 and 2). Other target sites are the sequences found around 50 to 100-bp upstream from TATA box in promoters of plant genes, *Arabidopsis thaliana* DREB1A (drought tolerance gene; Clone 3) and NIM1 (systemic acquired resistance; Clone 4).

In these experiments, the coding regions of designed ZFPs were cloned into the EcoRI and HindIII sites of expression vector pET-21a (Novagen). Resulting plasmids were then introduced into *E. coli* BL21(DE3)pLysS for protein overexpression. A 60-ml culture was grown to  $OD_{600} = 0.6-0.75$  at 37 °C, induced with 1 mM IPTG for 3 hr, and lysed using a ultrasonicator in cold lysis buffer [100 mM Tris-HCl, pH8.0/1 M NaCl/1 mM  $ZnCl_2$ /5 mM dithiothreitol containing one tablet of Complete, Mini, EDTA-free (Roche Molecular Biochemicals) per 10 ml lysis buffer. After treatment with polyethyleneimine (pH 7.0, 0.6%) and precipitated with 40%  $(NH_4)_2SO_4$ , the resulting pellet was redissolved in 50 mM Tris-HCl, pH 8.0/100 mM NaCl/0.1 mM  $ZnCl_2$ /5 mM dithiothreitol buffer and purified by chromatography on a Bio-Rex 70 column, eluting 300 mM NaCl buffer. All purified proteins were >95% homogeneous as judged by SDS/PAGE. Protein concentration was determined using Protein Assay ESL (Roche Molecular Biochemicals).

For the DNA binding assays, twenty six base-pair synthetic oligonucleotides, labeled at the 5'-end with  $[\gamma-^{32}P]ATP$ , were used in the gel-retardation assays. Probes for ZFPs with more than 5 finger domains were labeled with Klenow Fragment and  $[\alpha-^{32}P]dATP$  and  $[\alpha-^{32}P]dTTP$  to obtain high radioactivity. The ZFPs were preincubated on ice for 40 minutes in 10  $\mu$ l of 10 mM Tris-HCl, pH 7.5/100 mM NaCl/1 mM  $MgCl_2$ /0.1 mM  $ZnCl_2$ /1 mg/ml BSA/10% glycerol containing the radiolabeled probe (1 fmol per 10  $\mu$ l of buffer). 1  $\mu$ g of poly(dA-dT)<sub>2</sub> was then added, and incubation was continued for 20 minutes before loading onto a 6% nondenaturing polyacrylamide gel (0.5X TB) and

electrophoresing at 140 V for 2 hr at 4 °C. For multi-finger proteins, 0.03 fmol of radiolabeled probes were used. The radioactive signals were quantitated with a PhosphorImager (Molecular Dynamics) and exposed on x-ray films. The dissociation constants were calculated by curve fitting with the KALEIDAGRAPH program (Synergy Software).

Gel shift assays were performed with the designed 3-finger and 6-finger proteins and the  $K_d$  values were calculated. The measured  $K_d$  for clones 1-4 was 18, 15, 11 and 23 nM respectively. For Clones 5-7, the  $K_d$ s were all less than 3 pM.

10

**Table 5**

No.	Target Sequence	Amino Acids Used for Recognition											
		Zif1				Zif2				Zif3			
		-1	2	3	6	-1	2	3	6	-1	2	3	6
1	5' AGT AAG GTA G 3'	Gln	Asp	Ser	Arg	Arg	Asp	Asn	Gln	Thr	Thr	His	Gln
15 2	5' TTG GGT GCT C 3'	Thr	Ser	Asp	Arg	Thr	Asp	His	Arg	Arg	Asp	Ser	Thr
3	5' TAC GTG GCA T 3'	Gln	Asn	Asp	Arg	Arg	Asp	Ser	Arg	Glu	Asp	Asn	Thr
4	5' GGA GAT GAT A 3'	Thr	Thr	Asn	Arg	Thr	Asp	Asn	Arg	Gln	Asp	His	Arg
5	5' TTG GGT GCT TTG GGT GCT C 3'												
6	5' AGT AAG GTA GGA GAT GAT A 3'												
20 7	5' TAC GTG GCA TTG GGT GCT C 3'												

The target sequences of Clones 1-7 are designated as SEQ ID NOS: 61-67, respectively.

## WHAT IS CLAIMED IS:

1. An isolated, artificial zinc finger protein (ZFP) for binding to a target nucleic acid sequence, said ZFP comprising at least three zinc finger domains covalently joined to each other with from 0 to 10 amino acid residues, wherein the amino acids at positions -1, 2, 3  
5 and 6 of the  $\alpha$ -helix of the zinc finger are selected as follows:

at position -1, the amino acid is arginine, glutamine, threonine, methionine or glutamic acid;

at position 2, the amino acid is serine, asparagine, threonine or aspartic acid;

10 at position 3, the amino acid is histidine, asparagine, serine or aspartic acid; and

at position 6, the amino acid is arginine, glutamine, threonine, tyrosine, leucine or glutamic acid;

provided that said ZFP does not have an amino acid sequence consisting of any one of SEQ ID. NOS. 3-12.

15

2. An isolated, artificial zinc finger protein (ZFP) for binding to a target nucleic acid sequence, said ZFP comprising at least three zinc finger domains, each zinc finger domain independently represented by the formula

$-X_3\text{-Cys-X}_{2-4}\text{-Cys-X}_5\text{-Z}^1\text{-X-Z}^2\text{-Z}^3\text{-X}_2\text{-Z}^6\text{-His-X}_{3-5}\text{-His-X}_4\text{-}$ , said domains,

20 independently, covalently joined to each other with from 0 to 10 amino acid residues; wherein

X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain;

$Z^1$  is arginine, glutamine, threonine, methionine or glutamic acid;

25  $Z^2$  is serine, asparagine, threonine or aspartic acid;

$Z^3$  is histidine, asparagine, serine or aspartic acid; and

$Z^6$  is arginine, glutamine, threonine, tyrosine, leucine or glutamic acid;

provided that said protein does not have an amino acid sequence consisting of any one of SEQ ID. NOS. 3-12.

30

3. The ZFP of Claim 1 or 2, wherein said ZFP comprises from 3 to 40 zinc finger domains.

4. The ZFP of Claim 3, wherein said ZFP comprises from 3 to 15 zinc finger domains.
5. The ZFP of Claim 1 or 2, wherein said ZFP comprises 7, 8 or 9 zinc finger domains.
- 5 6. The ZFP of Claim 1 or 2, wherein said ZFP comprises 6 zinc finger domains.
7. The ZFP of Claim 1 or 2, wherein said ZFP consists essentially of 3 zinc finger domains.
8. The ZFP of any one of the preceding claims, wherein at least one of said zinc finger  
10 domains comprises the amino acid sequence -Pro-Tyr-Lys-Cys-Pro-Glu-Cys-Gly-Lys-Ser-  
Phe-Ser-Z<sup>1</sup>-Ser-Z<sup>2</sup>-Z<sup>3</sup>-Leu-Gln-Z<sup>6</sup>-His-Gln-Arg-Thr-His-Thr-Gly-Glu-Lys- (SEQ ID NO:  
13).
9. The ZFP of any one of the preceding claims, wherein at least one of said zinc finger  
15 domains comprises the amino acid sequence -Gln-His-Ala-Cys-Pro-Glu-Cys-Gly-Lys-Ser-  
Phe-Ser-Z<sup>1</sup>-Ser-Z<sup>2</sup>-Z<sup>3</sup>-Leu-Gln-Z<sup>6</sup>-His-Gln-Arg-Thr-His-Thr-Gly-Glu-Lys- (SEQ ID NO:  
68).
10. The ZFP of any one of the preceding claims, wherein at least one of said zinc finger  
20 domains comprises the amino acid sequence -Pro-Tyr-Lys-Cys-Pro-Glu-Cys-Gly-Lys-Ser-  
Phe-Ser-Z<sup>1</sup>-Ser-Z<sup>2</sup>-Z<sup>3</sup>-Leu Ser-Z<sup>6</sup>-His-Gln-Arg-Thr-His-Thr-Gly-Glu-Lys-(SEQ ID NO:  
69).
11. The ZFP of any one of Claims 2-7, wherein the X positions of at least one of said zinc  
25 finger domains comprise the corresponding amino acids from a Zif268 zinc finger domain.
12. The ZFP of any one of the preceding claims, wherein Z<sup>1</sup> is methionine in at least one  
of said zinc finger domains.
- 30 13. The ZFP of any one of the preceding claims, wherein Z<sup>1</sup> is glutamic acid in at least one  
of said zinc finger domains.



14. The ZFP of any one of the preceding claims, wherein  $Z^2$  is threonine in at least one of said zinc finger domains.

5 15. The ZFP of any one of the preceding claims, wherein  $Z^2$  is serine in at least one of said zinc finger domains.

16. The ZFP of any one of the preceding claims, wherein  $Z^2$  is asparagine in at least one of said zinc finger domains.

10 17. The ZFP of any one of the preceding claims, wherein  $Z^6$  is glutamic acid in at least one of said zinc finger domains.

18. The ZFP of any one of the preceding claims, wherein  $Z^6$  is threonine in at least one of said zinc finger domains.

15 19. The ZFP of any one of the preceding claims, wherein  $Z^6$  is tyrosine in at least one of said zinc finger domains.

20 20. The ZFP of any one of the preceding claims, wherein  $Z^6$  is leucine in at least one of said zinc finger domains.

21. The ZFP of any one of the preceding claims, wherein  $Z^2$  is aspartic acid in at least one of said zinc finger domains, but  $Z^1$  is not arginine in the same domain.

25 22. An isolated, artificial zinc finger protein (ZFP) comprising three zinc finger domains, each zinc finger domain represented by the formula -Pro-Tyr-Lys-Cys-Pro-Glu-Cys-Gly-Lys-Ser-Phe-Ser- $Z^1$ -Ser- $Z^2$ - $Z^3$ -Leu-Gln- $Z^6$ -His-Gln-Arg-Thr-His-Thr-Gly-Glu-Lys- (SEQ ID NO: 13), said domains directly joined to one to the other, wherein

$Z^1$  is arginine, glutamine, threonine, methionine or glutamic acid;

30  $Z^2$  is serine, asparagine, threonine or aspartic acid;

$Z^3$  is histidine, asparagine, serine or aspartic acid; and

$Z^6$  is arginine, glutamine, threonine, tyrosine, leucine or glutamic acid.

23. The ZFP of any one of the preceding claims, wherein

$Z^1$  is arginine, glutamine, threonine or glutamic acid;

$Z^2$  is serine, asparagine, threonine or aspartic acid;

5  $Z^3$  is histidine, asparagine, serine or aspartic acid; and

$Z^6$  is arginine, glutamine, threonine or glutamic acid.

24. A nucleic acid comprising a nucleotide sequence encoding a ZFP of any one of Claims  
1-23.

10

25. An expression vector comprising the nucleic of Claim 24.

26. A host cell comprising the expression vector of Claim 25.

15

27. A method of preparing a zinc finger protein which comprises

(a) culturing the host cell of Claim 26 for a time and under conditions to express  
said ZFP; and

(b) recovering said ZFP.

20

28. An isolated fusion protein comprising one or more ZFPs of the invention fused to one  
or more proteins of interest.

29. An isolated fusion protein comprising one or more ZFPs of the invention fused to one  
or more effector domains.

25

30. The fusion protein of Claim 2 comprising from one to six ZFPs and from two to six  
effector domains.

31. An isolated fusion protein comprising

30

(a) a first segment which is a ZFP of any one of Claims 1-23, and

(b) a second segment comprising a transposase, integrase, recombinase, resolvase,  
invertase, protease, DNA methyltransferase, DNA demethylase, histone acetylase, histone

deacetylase, nuclease, transcriptional repressor, transcriptional activator, single-stranded DNA binding protein, transcription factor recruiting protein nuclear-localization signal or cellular uptake signal.

- 5     32. An isolated fusion protein comprising
- (a) a first segment which is a ZFP of any one of Claims 1-23, and
  - (b) a second segment comprising a protein domain which exhibits transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone
- 10    acetylase activity, histone deacetylase activity, nuclease activity, nuclear-localization signaling activity, transcriptional repressor activity, transcriptional activator activity, single-stranded DNA binding activity, transcription factor recruiting activity, or cellular uptake signaling activity.
- 15    33. An isolated fusion protein comprising
- (a) a first segment which is a ZFP of any one of Claims 1-23, and
  - (b) a second segment comprising a protein domain capable of specifically binding to a binding moiety of a divalent ligand, said ligand capable of uptake by a cell.
- 20    34. The fusion protein of Claim 33, wherein the protein domain of said second segment is an S-protein, and S-tag or a single chain variable region (scFv) of an antibody.
35. An isolated fusion protein comprising
- (a) a first domain encoding a single chain variable region of an antibody;
- 25    (b) a second domain encoding a nuclear-localization signal; and
- (c) a third domain encoding transcriptional regulatory activity.
36. A nucleic acid comprising a nucleotide sequence encoding a ZFP of any one of Claims 28-35.
- 30    37. An expression vector comprising the nucleic of Claim 36.

38. A host cell comprising the expression vector of Claim 37.

39. A method of preparing a zinc finger protein which comprises

- 5 (a) culturing the host cell of Claim 38 for a time and under conditions to express said ZFP; and  
(b) recovering said ZFP.

40. A method of making a nucleic acid encoding a zinc finger protein (ZFP) comprising three contiguous zinc fingers domains, each separated from the other by no more than 10  
10 amino acids,

(a) preparing a mixture, under conditions for performing a polymerase-chain reaction (PCR), comprising:

- 15 (i) a first double-stranded oligonucleotide encoding a first zinc finger domain,  
(ii) a second double-stranded oligonucleotide encoding a second zinc finger domain,  
(iii) a third double-stranded oligonucleotide encoding a third zinc finger,  
(iv) a first PCR primer complementary to the 5' end of the first oligonucleotide,  
20 (v) a second PCR primer complementary to the 3' end of the third oligonucleotide,

wherein the 3' end of the first oligonucleotide is sufficiently complementary to the 5' end of the second oligonucleotide to prime synthesis of said second oligonucleotide therefrom,

25 wherein the 3' end of the second oligonucleotide is sufficiently complementary to the 5' end of the third oligonucleotide to prime synthesis of said third oligonucleotide therefrom, and

30 wherein the 3' end of the first oligonucleotide is not complementary to the 5' end of the third oligonucleotide and the 3' end of the second oligonucleotide is not complementary to the 5' end of the first oligonucleotide;

(b) subjecting the mixture to a PCR; and

(c) recovering the nucleic acid encoding the three zinc finger domains and preparing a nucleic acid encoding said ZFP.

41. A method of making a nucleic acid encoding a zinc finger protein (ZFP) comprising three zinc fingers domains, each domain independently represented by the formula

$$-X_3\text{-Cys-X}_{2-4}\text{-Cys-X}_{12}\text{-His-X}_{3-5}\text{-His-X}_4\text{-},$$

and said domains, independently, covalently joined with from 0 to 10 amino acid residues which comprises:

(a) preparing a mixture, under conditions for performing a polymerase-chain reaction (PCR), comprising:

- (i) a first double-stranded oligonucleotide encoding a first zinc finger domain,
- (ii) a second double-stranded oligonucleotide encoding a second zinc finger domain,
- (iii) a third double-stranded oligonucleotide encoding a third zinc finger,
- (iv) a first PCR primer complementary to the 5' end of the first oligonucleotide,
- (v) a second PCR primer complementary to the 3' end of the third oligonucleotide,

wherein the 3' end of the first oligonucleotide is sufficiently complementary to the 5' end of the second oligonucleotide to prime synthesis of said second oligonucleotide therefrom,

wherein the 3' end of the second oligonucleotide is sufficiently complementary to the 5' end of the third oligonucleotide to prime synthesis of said third oligonucleotide therefrom, and

wherein the 3' end of the first oligonucleotide is not complementary to the 5' end of the third oligonucleotide and the 3' end of the second oligonucleotide is not complementary to the 5' end of the first oligonucleotide;

(b) subjecting the mixture to a PCR; and

(c) recovering the nucleic acid encoding the three zinc finger domains and preparing a nucleic acid encoding said ZFP.

42. The method of Claim 40 or 41, wherein the first and second PCR primers independently include a restriction endonuclease recognition site.

43. The method of claim 42, wherein said restriction endonuclease recognition site is for BbsI, BsaI, BsmBI, or BspMI.

44. The method of claim 43, wherein said restriction endonuclease recognition site is for BsaI.

45. A method of making a nucleic acid encoding a zinc finger protein (ZFP) comprising four or more contiguous zinc fingers domains, each separated from the other by no more than 10 amino acids,

(a) preparing a first nucleic acid according to the method of Claim 42, wherein said second PCR primer includes a first restriction endonuclease recognition site;

(b) preparing a second nucleic acid according to the method of Claim 42, wherein said first and second PCR primers are complementary to the 5' and 3' ends, respectively, of the number of zinc finger domains selected for amplification,

wherein said first PCR primer includes a restriction endonuclease recognition site that, when subjected to cleavage by its corresponding restriction endonuclease, produces an end having a sequence which is complementary to and can anneal to, the end produced when said second PCR primer of step (a) is subjected to cleavage by its corresponding restriction endonuclease and

wherein said second PCR primer of step (b), optionally, includes a second restriction enzyme recognition site that, when subjected to cleavage produces an end that differs from and is not complementary to that produced from the first restriction endonuclease recognition site;

(c) optionally, preparing one or more additional nucleic acids by the method of Claim 42,

wherein said first and second PCR primers are complementary to the 5' and 3' ends, respectively, of the number of zinc finger domains selected for amplification,

wherein said first PCR primer for each additional nucleic acid includes a restriction endonuclease recognition site that, when subjected to cleavage by its corresponding

restriction endonuclease, produces an end having a sequence which is complementary to and can anneal to the end produced when the second PCR primer used for preparation of the second nucleic acid, or for the additional nucleic acid that is immediately upstream of the additional nucleic acid, is subjected to cleavage by its corresponding restriction


endonuclease, and

wherein said second PCR primer for each additional nucleic acid, optionally, includes a restriction endonuclease recognition site that, when subjected to cleavage produces an end that differs from and is not complementary to any previously used;

(d) cleaving said first nucleic acid, said second nucleic acid and said additional nucleic acids, if prepared, with their corresponding restriction endonucleases to produce cleaved first, second and additional, if prepared, nucleic acids; and

(e) ligating said cleaved first, second and additional, if prepared, nucleic acids to produce the nucleic acid encoding a zinc finger protein (ZFP) having four or more zinc fingers domains.

46. A method of making a nucleic acid encoding a zinc finger protein (ZFP) having four or more zinc fingers domains, each domain independently represented by the formula



and said domains, independently, covalently joined with from 0 to 10 amino acid residues which comprises:

(a) preparing a first nucleic acid according to the method of Claim 42, wherein said second PCR primer includes a first restriction endonuclease recognition site;

(b) preparing a second nucleic acid according to the method of Claim 42, wherein said first and second PCR primers are complementary to the 5' and 3' ends, respectively, of the number of zinc finger domains selected for amplification,

wherein said first PCR primer includes a restriction endonuclease recognition site that, when subjected to cleavage by its corresponding restriction endonuclease, produces an end having a sequence which is complementary to and can anneal to, the end produced when said second PCR primer of step (a) is subjected to cleavage by its corresponding restriction endonuclease and

wherein said second PCR primer of step (b), optionally, includes a second restriction enzyme recognition site that, when subjected to cleavage produces an end that

differs from and is not complementary to that produced from the first restriction endonuclease recognition site;

(c) optionally, preparing one or more additional nucleic acids by the method of Claim 42,

5 wherein said first and second PCR primers are complementary to the 5' and 3' ends, respectively, of the number of zinc finger domains selected for amplification,

wherein said first PCR primer for each additional nucleic acid includes a restriction endonuclease recognition site that, when subjected to cleavage by its corresponding restriction endonuclease, produces an end having a sequence which is complementary to  
10 and can anneal to the end produced when the second PCR primer used for preparation of the second nucleic acid, or for the additional nucleic acid that is immediately upstream of the additional nucleic acid, is subjected to cleavage by its corresponding restriction endonuclease, and

wherein said second PCR primer for each additional nucleic acid, optionally,  
15 includes a restriction endonuclease recognition site that, when subjected to cleavage produces an end that differs from and is not complementary to any previously used;

(d) cleaving said first nucleic acid, said second nucleic acid and said additional nucleic acids, if prepared, with their corresponding restriction endonucleases to produce cleaved first, second and additional, if prepared, nucleic acids; and

20 (e) ligating said cleaved first, second and additional, if prepared, nucleic acids to produce the nucleic acid encoding a zinc finger protein (ZFP) having four or more zinc fingers domains.

47. The method of Claim 45 or 46, wherein each restriction endonuclease is,  
25 independently, BbsI, BsaI, BsmBI, or BspMI, and each endonuclease produces a unique pair of cleavable, annealable ends.

48. The method of Claim 45 or 46, wherein the restriction endonuclease is BsaI and each use thereof produces a unique pair of cleavable, annealable ends.

30 49. The method of Claim 45 or 50, wherein step (c) is omitted and said nucleic acid encoding a zinc finger protein (ZFP) has four, five or six zinc finger domains.



50. The method of Claim 49, wherein said restriction endonuclease is BbsI, BsaI, BsmBI, or BspMI.

5 51. The method of Claim 49, wherein said restriction endonuclease is BsaI.

52. The method of Claim 45 or 46, wherein the PCR primers for the second nucleic acid were selected to amplify three zinc finger domains, one additional nucleic acid is prepared by step (c), and said nucleic acid encoding a zinc finger protein (ZFP) has seven, eight or  
10 nine zinc finger domains.

53. The method of Claim 52, wherein each restriction endonuclease is, independently, BbsI, BsaI, BsmBI, or BspMI, and each endonuclease produces a unique pair of cleavable, annealable ends.

15

54. The method of Claim 52, wherein the restriction endonuclease is BsaI and each use thereof produces a unique pair of cleavable, annealable ends.

55. The method of any one of claims 40-54, wherein the sequences of said  
20 oligonucleotides are selected to provide for optimal codon usage for an organism.

56. The method of Claim 55, wherein said organism is a bacterium, a fungus, a yeast, an animal, an insect or a plant.

25 57. The method of Claim 56, wherein said bacterium is *E. coli*.

58. The method of Claim 56, wherein said animal is a human or a commercial animal.

59. The method of Claim 56, wherein said plant is a cereal plant.

30

60. The method of Claim 56, wherein said plant is rice, tomato or corn.

61. The method of any one of Claims 56, 59, or 60, wherein said plant is a transgenic plant.

62. An expression vector comprising a nucleic acid prepared by the method of any one of Claims 40-61.

63. A host cell comprising the expression vector of Claim 62.

64. A method of preparing a zinc finger protein which comprises

(a) culturing the host cell of Claim 63 for a time and under conditions to express said ZFP; and

(b) recovering said ZFP.

65. A method of designing one or more zinc finger domains, which comprises identifying a target nucleic acid sequence having four bases and determining the identity of the amino acids at positions -1, 2, 3 and 6 of the  $\alpha$ -helix of the zinc finger domain as follows:

(a) if the first base is G, then  $Z^6$  is arginine or lysine,  
if the first base is A, then  $Z^6$  is glutamine or asparagine,  
if the first base is T, then  $Z^6$  is threonine, tyrosine, leucine, isoleucine or methionine,

if the first base is C, then  $Z^6$  is glutamic acid or aspartic acid,  
(b) if the second base is G, then  $Z^3$  is histidine or lysine,  
if the second base is A, then  $Z^3$  is asparagine or glutamine,  
if the second base is T, then  $Z^3$  is serine, alanine or valine,  
if the second base is C, then  $Z^3$  is aspartic acid or glutamic acid,

(c) if the third base is G, then  $Z^1$  is arginine or lysine,  
if the third base is A, then  $Z^1$  is glutamine or asparagine,  
if the third base is T, then  $Z^1$  is threonine, methionine leucine or isoleucine,  
if the third base is C, then  $Z^1$  is glutamic acid or aspartic acid,

(iv) if the complement of the fourth base is G, then  $Z^2$  is serine or arginine,  
if the complement of the fourth base is A, then  $Z^2$  is asparagine or glutamine,

if the complement of the fourth base is T, then  $Z^2$  is threonine, valine or alanine, and  
 if the complement of the fourth base is C, then  $Z^2$  is aspartic acid or glutamic acid.

5

66. The method of Claim 65 which further comprises preparing a ZFP comprising one or more of said zinc finger domains or a or a nucleic acid encoding said ZFP.

67. The method of Claim 65 or 66, wherein multiple zinc finger domains are designed.

10

68. The method of any one of Claims 65-67, wherein

- (a) if the first base is G, then  $Z^6$  is arginine,  
 if the first base is A, then  $Z^6$  is glutamine,  
 if the first base is T, then  $Z^6$  is threonine, tyrosine or leucine,  
 if the first base is C, then  $Z^6$  is glutamic acid,
- (b) if the second base is G, then  $Z^3$  is histidine,  
 if the second base is A, then  $Z^3$  is asparagine,  
 if the second base is T, then  $Z^3$  is serine,  
 if the second base is C, then  $Z^3$  is aspartic acid,
- (c) if the third base is G, then  $Z^1$  is arginine,  
 if the third base is A, then  $Z^1$  is glutamine,  
 if the third base is T, then  $Z^1$  is threonine or methionine,  
 if the third base is C, then  $Z^1$  is glutamic acid,
- (d) if the complement of the fourth base is G, then  $Z^2$  is serine,  
 if the complement of the fourth base is A, then  $Z^2$  is asparagine,  
 if the complement of the fourth base is T, then  $Z^2$  is threonine, and  
 if the complement of the fourth base is C, then  $Z^2$  is aspartic acid.

15

20

25

69. A method of designing a zinc finger domain of the formula

30

$-X_3\text{-Cys-}X_{2-4}\text{-Cys-}X_5\text{-}Z^1\text{-}X\text{-}Z^2\text{-}Z^3\text{-}X_2\text{-}Z^6\text{-His-}X_{3-5}\text{-His-}X_4\text{-}$ ,

wherein X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain which method comprises:

- (a) identifying a target nucleic acid sequence having four bases;
- (b) determining the identity of each X;
- (c) determining the identity of amino acids at positions  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$  as

follows:

- 5 (i) if the first base is G, then  $Z^6$  is arginine or lysine,  
if the first base is A, then  $Z^6$  is glutamine or asparagine,  
if the first base is T, then  $Z^6$  is threonine, tyrosine, leucine, isoleucine  
or methionine,  
if the first base is C, then  $Z^6$  is glutamic acid or aspartic acid,
- 10 (ii) if the second base is G, then  $Z^3$  is histidine or lysine,  
if the second base is A, then  $Z^3$  is asparagine or glutamine,  
if the second base is T, then  $Z^3$  is serine, alanine or valine,  
if the second base is C, then  $Z^3$  is aspartic acid or glutamic acid,
- 15 (iii) if the third base is G, then  $Z^1$  is arginine or lysine,  
if the third base is A, then  $Z^1$  is glutamine or asparagine,  
if the third base is T, then  $Z^1$  is threonine, methionine leucine or  
isoleucine,  
if the third base is C, then  $Z^1$  is glutamic acid or aspartic acid,
- 20 (iv) if the complement of the fourth base is G, then  $Z^2$  is serine or  
arginine,  
if the complement of the fourth base is A, then  $Z^2$  is asparagine or  
glutamine,  
if the complement of the fourth base is T, then  $Z^2$  is threonine, valine  
or alanine, and
- 25 if the complement of the fourth base is C, then  $Z^2$  is aspartic acid or  
glutamic acid; and
- (d) preparing a zinc finger protein comprising said zinc finger domain.

70. A method of designing a zinc finger domain of the formula

30  $-X_3\text{-Cys-}X_{2,4}\text{-Cys-}X_5\text{-}Z^1\text{-X-}Z^2\text{-}Z^3\text{-}X_2\text{-}Z^6\text{-His-}X_{3,5}\text{-His-}X_4\text{-}$ ,

wherein X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain which method comprises:

- (a) identifying a target nucleic acid sequence having four bases;
- (b) determining the identity of each X;
- (c) determining the identity of amino acids at positions  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$  as follows:

- 5                   (i)     if the first base is G, then  $Z^6$  is arginine,  
                       if the first base is A, then  $Z^6$  is glutamine,  
                       if the first base is T, then  $Z^6$  is threonine, tyrosine or leucine,  
                       if the first base is C, then  $Z^6$  is glutamic acid,
- 10                  (ii)    if the second base is G, then  $Z^3$  is histidine,  
                       if the second base is A, then  $Z^3$  is asparagine,  
                       if the second base is T, then  $Z^3$  is serine,  
                       if the second base is C, then  $Z^3$  is aspartic acid,
- 15                  (iii)   if the third base is G, then  $Z^1$  is arginine,  
                       if the third base is A, then  $Z^1$  is glutamine,  
                       if the third base is T, then  $Z^1$  is threonine or methionine,  
                       if the third base is C, then  $Z^1$  is glutamic acid,
- 20                  (iv)    if the complement of the fourth base is G, then  $Z^2$  is serine,  
                       if the complement of the fourth base is A, then  $Z^2$  is asparagine,  
                       if the complement of the fourth base is T, then  $Z^2$  is threonine, and  
                       if the complement of the fourth base is C, then  $Z^2$  is aspartic acid;  
                       and
- (d)   preparing a zinc finger protein comprising said zinc finger domain.

25   71. The method of any one of Claims 65-70, wherein if the first base is T then  $Z^6$  is threonine; and if the third base is T, then  $Z^1$  is threonine.

30   72. The method of any one of Claims 65-71, wherein the X positions of at least one of said zinc finger domains comprise the corresponding amino acids from an Sp1C or a Zif268 zinc finger domain.

73. The method of any one of Claims 65-72, wherein said ZFP is prepared recombinantly.

74. A method of designing a multi-domained zinc finger protein (ZFP) which comprises

(a) identifying a target nucleic acid sequence of length  $3N+1$  base pairs, wherein  $N$  is the number of overlapping 4 base pair segments of step (b);

(b) dividing said target nucleic acid sequence into overlapping 4 base pair segments, wherein the fourth base of each segment, up to the  $N-1$  segment, is the first base of the immediately following segment;

(c) designing a zinc finger domain for each 4 base pair segment by determining the identity of the amino acids at positions -1, 2, 3 and 6 of the  $\alpha$ -helix of the zinc finger domain as follows


- 10                   (i)     if the first base is G, then  $Z^6$  is arginine or lysine,  
                           if the first base is A, then  $Z^6$  is glutamine or asparagine,  
                           if the first base is T, then  $Z^6$  is threonine, tyrosine, leucine, isoleucine  
                           or methionine,  
                           if the first base is C, then  $Z^6$  is glutamic acid or aspartic acid,
- 15                   (ii)     if the second base is G, then  $Z^3$  is histidine or lysine,  
                           if the second base is A, then  $Z^3$  is asparagine or glutamine,  
                           if the second base is T, then  $Z^3$  is serine alanine or valine,  
                           if the second base is C, then  $Z^3$  is aspartic acid or glutamic acid,
- 20                   (iii)    if the third base is G, then  $Z^1$  is arginine or lysine,  
                           if the third base is A, then  $Z^1$  is glutamine or aspartic acid,  
                           if the third base is T, then  $Z^1$  is threonine, methionine , leucine or  
                           isoleucine,  
                           if the third base is C, then  $Z^1$  is glutamic acid or aspartic acid,
- 25                   (iv)     if the complement of the fourth base is G, then  $Z^2$  is serine or  
                           arginine,  
                           if the complement of the fourth base is A, then  $Z^2$  is asparagine or  
                           glutamine,  
                           if the complement of the fourth base is T, then  $Z^2$  is threonine, valine  
                           or alanine, and
- 30                   if the complement of the fourth base is C, then  $Z^2$  is aspartic acid or  
                           glutamic acid; and

75. The method of Claim 74 which further comprises preparing a ZFP comprising said zinc finger domains or a nucleic acid encoding said ZFP.

76. The method of Claims 74 or 75, wherein

- 5 (i) if the first base is G, then  $Z^6$  is arginine,  
if the first base is A, then  $Z^6$  is glutamine,  
if the first base is T, then  $Z^6$  is threonine, tyrosine or leucine,  
if the first base is C, then  $Z^6$  is glutamic acid,
- 10 (ii) if the second base is G, then  $Z^3$  is histidine,  
if the second base is A, then  $Z^3$  is asparagine,  
if the second base is T, then  $Z^3$  is serine,  
if the second base is C, then  $Z^3$  is aspartic acid,
- 15 (iii) if the third base is G, then  $Z^1$  is arginine,  
if the third base is A, then  $Z^1$  is glutamine,  
if the third base is T, then  $Z^1$  is threonine or methionine,  
if the third base is C, then  $Z^1$  is glutamic acid,
- 20 (iv) if the complement of the fourth base is G, then  $Z^2$  is serine,  
if the complement of the fourth base is A, then  $Z^2$  is asparagine,  
if the complement of the fourth base is T, then  $Z^2$  is threonine, and  
if the complement of the fourth base is C, then  $Z^2$  is aspartic acid.

77. A method of designing a multi-domained zinc finger protein (ZFP), each zinc finger domain independently represented by the formula



25 wherein X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain which method comprises:


- (a) identifying a target nucleic acid sequence of length  $3N+1$  base pairs, wherein N is the number of overlapping 4 base pair segments of step (b);
- (b) dividing said target nucleic acid sequence into overlapping 4 base pair segments,
- 30 wherein the fourth base of each segment, up to the N-1 segment, is the first base of the immediately following segment;
- (c) designing a zinc finger domain for each 4 base pair segment by

- (i) determining the identity of each X; and  
 (ii) determining the identity of amino acids at positions  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$  as follows:

- (1) if the first base is G, then  $Z^6$  is arginine or lysine,  
 if the first base is A, then  $Z^6$  is glutamine or asparagine,  
 if the first base is T, then  $Z^6$  is threonine, tyrosine, leucine,  
 isoleucine or methionine,  
 if the first base is C, then  $Z^6$  is glutamic acid or aspartic acid,  
 (2) if the second base is G, then  $Z^3$  is histidine or lysine,  
 if the second base is A, then  $Z^3$  is asparagine or glutamine,  
 if the second base is T, then  $Z^3$  is serine alanine or valine,  
 if the second base is C, then  $Z^3$  is aspartic acid or glutamic  
 acid,  
 (3) if the third base is G, then  $Z^1$  is arginine or lysine,  
 if the third base is A, then  $Z^1$  is glutamine or aspartic acid,  
 if the third base is T, then  $Z^1$  is threonine, methionine ,  
 leucine or isoleucine,  
 if the third base is C, then  $Z^1$  is glutamic acid or aspartic  
 acid,  
 (4) if the complement of the fourth base is G, then  $Z^2$  is serine or  
 arginine,  
 if the complement of the fourth base is A, then  $Z^2$  is  
 asparagine or glutamine,  
 if the complement of the fourth base is T, then  $Z^2$  is  
 threonine, valine or alanine, and  
 if the complement of the fourth base is C, then  $Z^2$  is aspartic  
 acid or glutamic acid; and

- (d) preparing a ZFP comprising N zinc finger domains.

78. A method of designing a multi-domained zinc finger protein (ZFP), each zinc finger domain independently represented by the formula





wherein X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain which method comprises:

(a) identifying a target nucleic acid sequence of length  $3N+1$  base pairs, wherein N is the number of overlapping 4 base pair segments of step (b);

(b) dividing said target nucleic acid sequence into overlapping 4 base pair segments, wherein the fourth base of each segment, up to the N-1 segment, is the first base of the immediately following segment;

(c) designing a zinc finger domain for each 4 base pair segment by

(i) determining the identity of each X; and

(ii) determining the identity of amino acids at positions  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^6$  as follows:

- (1) if the first base is G, then  $Z^6$  is arginine,  
if the first base is A, then  $Z^6$  is glutamine,  
if the first base is T, then  $Z^6$  is threonine, tyrosine or leucine,  
if the first base is C, then  $Z^6$  is glutamic acid,
- (2) if the second base is G, then  $Z^3$  is histidine,  
if the second base is A, then  $Z^3$  is asparagine,  
if the second base is T, then  $Z^3$  is serine,  
if the second base is C, then  $Z^3$  is aspartic acid,
- (3) if the third base is G, then  $Z^1$  is arginine,  
if the third base is A, then  $Z^1$  is glutamine,  
if the third base is T, then  $Z^1$  is threonine or methionine,  
if the third base is C, then  $Z^1$  is glutamic acid,
- (4) if the complement of the fourth base is G, then  $Z^2$  is serine,  
if the complement of the fourth base is A, then  $Z^2$  is asparagine,  
if the complement of the fourth base is T, then  $Z^2$  is threonine, and  
if the complement of the fourth base is C, then  $Z^2$  is aspartic acid; and

(d) preparing a ZFP comprising N zinc finger domains.

79. The method of any one of Claims 74-78 wherein the domains of said ZFP are covalently joined to each other with from 0 to 10 amino acid residues.

80. The method of any one of Claims 74-79 wherein N is from 3 to 40.

5

81. The method of Claim 80, wherein N is from 3 to 15.

82. The method of Claim 81, wherein N is from 7, 8 or 9.

10 83. The method of Claim 81, wherein N is 6.

84. The method of Claim 81, wherein N is 3.

15 85. The method of any one of Claims 74-84, wherein if the first base is T then Z<sup>6</sup> is threonine; and if the third base is T, then Z<sup>1</sup> is threonine.

86. The method of any one of Claims 74-85, wherein the X positions of at least one of said zinc finger domains comprise the corresponding amino acids from an Sp1C or a Zif268 zinc finger domain.

20

87. The method of any one of Claims 74-86, wherein said ZFP is prepared recombinantly.

25 88. A method of binding a target nucleic acid with an artificial zinc finger protein (ZFP) which comprises contacting a target nucleic acid with a ZFP of any one of Claims 1-23 in an amount and for a time sufficient for said ZFP to bind to said target nucleic acid.

30 89. A method of binding a target nucleic acid with a multi-domained zinc finger protein (ZFP) which comprises contacting a target nucleic acid of length 3N+1 base pairs, wherein N is the number of overlapping 4 base pair segments in said target nucleic acid and wherein the fourth base of each segment, up to the N-1 segment, is the first base of the immediately following segment, with an amount of a multi-domained ZFP prepared according to any

one of the methods of Claims 74-87 and for a time sufficient for said ZFP to bind to said target nucleic acid.

5 90. The method of Claim 88 or 89, wherein said ZFP is introduced into a cell via a nucleic acid encoding said ZFP.

91. The method of any one of Claims 88-90, wherein said target nucleic acid encodes a plant gene.

10 92. The method of Claim 91, wherein said plant gene is from tomato, corn or rice.

93. The method of any one of Claims 88-90, wherein said target nucleic acid encodes cytokine, an interleukin, and oncogene, an angiogenesis factor or a drug resistance gene.

15 94. A method of modulating expression of a gene which comprises contacting a regulatory control element of said gene with a ZFP of any one of Claims 1-23 in an amount and for a time sufficient for said ZFP to alter expression of said gene.

20 95. A method of modulating expression of a gene which comprises contacting a regulatory control element of said gene with an amount of a multi-domained zinc finger protein (ZFP) prepared according to any one of the methods of Claims 74-87 and for a time sufficient for said ZFP to alter expression of said gene.

25 96. The method of Claim 94 or 95, wherein modulating expression is activating expression of said gene.

97. The method of Claim 94 or 95, wherein modulating expression is repressing expression of said gene.

30 98. The method of any one of Claims 94-97, wherein said ZFP is introduced into a cell via a nucleic acid encoding said ZFP.

99. The method of any one of Claims 94-98, wherein said gene encodes a plant gene.

100. The method of Claim 99, wherein said plant gene is from tomato, corn or rice.

5 101. The method of any one of Claims 94-98, wherein said gene encodes cytokine, an interleukin, an oncogene, an angiogenesis factor or a drug resistance gene.

102. A method of modulating expression of a gene which comprises contacting a target  
10 nucleic acid in sufficient proximity to said gene with a fusion protein of a ZFP of any one of  
Claims 1-23 fused to a transcriptional regulatory domain, wherein said fusion protein  
contacts said nucleic acid in an amount and for a time sufficient for said transcriptional  
regulatory domain to alter expression of said gene.

103. A method of modulating expression of a gene which comprises contacting a target  
15 nucleic acid sequence in sufficient proximity to said gene with a fusion protein of a multi-  
domained zinc finger protein (ZFP) prepared according to any one of the methods of  
Claims 74-87 and fused to a transcriptional regulatory domain, wherein said fusion protein  
contacts said nucleic acid in an amount and for a time sufficient for said transcriptional  
regulatory domain to alter expression of said gene.

20

104. The method of Claim 102 or 103, wherein said transcriptional regulatory domain  
activates expression of said gene.

105. The method of Claim 102 or 103, wherein said transcriptional regulatory domain  
25 represses expression of said gene.

106. The method of any one of Claims 102-105, wherein said fusion protein is introduced  
into a cell via a nucleic acid encoding said fusion protein.

30 107. The method of any one of Claims 102-106, wherein said gene encodes a plant gene.

108. The method of Claim 107, wherein said plant gene is from tomato, corn or rice.

109. The method of any one of Claims 102-106, wherein said gene encodes cytokine, an interleukin, an oncogene, an angiogenesis factor or a drug resistance gene.

5 110. A method of altering genomic structure which comprises contacting a target genomic site with a fusion protein of a ZFP of any one of Claims 1-23 fused to a protein domain which exhibits transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity or nuclease  
10 activity, wherein said fusion protein contacts said target genomic site in an amount and for a time sufficient to alter genomic structure in or near said site.

111. A method of altering genomic structure which comprises contacting a target genomic site with a fusion protein of a multi-domained zinc finger protein (ZFP) prepared according  
15 to any one of the methods of Claims 74-87 and fused to a protein domain which exhibits transposase activity, integrase activity, recombinase activity, resolvase activity, integrase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity or nuclease activity, wherein said fusion protein contacts said target genomic site in an amount and for a time sufficient to  
20 alter genomic structure in or near said site.

112. The method of Claim 110 or 111, wherein said fusion protein further comprises a nuclear-localization signal.

25 113. The method of any one of Claims 110-112, wherein said fusion protein is introduced into a cell via a nucleic acid encoding said fusion protein.

114. The method of Claim 110 or 111, wherein said fusion protein further comprises a cellular-uptake signal.

30 115. The method of any one of Claims 110-114, wherein said target genomic site is in or near a gene encodes a plant gene.

116. The method of Claim 115, wherein said plant gene is from tomato, corn or rice.

117. The method of any one of Claims 110-114, wherein said target genomic site is in or  
5 near a gene encoding a cytokine, an interleukin, an oncogene, an angiogenesis factor or for drug resistance.

118. A method of inhibiting viral replication which comprises

- (a) introducing into a cell a nucleic acid encoding a ZFP of any one of Claims 1-23,  
10 wherein said ZFP is competent to bind to a target site required for viral replication, and  
(b) obtaining sufficient expression of said ZFP in said cell to inhibit viral replication.

119. A method of inhibiting viral replication which comprises

- (a) introducing into a cell a nucleic acid encoding a multi-domained zinc finger  
15 protein (ZFP) prepared according to any one of the methods of Claims 74-87, wherein said ZFP is competent to bind to a target site required for viral replication, and  
(b) obtaining sufficient expression of said ZFP in said cell to inhibit viral replication.

20

120. A method of inhibiting viral replication which comprises

- (a) introducing into a cell a nucleic acid encoding a fusion protein of a ZFP of any  
one of Claims 1-23 fused to a single-stranded DNA binding protein, wherein said fusion  
protein is competent to bind to a target site required for viral replication, and  
25 (b) obtaining sufficient expression of said fusion protein in said cell to inhibit viral replication.

121. A method of inhibiting viral replication which comprises

- (a) introducing into a cell a nucleic acid encoding a fusion protein of a multi-  
30 domained zinc finger protein (ZFP) prepared according to any one of the methods of Claims 74-87 fused to a single-stranded DNA binding protein, wherein said fusion protein is competent to bind to a target site required for viral replication, and

(b) obtaining sufficient expression of said fusion protein in said cell to inhibit viral replication.

122. The method of any one of Claims 118-121, wherein viral replication is inhibited for a plant virus, an animal virus or a human virus.

123. A method of modulating expression of a gene which comprises

(a) contacting a eukaryotic cell with a divalent ligand capable of entry into said cell and comprising a first and second switch moiety of different specificity, wherein said cell contains

(i) a first nucleic acid expressing a first fusion protein of a ZFP of any one of Claims 1-23 fused to a protein domain capable of specifically binding said first switch moiety, wherein said ZFP is specific for a target site in proximity to said gene, and

(ii) a second nucleic acid expressing a second fusion protein comprising a first domain capable of specifically binding said second switch moiety, a second domain which is a nuclear localization signal and a third domain which is a transcriptional regulatory domain;

(b) allowing said cell sufficient time to form a complex comprising said divalent ligand, said first fusion protein and said second fusion protein, to translocate said complex into the nucleus of said cell, to bind to said target site and to thereby to alter expression of said gene.

124. A method of modulating expression of a gene which comprises

(a) contacting a eukaryotic cell with a divalent ligand capable of entry into said cell and comprising a first and second switch moiety of different specificity, wherein said cell contains

(i) a first nucleic acid expressing a first fusion protein of a multi-domained zinc finger protein (ZFP) prepared according to any one of the methods of Claims 74-87 fused to a protein domain capable of specifically binding said first switch moiety, wherein said ZFP is specific for a target site in proximity to said gene, and

(ii) a second nucleic acid expressing a second fusion protein comprising a first domain capable of specifically binding said second switch moiety, a second domain which is a nuclear localization signal and a third domain which is a transcriptional regulatory domain;

5 (b) allowing said cell sufficient time to form a complex comprising said divalent ligand, said first fusion protein and said second fusion protein, to translocate said complex into the nucleus of said cell, to bind to said target site and to thereby alter expression of said gene.

10 125. The method of Claims 123 or 124, wherein said transcriptional regulatory domain activates expression of said gene.

126. The method of Claim 123 or 124, wherein said transcriptional regulatory domain represses expression of said gene.

15 127. The method of any one of Claims 123-126, wherein said protein domain capable of specifically binding said first switch moiety is an S-protein, an S-tag or a single chain variable region (scFv) of an antibody.

20 128. The method of any one of Claims 123-127, wherein said first switch moiety is an S-protein, an S-tag, or an antigen for a single chain variable region (scFv) of an antibody.

25 129. The method of any one of Claims 123-128, wherein said domain capable of specifically binding said second switch moiety is an S-protein, an S-tag or a single chain variable region (scFv) of an antibody.

130. The method any one of Claims 123-129, wherein said second switch moiety is an S-protein, an S-tag or an antigen for a single chain variable region (scFv) of an antibody.

30 131. An artificial transposase comprising a catalytic domain, a peptide dimerization domain and a ZFP domain wherein said ZFP domain is a ZFP of any one of Claims 1-23.



132. An artificial transposase comprising a catalytic domain, a peptide dimerization domain and a ZFP domain which is a multi-domained zinc finger protein (ZFP) prepared according to any one of the methods of Claims 74-87.

5 133. The transposase of Claim 131 or 132, which additionally comprises a terminal inverted repeat binding domain.

134. A method of target-specific introduction of an exogenous gene into the genome of an organism which comprises:

10 (a) introducing into a cell a first nucleic acid encoding a transposase of Claim 133, wherein said ZFP domain binds a first genomic target; a second nucleic acid encoding a transposase of Claim 133, wherein said ZFP domain binds a second genomic target; and a third nucleic acid encoding said exogenous gene, wherein said exogenous gene is flanked by sequences capable of being bound by the terminal inverted repeat binding domain of said  
15 transposases; and

(b) forming a complex among the genome, the third nucleic acid, and the two transposases sufficient for recombination to occur and thereby introduce said exogenous gene into the genome of the organism.

20 135. A method of target-specific excision of an endogenous gene from the genome of an organism which comprises:

(a) introducing into a cell a first nucleic acid encoding a transposase of Claim 131 or 132, wherein said ZFP domain binds a first genomic target; a second nucleic acid encoding a transposase of Claim 131 or 132, wherein said ZFP domain binds a second  
25 genomic target; and wherein the endogenous gene is flanked by said first and second genomic targets; and

(b) forming a complex among the genome and the two transposases sufficient for recombination to occur and thereby excise said endogenous gene from the genome of the organism.

30

136. A method for detecting an altered zinc finger recognition sequence which comprises:

(a) contacting a nucleic acid containing the zinc finger recognition sequence of interest with a ZFP of any one of Claims 1-23 specific for said sequence and conjugated to a signaling moiety, said ZFP present in an amount sufficient to allow binding of said ZFP to said zinc finger recognition sequence if said sequence was unaltered; and

5 (b) detecting binding of said ZFP to the zinc finger recognition sequence and thereby to ascertain that said zinc finger recognition sequence is altered if said binding is diminished or abolished relative to binding of said ZFP to the unaltered sequence.

137. A method for detecting an altered zinc finger recognition sequence which comprises:

10 (a) contacting a nucleic acid containing the zinc finger recognition sequence of interest with a multi-domained zinc finger protein (ZFP) prepared according to any one of the methods of Claims 74-87, said ZFP specific for said sequence and conjugated to a signaling moiety, said ZFP in an amount to allow binding of said ZFP to said zinc finger recognition sequence if said sequence was unaltered; and

15 (b) detecting binding of said ZFP to the zinc finger recognition sequence and thereby to ascertain that said zinc finger recognition sequence is altered if said binding is diminished or abolished relative to binding of said ZFP to the unaltered sequence.

138. The method of Claim 136 or 137, wherein the signaling moiety is a dye, biotin, a  
20 radioactive label, streptavidin or a marker protein.

139. The method of Claim 138, wherein said marker protein is  $\beta$ -galactosidase, GUS, a green fluorescent protein or a fluorescent mutant thereof, horse radish peroxidase, alkaline phosphatase or an antibody.

25

140. The method of any one of Claims 136-139, wherein said altered zinc finger recognition site comprises a mutation, insertion or deletion of one or more nucleotides in said site.

30 141. The method of Claim 140, wherein the mutation comprises a single nucleotide polymorphism (SNP).

142. A method of diagnosing a disease associated with abnormal genomic structure which comprises

- (a) isolating cells, blood or a tissue sample from a subject;
- (b) contacting nucleic acid from said cells, blood or said sample with a protein comprising a ZFP of any one of Claims 1-23, a signaling moiety and, optionally, a cellular uptake domain wherein said ZFP binds to a target site associated with said disease; and
- (c) detecting the binding of said protein to said nucleic acid to thereby make the diagnosis.

143. A method of diagnosing diseases associated with abnormal genomic structure which comprises

- (a) isolating cells, blood or a tissue sample from a subject;
- (b) contacting nucleic acid from said cells, blood or said sample with a protein comprising a ZFP of any one of Claims 74-87, a signaling moiety and, optionally, a cellular uptake domain wherein said ZFP binds to a target site associated with said disease; and
- (c) detecting the binding of said protein to said nucleic acid to thereby make the diagnosis.

144. The method of Claim 142 or 143, which further comprises quantitating amount of protein bound to said nucleic acids.

145. The method of any one of Claims 142-144, wherein said nucleic acid is *in situ*.

146. The method of any one of Claims 142-144 wherein said nucleic acid is extracted from said cells or said tissue sample before said contacting step.

147. A set of oligonucleotides comprising a number of separate oligonucleotides, each oligonucleotide encoding one zinc finger domain and the set of oligonucleotides including at least one oligonucleotide for more than half of the four base pair target sequence, wherein the amino acids at positions -1, 2, 3 and 6 of the  $\alpha$ -helix of the zinc finger are selected as follows:

at position -1, the amino acid is arginine, glutamine, threonine, methionine or glutamic acid;

at position 2, the amino acid is serine, asparagine, threonine or aspartic acid;

at position 3, the amino acid is histidine, asparagine, serine or aspartic acid; and


5 at position 6, the amino acid is arginine, glutamine, threonine, tyrosine, leucine or glutamic acid.

148. The set of Claim 147, wherein the number of oligonucleotides is at least 150.

10 149. The set of Claim 148, wherein the number of oligonucleotides ranges from about 200 to about 256.

150. The set of Claim 149, wherein the number of oligonucleotides is 256.

15 151. A set of 256 separate oligonucleotides, each oligonucleotide comprising a nucleotide sequence encoding one of the 256 zinc finger domains represented by the formula



wherein

20 X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain;

$Z^1$  is arginine, glutamine, threonine, or glutamic acid;

$Z^2$  is serine, asparagine, threonine or aspartic acid;

$Z^3$  is histidine, asparagine, serine or aspartic acid; and

$Z^6$  is arginine, glutamine, threonine, or glutamic acid.


25

152. The set of Claim 151, wherein each X at a given position in the formula is the same in each of the 256 zinc finger domains.

30 153. The set of Claim 151 or 152, wherein the X positions of said zinc finger domains comprise the corresponding amino acids from an Sp1C or a Zif268 zinc finger domain.

154. The set of any one of Claims 151-153, wherein the nucleotide sequence of said oligonucleotides are selected to provide for optimal codon usage for an organism.

155. A set of oligonucleotides for producing a nucleic acid encoding zinc finger proteins having three or more zinc finger domains, said set comprising three subsets of 256 separate oligonucleotides, each oligonucleotide comprising a nucleotide sequence encoding one of the 256 zinc finger domains represented by the formula



wherein

10 X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain;

$Z^1$  is arginine, glutamine, threonine, or glutamic acid;

$Z^2$  is serine, asparagine, threonine or aspartic acid;

$Z^3$  is histidine, asparagine, serine or aspartic acid; and

15  $Z^6$  is arginine, glutamine, threonine, or glutamic acid; and

wherein

the 3' end of the first subset oligonucleotides are sufficiently complementary to the 5' end of the second subset oligonucleotides to prime synthesis of said second subset oligonucleotides therefrom,

20 the 3' end of the second subset oligonucleotides are sufficiently complementary to the 5' end of the third subset oligonucleotides to prime synthesis of said third subset oligonucleotides therefrom,

the 3' end of the first subset oligonucleotides are not complementary to the 5' end of the third subset oligonucleotides, and

25 the 3' end of the second subset oligonucleotides are not complementary to the 5' end of the first subset oligonucleotides.

156. The set of Claim 155, wherein each X at a given position in the formula is the same for one subset of the 256 zinc finger domains.

30

157. The set of Claim 156, wherein each X at a given position in the formula is the same for two sub sets of the 256 zinc finger domains.


158. The set of Claim 157, wherein each X at a given position in the formula is the same for all three subsets of the 256 zinc finger domains.

5 159. The set of any one of Claims 155-158, wherein the X positions of said zinc finger domains comprise the corresponding amino acids from an Sp1C or a Zif268 zinc finger domain.

10 160. The set of any one of Claims 155-159, wherein the nucleotide sequence of said oligonucleotides are selected to provide for optimal codon usage for an organism.

161. A kit comprising a set of any one of Claims 147-160.

15 162. A single-stranded or double-stranded oligonucleotide encoding a zinc finger domain for an artificial zinc finger protein (ZFP), wherein said oligonucleotide is from about 84 nucleotides to about 130 nucleotides and comprising a sequence encoding a zinc finger domain independently represented by the formula



and, optionally, a linker of from 0 to 10 amino acid residues;

20 wherein

X is, independently, any amino acid and  $X_n$  represents the number of occurrences of X in the polypeptide chain;

$Z^1$  is arginine, glutamine, threonine, methionine or glutamic acid;

$Z^2$  is serine, asparagine, threonine or aspartic acid;

25  $Z^3$  is histidine, asparagine, serine or aspartic acid; and


$Z^6$  is arginine, glutamine, threonine, tyrosine, leucine or glutamic acid.

163. The oligonucleotide of Claim 162, wherein the X positions comprise the corresponding amino acids from an Sp1C or a Zif268 zinc finger domain.

30

164. The oligonucleotide of Claim 163, wherein the nucleotide sequence is selected to provide optimal code is usage for an organism.

1/9



**FIG. 1**

2/9




FIG. 2




3/9

5' NNN **G** 3'  
C --- **Asp** at position 2

5' NNN **A** 3'  
T --- **Thr** at position 2

5' NNN **T** 3'  
A --- **Asn** at position 2

5' NNN **C** 3'  
G --- **Ser** at position 2

**FIG. 3****FIG. 4**

4/9






FIG. 5


5/9



### 1) Estrogen Receptor Engineering




### 2) scFv Fusion & Divalent Chemicals



### 3) Protein-Peptide } Modulation with Chemicals

**FIG. 6**



**FIG. 7**






FIG. 8

8/9

**FIG. 9**

9/9

**FIG. 10**

## SEQUENCE LISTING

<110> Syngenta Participations AG  
 5 <120> Zinc Finger Domain Recognition Code and Uses Thereof  
 <130> S-50011A/NAD  
 <150> US 60/220,060  
 10 <151> 2000-07-21  
 <160> 69  
 <170> PatentIn version 3.0  
 15 <210> 1  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence  
 20 <220>  
 <223> Zinc finger domain.  
 <220>  
 25 <221> VARIANT  
 <222> (1)..(28)  
 <223> Amino acids 1-3, 8-19 and 25-28 are Xaa wherein Xaa = any amino acid.  
 <220>  
 30 <221> VARIANT  
 <222> (5)..(6)  
 <223> Amino acid 5 is Xaa wherein Xaa = any amino acid, amino acids 5 and 6 together represent from 2 to 4 amino acids in length.  
 35 <220>  
 <221> VARIANT  
 <222> (21)..(23)  
 <223> Amino acid 21 is Xaa wherein Xaa = any amino acid, amino acids 21-23 together represent from 3 to 5 amino acids in length.  
 40 <400>> 1  
 Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 45 1 5 10 15  
 Xaa Xaa Xaa His Xaa Xaa Xaa His Xaa Xaa Xaa Xaa  
 20 25  
 50 <210> 2  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence  
 55 <220>  
 <223> Zinc finger domain.  
 <220>



<221> VARIANT  
 <222> (1)..(28)  
 5 <223> Amino acids 1-3, 8-12, 14, 17-18 and 25-28 are Xaa wherein Xaa = any amino acid.  
 <220>  
 <221> VARIANT  
 <222> (5)..(6)  
 10 <223> Amino acid 5 is Xaa wherein Xaa = any amino acid, amino acids 5 and 6 together represent from 2 to 4 amino acids in length.  
 <220>  
 <221> VARIANT  
 15 <222> (21)..(23)  
 <223> Amino acid 21 is Xaa wherein Xaa = any amino acid, amino acids 21-23 together represent from 3 to 5 amino acids in length.  
 <220>  
 20 <221> VARIANT  
 <222> (13)..(13)  
 <223> Amino acid 13 is Xaa wherein Xaa = Z-1 wherein Z-1 = Arg or Lys, Gln or Asn, Thr, Met, Leu or Ile, or Glu or Asp.  
 25 <220>  
 <221> VARIANT  
 <222> (15)..(15)  
 <223> Amino acid 15 is Xaa wherein Xaa = Z2 wherein Z2 = Ser or Arg, Asn Gln, Thr, Val or Ala, or Asp or Glu.  
 30 <220>  
 <221> VARIANT  
 <222> (16)..(16)  
 <223> Amino acid 16 is Xaa wherein Xaa = Z3 wherein Z3 = His or Lys, Asn or Gln, Ser, Ala, or Val, or Asp or Glu.  
 35 <220>  
 <221> VARIANT  
 <222> (19)..(19)  
 40 <223> Amino acid 19 is Xaa wherein Xaa = Z6 wherein Z6 = Arg or Lys, Gln or Asn, Thr, Tyr, Leu, Ile or Met, or Glu or Asp.  
 <400>> 2  
 45 Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
 1 5 10 15  
 Xaa Xaa Xaa His Xaa Xaa Xaa His Xaa Xaa Xaa Xaa  
 20 25  
 50  
 <210> 3  
 <211> 196  
 <212> PRT  
 55 <213> Artificial Sequence  
 <220>  
 <223> Zinc finger protein.

&lt;400&gt;&gt; 3

5 Val Pro Ile Pro Gly Lys Lys Lys Gln His Ile Cys His Ile Gln Gly  
 1 5 10 15  
 Cys Gly Lys Val Tyr Gly Gln Ser Ser Asp Leu Gln Arg His Leu Arg  
 20 25 30  
 10 Trp His Thr Gly Glu Arg Pro Phe Met Cys Thr Trp Ser Tyr Cys Gly  
 35 40 45  
 Lys Arg Phe Thr Arg Ser Ser Asn Leu Gln Arg His Lys Arg Thr His  
 50 55 60  
 15 Thr Gly Glu Lys Lys Phe Ala Cys Pro Glu Cys Pro Lys Arg Phe Met  
 65 70 75 80  
 Arg Ser Asp Glu Leu Ser Arg His Ile Lys Thr His Gln Asn Lys Lys  
 85 90 95  
 20 Asp Gly Gly Gly Ser Gly Lys Lys Lys Gln His Ile Cys His Ile Gln  
 100 105 110  
 Gly Cys Gly Lys Val Tyr Gly Thr Thr Ser Asn Leu Arg Arg His Leu  
 115 120 125  
 25 Arg Trp His Thr Gly Glu Arg Pro Phe Met Cys Thr Trp Ser Tyr Cys  
 130 135 140  
 30 Gly Lys Arg Phe Thr Arg Ser Ser Asn Leu Gln Arg His Lys Arg Thr  
 145 150 155 160  
 His Thr Gly Glu Lys Lys Phe Ala Cys Pro Glu Cys Pro Lys Arg Phe  
 165 170 175  
 35 Met Arg Ser Asp His Leu Ser Arg His Ile Lys Thr His Gln Asn Lys  
 180 185 190  
 40 Lys Gly Gly Ser  
 195

&lt;210&gt; 4

&lt;211&gt; 99

45 &lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Zinc finger protein.

50

&lt;400&gt; 4

55 Val Pro Ile Pro Gly Lys Lys Lys Gln His Ile Cys His Ile Gln Gly  
 1 5 10 15  
 Cys Gly Lys Val Tyr Gly Thr Thr Ser Asn Leu Arg Arg His Leu Arg  
 20 25 30  
 Trp His Thr Gly Glu Arg Pro Phe Met Cys Thr Trp Ser Tyr Cys Gly

35                                      40                                      45  
 5    Lys Arg Phe Thr Arg Ser Ser Asn Leu Gln Arg His Lys Arg Thr His  
      50                                      55                                      60  
      Thr Gly Glu Lys Lys Phe Ala Cys Pro Glu Cys Pro Lys Arg Phe Met  
      65                                      70                                      75                                      80  
 10   Arg Ser Asp His Leu Ser Arg His Ile Lys Thr His Gln Asn Lys Lys  
                                           85                                      90                                      95  
      Gly Gly Ser  
 15  
      <210> 5  
      <211> 99  
      <212> PRT  
 20   <213> Artificial Sequence  
      <220>  
      <223> Zinc finger protein.  
 25   <400> 5  
      Met Glu Lys Leu Arg Asn Gly Ser Gly Asp Pro Gly Lys Lys Lys Gln  
      1                                      5                                      10                                      15  
 30   His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu  
                                           20                                      25                                      30  
      Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro  
                                           35                                      40                                      45  
 35   Glu Cys Gly Lys Ser Phe Ser Arg Ser Ser His Leu Gln Gln His Gln  
                                           50                                      55                                      60  
 40   Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys  
      65                                      70                                      75                                      80  
      Ser Phe Ser Arg Ser Asp His Leu Ser Arg His Gln Arg Thr His Gln  
                                           85                                      90                                      95  
 45   Asn Lys Lys  
      <210> 6  
 50   <211> 99  
      <212> PRT  
      <213> Artificial Sequence  
      <220>  
 55   <223> Zinc finger protein.  
      <400> 6

Met Glu Lys Leu Arg Asn Gly Ser Gly Asp Pro Gly Lys Lys Lys Gln  
 1 5 10 15  
 5 His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu  
 20 25 30  
 Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro  
 35 40 45  
 10 Glu Cys Gly Lys Ser Phe Ser Glu Ser Ser Asp Leu Gln Arg His Gln  
 50 55 60  
 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys  
 65 70 75 80  
 15 Ser Phe Ser Arg Ser Asp His Leu Ser Arg His Gln Arg Thr His Gln  
 85 90 95  
 20 Asn Lys Lys  
 <210> 7  
 <211> 99  
 25 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> Zinc finger protein.  
 30 <400> 7  
 Met Glu Lys Leu Arg Asn Gly Ser Gly Asp Pro Gly Lys Lys Lys Gln  
 1 5 10 15  
 35 His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu  
 20 25 30  
 Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro  
 35 40 45  
 40 Glu Cys Gly Lys Ser Phe Ser Arg Ser Ser His Leu Gln Glu His Gln  
 50 55 60  
 45 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys  
 65 70 75 80  
 Ser Phe Ser Arg Ser Asp His Leu Ser Arg His Gln Arg Thr His Gln  
 85 90 95  
 50 Asn Lys Lys  
 55 <210> 8  
 <211> 99  
 <212> PRT  
 <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Zinc finger protein.

5 &lt;400&gt; 8

Met Glu Lys Leu Arg Asn Gly Ser Gly Asp Pro Gly Lys Lys Lys Gln  
 1 5 10 15

10 His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu  
 20 25 30

Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro  
 35 40 45

15 Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Gln Arg His Gln  
 50 55 60

20 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys  
 65 70 75 80

Ser Phe Ser Arg Ser Asp His Leu Ser Arg His Gln Arg Thr His Gln  
 85 90 95

25 Asn Lys Lys

&lt;210&gt; 9

30 &lt;211&gt; 99

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

35 &lt;223&gt; Zinc finger protein.

&lt;400&gt; 9

40 Met Glu Lys Leu Arg Asn Gly Ser Gly Asp Pro Gly Lys Lys Lys Gln  
 1 5 10 15

His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu  
 20 25 30

45 Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro  
 35 40 45

Glu Cys Gly Lys Ser Phe Ser Arg Ser Ser Asn Leu Gln Glu His Gln  
 50 55 60

50 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys  
 65 70 75 80

55 Ser Phe Ser Arg Ser Asp His Leu Ser Arg His Gln Arg Thr His Gln  
 85 90 95

Asn Lys Lys

<210> 10  
 <211> 99  
 <212> PRT  
 5 <213> Artificial Sequence  
  
 <220>  
 <223> Zinc finger protein.  
  
 10 <400> 10  
  
 Met Glu Lys Leu Arg Asn Gly Ser Gly Asp Pro Gly Lys Lys Lys Gln  
 1 5 10 15  
 15 His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu  
 20 25 30  
 Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro  
 35 40 45  
 20 Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asp Leu Gln Arg His Gln  
 50 55 60  
 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys  
 25 65 70 75 80  
 Ser Phe Ser Arg Ser Asp His Leu Ser Arg His Gln Arg Thr His Gln  
 85 90 95  
 30 Asn Lys Lys  
  
 <210> 11  
 <211> 229  
 35 <212> PRT  
 <213> Human  
  
 <400> 11  
  
 40 Met Arg Leu Ala Lys Pro Lys Ala Gly Ile Ser Arg Ser Ser Ser Gln  
 1 5 10 15  
 Gly Lys Ala Tyr Glu Asn Lys Arg Lys Thr Gly Arg Gln Arg Glu Lys  
 20 25 30  
 45 Trp Gly Met Thr Ile Arg Phe Asp Ser Ser Phe Ser Arg Leu Arg Arg  
 35 40 45  
 Ser Leu Asp Asp Lys Pro Tyr Lys Cys Thr Glu Cys Glu Lys Ser Phe  
 50 55 60  
 Ser Gln Ser Ser Thr Leu Phe Gln His Gln Lys Ile His Thr Gly Lys  
 65 70 75 80  
 55 Lys Ser His Lys Cys Ala Asp Cys Gly Lys Ser Phe Phe Gln Ser Ser  
 85 90 95  
 Asn Leu Ile Gln His Arg Arg Ile His Thr Gly Glu Lys Pro Tyr Lys

100 105 110  
 Cys Asp Glu Cys Gly Glu Ser Phe Lys Gln Ser Ser Asn Leu Ile Gln  
 115 120 125  
 5 His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Gln Cys Asp Glu Cys  
 130 135 140  
 Gly Arg Cys Phe Ser Gln Ser Ser His Leu Ile Gln His Gln Arg Thr  
 10 145 150 155 160  
 His Thr Gly Glu Lys Pro Tyr Gln Cys Ser Glu Cys Gly Lys Cys Phe  
 165 170 175  
 15 Ser Gln Ser Ser His Leu Arg Gln His Met Lys Val His Lys Glu Glu  
 180 185 190  
 Lys Pro Arg Lys Thr Arg Gly Lys Asn Ile Arg Val Lys Thr His Leu  
 195 200 205  
 20 Pro Ser Trp Lys Ala Gly Thr Glu Gly Ser Leu Trp Leu Val Ser Val  
 210 215 220  
 Lys Tyr Arg Ala Phe  
 25 225  
 <210> 12  
 <211> 393  
 30 <212> PRT  
 <213> Mouse  
 <400> 12  
 35 Met Ser Glu Glu Pro Leu Glu Asn Ala Glu Lys Asn Pro Gly Ser Glu  
 1 5 10 15  
 Glu Ala Phe Glu Ser Gly Asp Gln Ala Glu Arg Pro Trp Gly Asp Leu  
 20 25 30  
 40 Thr Ala Glu Glu Trp Val Ser Tyr Pro Leu Gln Gln Val Thr Asp Leu  
 35 40 45  
 Leu Val His Lys Glu Ala His Ala Gly Ile Arg Tyr His Ile Cys Ser  
 50 50 55 60  
 Gln Cys Gly Lys Ala Phe Ser Gln Ile Ser Asp Leu Asn Arg His Gln  
 65 70 75 80  
 50 Lys Thr His Thr Gly Asp Arg Pro Tyr Lys Cys Tyr Glu Cys Gly Lys  
 85 90 95  
 Gly Phe Ser Arg Ser Ser His Leu Ile Gln His Gln Arg Thr His Thr  
 100 105 110  
 55 Gly Glu Arg Pro Tyr Asp Cys Asn Glu Cys Gly Lys Ser Phe Gly Arg  
 115 120 125  
 Ser Ser His Leu Ile Gln His Gln Thr Ile His Thr Gly Glu Lys Pro

	130		135		140												
5	His 145	Lys	Cys	Thr	Glu	Cys 150	Ala	Lys	Ala	Ser 155	Ala	Ala	Ser	Pro	His	Leu 160	
	Ile	Gln	His	Gln	Arg 165	Thr	His	Ser	Gly	Glu 170	Lys	Pro	Tyr	Glu	Cys 175	Glu	
10	Glu	Cys	Gly	Lys 180	Ser	Phe	Ser	Arg	Ser 185	Ser	His	Leu	Ala	Gln 190	His	Gln	
	Arg	Thr	His 195	Thr	Gly	Glu	Lys	Pro 200	Tyr	Glu	Cys	His	Glu 205	Cys	Gly	Arg	
15	Gly	Phe 210	Ser	Glu	Arg	Ser	Asp 215	Leu	Ile	Lys	His	Tyr 220	Arg	Val	His	Thr	
	Gly	Glu	Arg	Pro	Tyr	Lys 230	Cys	Asp	Glu	Cys	Gly 235	Lys	Asn	Phe	Ser	Gln 240	
20	Asn	Ser	Asp	Leu	Val 245	Arg	His	Arg	Arg	Ala 250	His	Thr	Gly	Glu	Lys 255	Pro	
	Tyr	His	Cys	Asn	Glu	Cys	Gly	Glu	Asn 265	Phe	Ser	Arg	Ile	Ser	His	Leu 270	
25	Val	Gln	His	Gln	Arg	Thr	His 280	Thr	Gly	Glu	Lys	Pro	Tyr 285	Glu	Cys	Thr	
30	Ala	Cys	Gly	Lys	Ser	Phe	Ser 295	Arg	Ser	Ser	His	Leu 300	Ile	Thr	His	Gln	
	Lys	Ile	His	Thr	Gly	Glu	Lys 310	Pro	Tyr	Glu	Cys 315	Asn	Glu	Cys	Trp	Arg 320	
35	Ser	Phe	Gly	Glu	Arg	Ser	Asp	Leu	Ile	Lys 330	His	Gln	Arg	Thr	His 335	Thr	
	Gly	Glu	Lys	Pro	Tyr	Glu	Cys	Val	Gln 345	Cys	Gly	Lys	Gly	Phe 350	Thr	Gln	
40	Ser	Ser	Asn	Leu	Ile	Thr	His 360	Gln	Arg	Val	His	Thr	Gly 365	Glu	Lys	Pro	
	Tyr	Glu	Cys	Thr	Glu	Cys	Asp 375	Lys	Ser	Phe	Ser	Arg 380	Ser	Ser	Ala	Leu	
45	Ile	Lys	His	Lys	Arg	Val	His	Thr	Asp								
50	385				390												
	<210>	13															
	<211>	28															
55	<212>	PRT															
	<213>	Artificial Sequence															
	<220>																
	<223>	Zinc finger domain.															



<220>  
 <221> VARIANT  
 <222> (13)..(13)  
 5 <223> Amino acid 13 is Xaa wherein Xaa = Z-1 wherein Z-1 = Arg or Lys,  
 Gln or Asn, Thr, Met, Leu or Ile, or Glu or Asp.

<220>  
 <221> VARIANT  
 10 <222> (15)..(15)  
 <223> Amino acid 15 is Xaa wherein Xaa = Z2 wherein Z2 = Ser or Arg,  
 Asn or Gln, Thr, Val, or Ala, or Asp or Glu.

<220>  
 15 <221> VARIANT  
 <222> (16)..(16)  
 <223> Amino acid 16 is Xaa wherein Xaa = Z3 wherein Z3 = His or Lys,  
 Asn or Gln, Ser, Ala, or Val, or Asp or Glu.

20 <220>  
 <221> VARIANT  
 <222> (19)..(19)  
 <223> Amino acid 19 is Xaa wherein Xaa = Z6 wherein Z6 = Arg or Lys,  
 Gln or Asn, Thr, Tyr, Leu, Ile or Met, or Glu or Asp.

25 <400> 13  
  
 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa Ser Xaa Xaa  
 1 5 10 15  
 30 s  
 Leu Gln Xaa His Gln Arg Thr His Thr Gly Glu Lys  
 20 25

35 <210> 14  
 <211> 10  
 <212> DNA  
 <213> Tomato golden mosaic virus

40 <400> 14  
 agtaaggtag 10

45 <210> 15  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence

50 <220>  
 <223> Zinc finger domain.  
  
 <400> 15  
  
 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Asp Ser  
 1 5 10 15  
 55 Leu Gln Arg His Gln Arg Thr His Thr Gly Glu Lys  
 20 25

5 <210> 16  
 <211> 28  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Zinc finger domain.  
  
 10 <400> 16  
  
 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn  
 1 5 10 15  
  
 15 Leu Gln Gln His Gln Arg Thr His Thr Gly Glu Lys  
 20 25  
  
 <210> 17  
 <211> 28  
 20 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Zinc finger domain.  
  
 25 <400> 17  
  
 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Thr His  
 1 5 10 15  
  
 30 Leu Gln Gln His Gln Arg Thr His Thr Gly Glu Lys  
 20 25  
  
 35 <210> 18  
 <211> 11  
 <212> PRT  
 <213> Human immunodeficiency virus  
  
 40 <400> 18  
  
 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10  
  
 45 <210> 19  
 <211> 30  
 <212> PRT  
 <213> Artificial Sequence  
  
 50 <220>  
 <223> Acid dimerization peptide.  
  
 <400> 19  
  
 55 Ala Gln Leu Glu Lys Glu Leu Gln Ala Leu Glu Lys Glu Asn Ala Gln  
 1 5 10 15  
  
 Leu Glu Trp Glu Leu Gln Ala Leu Glu Lys Glu Leu Ala Gln

20 25 30

5 <210> 20  
 <211> 30  
 <212> PRT  
 <213> Artificial Sequence

10 <220>  
 <223> Basic dimerization peptide.  
 <400> 20

15 Ala Gln Leu Lys Lys Lys Leu Gln Ala Leu Lys Lys Lys Asn Ala Gln  
 1 5 10 15  
 Leu Lys Trp Lys Leu Gln Ala Leu Lys Lys Lys Leu Ala Gln  
 20 25 30

20 <210> 21  
 <211> 20  
 <212> PRT  
 <213> Artificial Sequence

25 <220>  
 <223> Flexible linker.  
 <400> 21

30 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
 1 5 10 15  
 Gly Gly Gly Ser  
 20

35

40 <210> 22  
 <211> 9  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> Flexible linker.  
 <400> 22  
 gcagaagcc

50 <210> 23  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

55 <220>  
 <223> Flexible linker.  
 <400> 23

9

Gly Gly Gly Gly Ser  
1 5

5 <210> 24  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> All target polynucleotide.

15 <400> 24  
 tatatataag taaggtagta tatata 26

20 <210> 25  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Target polynucleotide for zinc finger protein Zif268.

25 <400> 25  
 tatatatagc gtgggcgtta tatata 26

30 <210> 26  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <223> ZFP target sequence.

<400> 26  
 tatatataag taaggtagta tatata 26

40 <210> 27  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> ZFP target sequence.

50 <400> 27  
 tatatataag taaggtaata tatata 26

55 <210> 28  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> ZFP target sequence.

<400> 28  
 tatatataag taaggtatta tatata 26  
 5  
 <210> 29  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
 10  
 <220>  
 <223> ZFP target sequence.  
 15  
 <400> 29  
 tatatataag taaggtacta tatata 26  
 20  
 <210> 30  
 <211> 84  
 <212> PRT  
 <213> Artificial Sequence  
 25  
 <220>  
 <223> Zinc finger protein.  
 30  
 <220>  
 <221> VARIANT  
 <222> (15)..(15)  
 <223> Amino acid 15 is "Xaa" wherein "Xaa" = Asp or Gly.  
 <400> 30  
 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser Xaa Ala  
 35  
 1 5 10 15  
 Leu Gln Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys  
 20 25 30  
 40  
 Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Gln Lys His  
 35 40 45  
 45  
 Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly  
 50 55 60  
 Lys Ser Phe Ser Arg Ser Asp His Leu Gln Arg His Gln Arg Thr His  
 65 70 75 80  
 50 Thr Gly Glu Lys  
 55  
 <210> 31  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

<223> Degenerate DNA probe.  
 <220>  
 <221> misc\_feature  
 5 <222> (7)..(10)  
 <223> Nucleotides 7-10 are "n" wherein "n" = g, a, t, or c.  
 <400> 31  
 10 ggggaannnn 10  
 <210> 32  
 <211> 26  
 <212> DNA  
 15 <213> Artificial Sequence  
 <220>  
 <223> Zinc finger domain target sequence.  
 20 <220>  
 <221> misc\_feature  
 <222> (14)..(16)  
 <223> Nucleotides 14-16 are "n" wherein "n" = g, a, t, or c.  
 25 <400> 32  
 tatatatagg ggaannngta tatata 26  
 <210> 33  
 30 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
 35 <220>  
 <223> Zinc finger domain target sequence.  
 <220>  
 <221> misc\_feature  
 40 <222> (15)..(17)  
 <223> Nucleotides 15-17 are "n" wherein "n" = g, a, t, or c.  
 <400> 33  
 45 tatatatagg ggaannnata tatata 26  
 <210> 34  
 <211> 26  
 <212> DNA  
 50 <213> Artificial Sequence  
 <220>  
 <223> Zinc finger domain target sequence.  
 55 <220>  
 <221> misc\_feature  
 <222> (15)..(17)  
 <223> Nucleotides 15-17 are "n" wherein "n" = g, a, t, or c.

<400> 34  
 tatatatagg ggaannntta tatata 26

5 <210> 35  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

10 <220>  
 <223> Zinc finger domain target sequence.

<220>  
 <221> misc\_feature  
 15 <222> (15)..(17)  
 <223> Nucleotides 15-17 are "n" wherein "n" = g, a, t, or c.

<400> 35  
 20 tatatatagg ggaannncta tatata 26

<210> 36  
 <211> 60  
 <212> DNA  
 25 <213> Artificial Sequence

<220>  
 <223> Partial zinc finger domain oligomer.

30 <220>  
 <221> misc\_feature  
 <222> (45)..(56)

<223> Nucleotides 45-47 and 51-56 are "n" wherein "n" = g, a, t, or c.  
 35

<400> 36  
 ggggagaagc cgtataaatg tccggaatgt ggtaaaagtt ttagcnnnag cnnnnnnnttg 60

40 <210> 37  
 <211> 60  
 <212> DNA  
 <213> Artificial Sequence

45 <220>  
 <223> Partial zinc finger domain oligomer.

<220>  
 <221> misc\_feature  
 50 <222> (37)..(51)  
 <223> Nucleotides 37-39 and 46-51 are "n" wherein "n" = g, a, t, or c.

<400> 37  
 55 tttgtatggg ttttcaccgg tatgggtacg ctgatgnnnc tgcaannnnn ngctnnngct 60

<210> 38  
 <211> 60  
 <212> DNA

<213> Artificial Sequence  
 <220>  
 <223> Partial zinc finger domain oligomer.  
 5  
 <220>  
 <221> misc\_feature  
 <222> (46)..(57)  
 <223> Nucleotides 46-48 and 52-57 are "n" wherein "n" = g, a, t, or c.  
 10  
 <400> 38  
 ggtgaaaaac catacaaatg tccagagtgc ggcaaatctt tctctnnmtc tnnnnnnctt 60  
 15  
 <210> 39  
 <211> 60  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Partial zinc finger domain oligomer.  
 <220>  
 <221> misc\_feature  
 25  
 <222> (37)..(51)  
 <223> Nucleotides 37-39 and 46-51 are "n" wherein "n" = g, a, t, or c.  
 <400> 39  
 cttgtaaggc ttctcgccag tgtgagtacg ctgatgnnnc tgaagnnnnn nagannnaga 60  
 30  
 <210> 40  
 <211> 56  
 35  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Partial zinc finger domain oligomer.  
 40  
 <220>  
 <221> misc\_feature  
 <222> (48)..(58)  
 <223> Nucleotides 48-50 and 54-58 are "n" wherein "n" = g, a, t, or c.  
 45  
 <400> 40  
 ggcgagaagc cttacaagtg ccctgaatgc gggaagagct ttagtnnnag tnnnnn 56  
 50  
 <210> 41  
 <211> 55  
 <212> DNA  
 <213> Artificial Sequence  
 55  
 <220>  
 <223> Partial zinc finger domain oligomer.  
 <220>  
 <221> misc\_feature



<222> (28)..(48)

<223> Nucleotides 28-30, 37-42 and 46-48 are "n" wherein "n" = g, a, t, or c

5 <400> 41  
cttctccccc gtgtgcgtgc gttggtgnnn ttgtaannnn nnactnnnac taaag 55

10 <210> 42  
<211> 45  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> PCR primer.

<400> 42  
gggcccggtc tcgaattcgg ggagaagccg tataaatgtc cggaa 45

20 <210> 43  
<211> 48  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> PCR primer.

30 <400> 43  
cccggggggtc tcaagctttt acttctcccc cgtgtgcgtg cgttggtg 48

35 <210> 44  
<211> 10  
<212> DNA  
<213> Beet curly top virus

40 <400> 44  
ttgggtgctc 10

45 <210> 45  
<211> 60  
<212> DNA  
<213> Artificial Sequence

50 <220>  
<223> Partial zinc finger domain oligomer.

<400> 45  
ggggagaagc cgtataaatg tccggaatgt ggtaaaagtt ttagcaccag cagcgatttg 60

55 <210> 46  
<211> 60  
<212> DNA  
<213> Artificial Sequence

<220>  
 <223> Partial zinc finger domain oligomer.

<400> 46  
 5 tttgtatggt ttttcaccgg tatgggtacg ctgatgacgc tgcaaactgc tgcgtggtgct 60

<210> 47  
 <211> 60  
 10 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Partial zinc finger domain oligomer.

15 <400> 47  
 ggtgaaaaac catacaaatg tccagagtgc ggcaaactct tctctacctc tgatcatctt 60

20 <210> 48  
 <211> 60  
 <212> DNA  
 <213> Artificial Sequence

25 <220>  
 <223> Partial zinc finger domain oligomer.

<400> 48  
 30 cttgtaaggc ttctcgccag tgtgagtacg ctgatgacgc tgaagatgat cagaggtaga 60

<210> 49  
 <211> 56  
 35 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Partial zinc finger domain oligomer.

40 <400> 49  
 ggcgagaagc cttacaagtg ccctgaatgc gggaagagct ttagtcgtag tgatag 56

45 <210> 50  
 <211> 55  
 <212> DNA  
 <213> Artificial Sequence

50 <220>  
 <223> Partial zinc finger domain oligomer.

<400> 50  
 55 cttctccccc gtgtgcgtgc gttggtgggt ttgtaagcta tcactacgac taaag 55

<210> 51  
 <211> 16  
 <212> DNA

<213> Arabidopsis  
 <400> 51  
 atagtttacg tggcat 16  
 5  
 <210> 52  
 <211> 10  
 <212> DNA  
 10 <213> Arabidopsis  
 <400> 52  
 atagtttacg 10  
 15  
 <210> 53  
 <211> 10  
 <212> DNA  
 20 <213> Arabidopsis  
 <400> 53  
 tacgtggcat 10  
 25 <210> 54  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence PCR Primer  
 30 <400> 54  
 ttcagggcgg tctctcggct tctcgccagt gtgagtacgc tgatg 45  
 35 <210> 55  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence  
 40 <220>  
 <223> PCR primer.  
 <400> 55  
 cgaattcggg tctcagccgt ataaatgtcc ggaatgtggt aaaa 44  
 45  
 <210> 56  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence  
 50 <220>  
 <223> PCR primer.  
 <400> 56  
 55 tgcggccggg tctctcggct tctccccgt gtgcgtgcgt tgggtg 45  
 <210> 57  
 <211> 19

<212> DNA  
 <213> Artificial Sequence  
 <220>  
 5 <223> ZFP target sequence.  
 <400> 57  
 ttgggtgctt tgggtgctc 19  
 10  
 <210> 58  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence  
 15 <220>  
 <223> ZFP target sequence.  
 <400> 58  
 20 ttgggtgctt 10  
 <210> 59  
 <211> 10  
 25 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 30 <223> ZFP target sequence.  
 <400> 59  
 ttgggtgctc 10  
 35  
 <210> 60  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence  
 40  
 <220>  
 <223> ZFP target probe.  
 <400> 60  
 45 tatatatatt ggggtgctttg ggtgctctat atata 35  
 <210> 61  
 <211> 10  
 50 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> ZFP target sequence.  
 55  
 <400> 61  
 agtaaggtag 10

5       <210> 62  
           <211> 10  
           <212> DNA  
           <213> Artificial Sequence  
           <220>  
           <223> ZFP target sequence.  
 10       <400> 62  
           ttgggtgctc 10

15       <210> 63  
           <211> 10  
           <212> DNA  
           <213> Artificial Sequence  
           <220>  
 20       <223> ZFP target sequence.  
           <400> 63  
           tacgtggcat 10

25       <210> 64  
           <211> 10  
           <212> DNA  
           <213> Artificial Sequence  
 30       <220>  
           <223> ZFP target sequence.  
           <400> 64  
 35       ggagatgata 10

40       <210> 65  
           <211> 19  
           <212> DNA  
           <213> Artificial Sequence  
           <220>  
 45       <223> ZFP target sequence.  
           <400> 65  
           ttgggtgctt tgggtgctc 19

50       <210> 66  
           <211> 19  
           <212> DNA  
           <213> Artificial Sequence  
 55       <220>  
           <223> ZFP target sequence.  
           <400> 66  
           agtaaggtag gagatgata 19

5      <210> 67  
       <211> 19  
       <212> DNA  
       <213> Artificial Sequence  
  
       <220>  
       <223> ZFP target sequence.  
 10  
       <400> 67  
       tacgtggcat tgggtgctc 19  
  
 15      <210> 68  
       <211> 28  
       <212> PRT  
       <213> Artificial Sequence  
  
 20      <220>  
       <223> Zinc finger domain.  
  
       <220>  
       <221> VARIANT  
 25      <222> (13)..(13)  
       <223> Amino acid 13 is "Xaa" wherein "Xaa" = Z1 wherein Z1 = Arg, Gln,  
             Thr, Met or Glu  
  
       <220>  
 30      <221> VARIANT  
       <222> (15)..(15)  
  
       <223> Amino acid 15 is "Xaa" wherein "Xaa" = Z2 wherein Z2 = Ser, Asn,  
             Thr, or Asp  
 35  
       <220>  
       <221> VARIANT  
       <222> (16)..(16)  
       <223> Amino acid 16 is "Xaa" wherein "Xaa" = Z3 wherein Z3 = His, Asn,  
 40      Ser, or Asp  
  
       <220>  
       <221> VARIANT  
       <222> (19)..(19)  
 45      <223> Amino acid 19 is "Xaa" wherein "Xaa" = Z6 wherein Z6 = Arg, Gln,  
             Thr, Tyr, Leu, or Glu  
  
       <400> 68  
  
 50      Gln His Ala Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa Ser Xaa Xaa  
       1                   5                   10                   15  
  
       Leu Gln Xaa His Gln Arg Thr His Thr Gly Glu Lys  
           20                   25  
 55  
       <210> 69  
       <211> 28  
       <212> PRT  
       <213> Artificial Sequence

<220>  
 <223> Zinc finger domain.

5 <220>  
 <221> VARIANT  
 <222> (13)..(13)  
 <223> Amino acid 13 is "Xaa" wherein "Xaa" = Z1 wherein Z1 = Arg, Gln,  
 10 Thr, Met, or Glu

<220>  
 <221> VARIANT  
 <222> (15)..(15)  
 <223> Amino acid 15 is "Xaa" wherein "Xaa" = Z2 wherein Z2 = Ser, Asn,  
 15 Thr, or Asp.

<220>  
 <221> VARIANT  
 <222> (16)..(16)  
 20 <223> Amino acid 16 is "Xaa" wherein "Xaa" = Z3 wherein Z3 = His, Asn,  
 Ser, or Asp

<220>  
 <221> VARIANT  
 25 <222> (19)..(19)  
 <223> Amino acid 19 is "Xaa" wherein "Xaa" = Z6 wherein Z6 = Arg, Gln,  
 Thr, Tyr, Leu, or Glu.

<400> 69  
 30

Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa Ser Xaa Xaa  
 1 5 10 15

35 Leu Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys  
 20 25